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ABSTRACT 
 
 
The establishment of an outpatient prescription drug benefit in Medicare, Medicare Part 
D, was one of the more significant events in United States healthcare reform history.   
Many seniors have chosen to enroll in the plan as the program has an enrollment of over 
27 million.  One central premise of Medicare Part D was that the plan would be 
administered entirely through private insurance plans.  Because many plans would be 
competing against one another for potential beneficiaries, it was expected that companies 
would offer seniors plans with high quality benefits at lower costs that would presumably 
be attractive to seniors.  However, in order for this strategy to succeed, seniors must be 
sensitive to differences in price and the quality of benefits amongst different plans.  This 
study sought to evaluate the relative importance seniors place on different attributes of 
Medicare Part D drug plans using a marketing technique called conjoint analysis.  
 
An Adaptive Choice Based Conjoint Analysis Survey was constructed and administered 
to 497 seniors in the Greater Memphis/Shelby County Area.  Seniors were recruited from 
local senior centers or senior apartment homes.  The survey consisted of 7 attributes:  
premiums, brand copayments, generic copayments, deductible amounts, doughnut hole 
coverage, formulary provisions, and eligibility requirements for medication therapy 
management services.  
 
The most important attribute in the aggregate sample was premiums with an importance 
score of 50.3%, followed by the formulary provisions (importance score of 12.1%), 
deductible (11.6%) and pharmacy access (10.1%).  Seniors with higher incomes, those 
taking more than seven medications, and those with monthly medication costs above $80 
were less sensitive to premium increases than other groups.  As a group, the seniors were 
willing to pay approximately $20 more in monthly premiums to go from plans with the 
maximum allowed deductible to plans with no deductible and only $3 more to have full 
coverage of generics in the doughnut hole; however these values differed amongst 
different segments.  For example, seniors with reported medication costs of at least $80 
per month are willing to spend on average $20 per month for doughnut hole coverage. 
 
Adaptive Choice Based Conjoint Analysis represents a feasible way to elicit preferences 
for features in Medicare Part D drug plans.  Seniors are sensitive to differences in cost 
and breadth of coverage across plans, although only a subset of seniors is sensitive to the 
doughnut hole.  Seniors are particularly concerned with low premiums in their particular 
plans, although seniors with higher incomes, those taking more medications, and those 
with higher out of pocket medication costs are less sensitive to changes in premiums.  
The delivery system characteristics are also an important consideration for seniors in 
purchasing Medicare Part D plans, as most seniors exhibited strong preferences for being 
able to retain their relationship with their current pharmacy. 
  
vi 
 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
Medicare and the Provision of Health Care Services ......................................................1 
The Impact of Medicare Part D .......................................................................................2 
Competitive Markets in Health Care ...............................................................................3 
Evolution of Studies within Consumer Choice ................................................................6 
Overview of Analysis ......................................................................................................6 
Consumer Choice in Prescription Drug Markets .............................................................9 
Statement of Problem .....................................................................................................10 
Conceptual Models ........................................................................................................11 
Berki and Ashcraft’s Model of Health Care Plan Choice ..........................................11 
Cline and Mott’s Model of Prescription Drug Plan Choice .......................................13 
Conceptual Model for Prescription Drug Plan Choice in Medicare Part D ...............13 
Specific Aims and Hypotheses ......................................................................................16 
Definition of Terms .......................................................................................................18 
CHAPTER 2. LITERATURE REVIEW .......................................................................21 
Introduction ....................................................................................................................21 
Overview of Studies on Prescription Drug Plan Choice ................................................21 
Prescription Drug Plan Choice in Seniors before Medicare Part D ...........................21 
Conjoint Analysis in Prescription Drug Plan Choice ................................................22 
Prescription Drug Plan Choice in Medicare Part D ...................................................23 
Conceptual Model Variables in the Literature ...............................................................25 
Premiums ...................................................................................................................25 
Doughnut Hole Coverage ..........................................................................................26 
Deductibles ................................................................................................................28 
Copayments ................................................................................................................29 
Control Mechanisms ..................................................................................................29 
Pharmacy Access .......................................................................................................30 
Medication Therapy Management Services ...............................................................31 
Expected Utilization Patterns .....................................................................................31 
Economic Characteristics ...........................................................................................32 
Risk Factors ...............................................................................................................33 
Beliefs about Medicine ..............................................................................................33 
Attribute Preferences .................................................................................................33 
Summary ........................................................................................................................33 
CHAPTER 3. METHODS ..............................................................................................35 
Overview ........................................................................................................................35 
Rationale of Adaptive Choice-Based Conjoint Analysis as Survey Technique ............35 
Full Profile Conjoint Analysis ...................................................................................35 
Adaptive Conjoint Analysis .......................................................................................36 
Choice-Based Conjoint Analysis ...............................................................................37 
Potential Problems with Using Traditional Conjoint Analysis Methods ...................37 
vii 
 
Adaptive Choice-Based Conjoint Analysis................................................................38 
Operationalization of Variables .....................................................................................39 
Variables outside of Conceptual Model .....................................................................39 
Explanatory Variables within Conceptual Model ......................................................39 
Operationalization of Premiums, Deductibles, and Doughnut Hole ..........................41 
Operationalization of Copayments ............................................................................46 
Operationalization of Control Mechanisms ...............................................................48 
Operationalization of Delivery System Characteristics .............................................50 
Survey Instrumentation ..................................................................................................51 
Study Design ..................................................................................................................52 
Sample Size ....................................................................................................................53 
Study Setting ..................................................................................................................54 
Data Analysis .................................................................................................................55 
Part Worth Values ......................................................................................................55 
Importance Scores ......................................................................................................57 
Willingness to Pay .....................................................................................................57 
Protection of Human Subjects .......................................................................................57 
CHAPTER 4. RESULTS .................................................................................................58 
Description of Sample Characteristics ...........................................................................58 
Results by Age ...............................................................................................................68 
Results by Gender ..........................................................................................................71 
Results by Race ..............................................................................................................74 
Results by Income ..........................................................................................................78 
Results by Medical Preferences .....................................................................................82 
Results by Number of Prescription Medications ...........................................................86 
Results by Pharmacy Preferences ..................................................................................95 
Results by Education .....................................................................................................95 
Results by Disease Burden ..........................................................................................102 
Results by Out of Pocket Medication Cost ..................................................................102 
CHAPTER 5. DISCUSSION ........................................................................................111 
LIST OF REFERENCES ..............................................................................................115 
APPENDIX A. MEDICAL CARE PREFERENCE SCALE .....................................125 
APPENDIX B. CONJOINT ANALYSIS SURVEY ...................................................126 
APPENDIX C. CONSENT FORM ..............................................................................130 
VITA................................................................................................................................131 
 
  
viii 
 
LIST OF TABLES 
 
Table 1-1.  Part worths for hypothetical study ..................................................................7 
Table 3-1.  Operationalization of variables outside conceptual model ...........................40 
Table 3-2.  Operationalization of explanatory variables in conceptual model ................42 
Table 3-3.  Plans with maximum deductible and no gap coverage in 2010 ....................44 
Table 3-4.  Plans with intermediate deductible and no gap coverage in 2010 ................44 
Table 3-5.  Plans with no deductible and no gap coverage in 2010 ................................45 
Table 3-6.  Plans with no deductible featuring gap coverage in 2010 ............................45 
Table 3-7.  Summed pricing for premium .......................................................................47 
Table 3-8.  Attributes and levels used in conjoint analysis survey .................................49 
Table 4-1.  Demographics of sample...............................................................................59 
Table 4-2.  Medical care specific variables .....................................................................60 
Table 4-3.  Part worths for aggregate sample ..................................................................62 
Table 4-4.  Part worths for aggregate sample rescaled ....................................................65 
Table 4-5.  Importance scores for total sample ...............................................................66 
Table 4-6.  Marginal WTP for aggregate sample rescaled ..............................................67 
Table 4-7.  Part worth values by age rescaled .................................................................69 
Table 4-8.  Importance scores by age ..............................................................................70 
Table 4-9.  Marginal WTP by age rescaled .....................................................................72 
Table 4-10.  Part worth values by gender rescaled ............................................................73 
Table 4-11.  Importance scores by gender ........................................................................75 
Table 4-12.  Marginal WTP by gender rescaled ...............................................................76 
Table 4-13.  Part worth values by race rescaled ................................................................77 
Table 4-14.  Importance scores by race .............................................................................79 
Table 4-15.  Marginal WTP by race rescaled ....................................................................80 
ix 
 
Table 4-16.  Part worth values by income rescaled ...........................................................81 
Table 4-17.  Importance scores by income ........................................................................83 
Table 4-18.  Marginal WTP by income rescaled ...............................................................84 
Table 4-19.  Part worth values by medical preferences rescaled ......................................85 
Table 4-20.  Importance scores by medical preferences score ..........................................87 
Table 4-21.  Marginal WTP by medical preferences rescaled ..........................................88 
Table 4-22.  Part worth values by number of prescription medications rescaled .............89 
Table 4-23.  Importance scores by number of prescription medications ..........................92 
Table 4-24.  Marginal WTP by number of prescription medications rescaled .................93 
Table 4-25.  Part worth values by pharmacy preferences rescaled ...................................96 
Table 4-26.  Importance scores by pharmacy preferences ................................................97 
Table 4-27.  Marginal WTP by pharmacy preferences rescaled .......................................98 
Table 4-28.  Part worth values by education rescaled .......................................................99 
Table 4-29.  Importance scores by education ..................................................................100 
Table 4-30.  Marginal WTP by education rescaled .........................................................101 
Table 4-31.  Part worth values by disease burden rescaled .............................................103 
Table 4-32.  Importance scores by disease burden ..........................................................104 
Table 4-33.  Marginal WTP by disease burden rescaled .................................................105 
Table 4-34.  Part worth values by out of pocket medication cost rescaled .....................106 
Table 4-35.  Importance scores by out of pocket medication cost ..................................108 
Table 4-36.  Marginal WTP by monthly out of pocket medicine cost rescaled ..............109 
 
  
1 
 
CHAPTER 1.    INTRODUCTION 
 
 
Medicare and the Provision of Health Care Services 
 
Medicare was established in 1965 through Title XVIII of the Social Security Act at a 
means of helping to provide security against the disproportionate health care risks borne 
by seniors at least 65 years old, and younger individuals under 65 with certain disabilities 
including end stage renal disease.1  The majority of the programs enrollees are senior 
citizens; in 2010 there were 47 million total beneficiaries with 39 million senior citizens.1 
Medicare is the nation’s largest health insurance program in both enrollment and 
expenditures, as federal spending on the benefits amounts to over $500 billion dollars.1  
The vast majority of the nearly 40 million Americans over the age of 65 are automatically 
enrolled in Medicare Part A, which provides coverage for inpatient hospital visits and 
skilled nursing visits among other services.1 Virtually all (95%) of these seniors are 
automatically enrolled in Medicare Part B which covers outpatient hospital services, 
physician visits, preventive care, and other types of services.1  During the 1970’s 
beneficiaries were also given the option of enrolling in Medicare Part C where their 
services would be provided through a privately owned managed care corporation under 
the jurisdiction of Medicare Part D.1  These companies were required to provide at 
minimum the benefits available in Medicare A and B, and offer additional services at 
their discretion.1,2 
 
One notable exception to the services provided in Medicare A and B is prescription drug 
coverage.  Medicare Part D, the outpatient prescription drug benefit available through 
Medicare, was enacted through the passage of the Medicare Modernization Act of 2003 
(MMA) with the intention of helping to alleviate the burden of prescription drug costs for 
seniors, particularly those with no previous drug coverage and those with inadequate 
prescription coverage.2  The program was not formally implemented until 2006.2  The 
rationale for prescription drug coverage to be included in Medicare has been well 
documented.  Senior citizens tend to have more chronic diseases which require 
pharmacologic therapy.  Recent research indicated that senior citizens had nearly 23 
prescriptions filled on an annual basis, nearly double that of the average for the U.S. 
population as whole.3,4   
 
Approximately 65%-74% of seniors had some type of drug coverage in 1996-2003, 
primarily through Medicare Advantage Plans, Medicaid, employer sponsored insurance 
or plans purchased through the individual market, meaning there were well over 11 
million seniors without prescription drug coverage.5-9  One may surmise that most of the 
seniors without prescription coverage may not be taking any medications, but this is not 
always true, as between 80%-90% of the seniors without prescription insurance at this 
time were using some type of prescription medication.8,9  The research during this period 
demonstrated that although seniors without prescription insurance used fewer 
prescriptions, they incurred higher medication related expenses.6  As a result, seniors 
without prescription drug coverage were five times as likely to report experiencing 
financial hardship as a result of expenses related to prescription drugs.8  Seniors adapted 
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many maladaptive behaviors to cope with the high medication expenses such as not 
obtaining refills of medications, skipping doses of medications, or splitting pills.8  For 
example, in 2004 half of seniors without prescription drug coverage reported being 
noncompliant with medications for treatment of heart failure and diabetes.9   
 
 
The Impact of Medicare Part D 
 
Following the implementation of Medicare Part D, seniors had several options for enrolling in 
the program.2,10   Senior Citizens who had prior coverage which was actuarially superior to 
Medicare Part D were encouraged to retain their current coverage.2,10  This group consisted 
primarily of individuals who had previous coverage from employers which received a 
government subsidy to continue providing the insurance.2,10  Seniors could also access 
prescription drug coverage through enrollment in a Medicare Part C (Medicare Advantage) 
program.1,2,10  The majority of seniors enrolled in Medicare Advantage already had some type 
of prescription drug coverage.1   Seniors were already afforded these opportunities for 
accessing prescription drug coverage prior to passage of the MMA, but the legislation also 
created stand alone drug plans.  These were known as Prescription Drug Plans (PDPs).1,2  
Senior citizens with limited incomes (less than 150% of poverty) and limited assets were 
eligible to receive a low income subsidy.10  Certain seniors who met these qualifications were 
automatically enrolled into the Part D program and the low income subsidy programs, 
including those eligible for Medicaid (dual eligibles) and those only receiving SSI.10  These 
were the only individuals automatically enrolled in Medicare Part D; enrollment was 
completely voluntary for other seniors.10  However, unless they have creditable coverage 
superior to Medicare Part D, seniors are charged a penalty of 1% of the average national 
monthly premium for each month they delay enrollment in the program upon reaching 
eligibility.2,10    
 
Medicare Part D is unique in that insurers are required to offer a prescription insurance 
plan which has benefits that are actuarially equivalent to or at least as good as the 
standard prescription benefit specified by the Center for Medicare and Medicaid Services 
(CMS).1,2,10  For plans covering beneficiaries in 2011 this is defined as a plan with a $310 
deductible and 25% costs haring for the patient up to $2,840.10  After reaching $2,840 in 
total drug costs, the patient is responsible for 50% of the cost of brand name drugs and 
93% of the cost of generic drugs until a total drug cost of $6,448 is reached.10  The 
sudden increase in copayments for seniors between $2,840 and $6,448 in drug costs has 
been termed the doughnut hole, and has been a major target of recent health care 
reform.10   Prior to 2011, beneficiaries were solely responsible for all medication costs 
during this period.10  However with the passage of the Affordable Care Act of 2010, drug 
manufacturers and prescription drug plans are slated to assume progressively greater cost 
sharing during this period so that patients will also have cost sharing of 25% during this 
phase of the plan by 2020.10  Upon reaching $6,448 in total drug costs, catastrophic 
coverage takes over, and the beneficiary is only responsible for 5% of the costs.10   
 
However insurers are not restricted to this format in determining structure of their plans.  
They have the latitude to determine their copayment structures as long as their plans are 
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actuarially equivalent to the standard benefit.11  In fact, less than 15% of PDPs use the 
structure whereby patients pay 25% for each medication.11  The majority of PDPs use 
tiers to divide medications into three types of classes: generic, brand, and specialty.11  
Specialty medications are drugs used in cases where there is no alternative pharmacologic 
therapy available, and the cost is at least $600 per month.11  The most popular 
arrangement for the formulary is to have one tier for generic medications, one tier for 
specialty medications, and two tiers for brand name medications: preferred brand and non 
preferred brand.11  However, there is wide variation in the arrangement of tiers available, 
and there is no typical structure.11   It is most common for plans to have a flat dollar 
copayment on brand and generic medications while charging a coinsurance rate between 
25%-33% on specialty medications.11 
 
There is also considerable variation in the amount of deductibles offered by PDPs.11  In a 
given year approximately a third of PDPs charge the maximum allowed deductible, 
which is the deductible specified in the standard benefit plan.11  There are a smaller 
percentage of plans which may have a deductible smaller than the maximum allowed 
deductible.11  In a given year, at least 40% of PDPs have no deductible.11  Finally, there is 
also variation in the doughnut hole coverage offered by PDPs.  Although most plans do 
not have doughnut hole coverage, there are a few plans which do.12  Even among those 
offering doughnut hole coverage, there are differences among plans as plans may cover 
all, some, or only a few generics.12  It is rare for plans to cover brand name drugs during 
this time.12   
 
With all of the variation in plans, it is quite obvious that many may offer coverage which 
is in fact superior to that specified through the standard benefit.  Plans which do feature 
this type of coverage where their actuarial value is superior to that of the standard benefit 
are called enhanced plans.13  Plans may offer enhanced coverage through a variety of 
mechanisms.  For example, plans may have a 25% coinsurance rate on all medications 
but offer coverage in the doughnut hole.  Alternatively, plans may have a 25% 
coinsurance rate and no gap coverage, but they could have a partial deductible or no 
deductible at all.  Some plans may have enhanced coverage, because although they have 
the maximum allowed deductible and include no gap coverage, the coinsurance on the 
medications is lower than that specified in the standard benefit plan.13   
 
 
Competitive Markets in Health Care 
     
One central premise of the PDPs is that they are administered entirely through private 
companies, and seniors must choose from among the plans which are offered to them.2    
This was done in order to use market based principles of competition whereby plans 
would be compelled to compete with each other so that seniors would have premiums 
close to marginal cost.14  This continued the trend of moving away from the fee for 
service structure which Medicare was established under in 1965.1  The advent of 
Medicare Part C in the 1970s demonstrated that private organizations could be used to 
deliver services to seniors in the Medicare program.15  Most of these plans are preferred 
provider organizations (PPOs) or health maintenance organizations (HMOs).15  Although 
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a small portion of seniors are enrolled in Medicare Advantage plans (24% in 2010), the 
research done in this area provides valuable insight to the behavior of senior citizens in 
competitive health care markets.15  
 
The literature is replete with examples of studies which demonstrate the sensitivity of the 
general population to changes in the price of health care plans.14,16-18  However, one 
cannot assume that seniors share the same sensitivity to price as the younger population.  
Indeed, LaTour and colleagues concluded in their 1986 qualitative research that Medicare 
beneficiaries had relatively low price elasticity, although they did not quantify the extent 
of the seniors relative price elasticity.19  However, seniors demonstrate a different degree 
of price sensitivity when compared to the younger population.  Buchmueller 
demonstrated this phenomena in his 2000 study.20  Before 1994, Medicare eligible 
retirees of the University of California system were not required to pay premiums on any 
of the health insurance plans offered to them.20  However, fiscal pressures caused the 
university to reduce it’s contribution to a fixed amount so that the retirees were exposed 
to premiums in several plans.20  Buchmueller’s results indicated that in general 
beneficiaries were more likely to switch plans as the premiums increased.20  For example, 
a premium increase of $20 induced 3% of beneficiaries to switch plans, whereas a 
premium increase of $50 induced 4.4% of beneficiaries to switch to another plan.20  
However age was a statistically significant variable in his probit regression model as 
increased age decreased the likelihood that an individual would switch plans.20  
 
However it is important to note that Buchmueller’s study did not explore the importance 
of the benefit package offered to employees.  This is not an inconsequential omission, as 
Berki and Ashcroft’s conceptual model of health plan choice16 shows that both cost and 
benefits are of importance in selecting health care plans.  Berki’s financial loss 
hypothesis essentially states that, if all other factors are held constant, individuals or 
families will attempt to choose plans that minimize their expected financial outlays based 
upon the amount of services they believe will be incurred.16  Yet, this is not a function of 
premium price only, but also copayments. So in studies examining the propensity of 
beneficiaries switching plans due to premiums, it is important to study the benefits 
package as beneficiaries may be willing to remain in plans with higher premiums if their 
copayments are low relative to other plans. 
 
Berki’s risk perception hypothesis proposes that when purchasing health insurance, if 
other factors are held the same, decision makers will avoid plans that do not have services 
that they believe they will utilize.16 This more directly addresses the benefits package.  If 
a health care plan offers services that are absent from other plans, it is conceivable that 
beneficiaries will choose to enroll in this plan even though it may have higher costs.   
 
In addition, The Berki and Ashcraft Model acknowledges that the choice of consumers in 
deciding upon a health plan is influenced not only by the expected financial outlays and 
benefits, but also the context in which those services are delivered.16  The beneficiary’s 
personal attribute preferences are a set of preferences which describe how strongly the 
consumers feel about who, how, where, and in what setting the services are delivered.16 
The personal attribute preferences directly influence how consumers feel about the 
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delivery system characteristics of different plans.16  The delivery system characteristics 
are concerned with questions such as from what providers (e.g. physicians and/or 
hospitals) the beneficiary will be able to obtain coverage, and how many services will 
they be able to obtain in one setting.16  So, if it is important for a particular individual to 
retain their current physician, they may be willing to pay more for plans which allow 
them to do this. 
 
Feldman and colleagues conducted one of the first studies which examined the 
relationship between both benefits and premiums in the senior population.21  In their study 
of national 1989 data on Medicare Part C, they found that senior citizen’s had a price 
elasticity of -2, meaning that a one percent increase in price decreased the enrollment in a 
plan by two percent.21  They also attempted to study the effect of optional benefits on 
enrollee choice, but they concluded that offering extra benefits provided no incentive for 
beneficiaries to enroll in a plan.21  Later studies cited the crude measure of optional 
benefits as a possible detriment in evaluating the significance of optional benefits to the 
senior population.22  The next study conducted to evaluate senior citizen’s sensitivity to 
price and benefits in the Medicare Part C market was published in 2003.22  Dowd and 
colleagues found a much smaller price elasticity of -0.65 indicating that  a ten percent 
increase in price would lead to a decrease in enrollment of 6.5%.22  Moreover, they were 
able to demonstrate that the inclusion of certain benefits, including prescription drug 
coverage, were associated with higher enrollment in plans.22  Atherly and associates 
provided the first study of beneficiary choice of a Medicare Part C plan which used 
individual level national data.23  They found a price elasticity of -0.13 and also concluded 
that the inclusion of optional benefits was associated with greater enrollment.23  In 
addition, because they used individual level data, they attempted to study the impact of 
beneficiaries’ demographic characteristics on their choice of a Medicare Part C plan as 
opposed to traditional fee for service Medicare.23   
 
The importance of defining the demographic characteristics of the beneficiaries and 
evaluating how they influence the choice of health plans is intuitively an important 
subject.  Indeed, in their review of consumer health plan choice Scanlon and colleagues 
describe two broad groups of variables that should be included in health plan choice.18   
Primary variables deal with the health plan itself, and include features such as price, 
perceived quality of the plans, choice of provider, the benefits provided, and 
convenience.18  Secondary variables on the other hand are concerned with external 
variables which may influence plan choice such as the demographic characteristics of the 
consumer, the health status of the consumer, and the economic status of the person 
choosing a plan.18  The secondary variables impact how much weight a particular 
individual may place on a primary variable.18  At the time of their review, these authors 
concluded that there was insufficient evidence in regards to how secondary variables 
influence health plan choice, although there has been a movement towards more of these 
secondary variables being included in these studies.18  Knowing how secondary variables 
interact with primary variables would be of particular interest for those in the marketing 
field of healthcare plans, as this information would allow them to devise plans which 
would appeal to potential consumers based on the unique preferences which they have.   
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Evolution of Studies within Consumer Choice 
 
In the past marketing managers attempted to devise new health care plans on the basis of 
factors such as the opinions of what health care professionals felt should be included as 
coverage options.24  However, through the course of time companies designing insurance 
plans have attempted to prospectively gauge what types of plans would offer the greatest 
appeal to the consumers who would be purchasing the plans.  One example of how 
managed care companies have done this is through the use of decision support systems, 
where information regarding the use of consumer preferences and competitor offerings is 
gathered in order to make effective plans that will be successful when placed on the 
market.25  These practices have become more commonplace as competition has increased 
and more effort has been placed on being able to more fully comprehend consumer 
choice.14,16-18,26   More specifically, devisors of health care plans have come to recognize 
that when individuals have the option to choose among different plans, a model of choice 
behavior is helpful in studying consumer’s decision making process.  Models conforming 
to these principles assume that individuals will choose the health plan which offers them 
the highest level of utility according to their personal tastes and satisfaction.16   
 
The methodological approaches in the marketing area have evolved over time, 
particularly those involving primary data collection.28-31  Historical approaches that have 
been used include asking open ended questions28 or asking patients to evaluate plans on 
the basis of a single attribute such as the premium.29  However, these approaches have 
acknowledged limitations.  Asking consumers of health care plans to evaluate only one 
attribute at a time is limited because it is recognized that in actual situations, individuals 
consider multiple attributes of potential plans simultaneously when making purchasing 
decisions.32 Asking consumers open ended questions is limited also, as research shows 
that consumers self reported importance of health plan attributes is an inaccurate measure 
of the actual importance they place on different attributes.33   
 
 
Overview of Analysis 
 
A marketing research technique that aligns more strongly with the principles of models of 
choice behavior and bypasses these limitations is conjoint analysis. Conjoint analysis 
operates on the premise that consumers choose products or services on the basis of the 
combined value of the aggregate attributes which compose the product or service.34,35  So 
within conjoint analysis, products or services are composed of certain attributes which are 
further subdivided into different levels which carry a distinct value or part-worth for each 
person.35   Within health insurance, possible attributes include the premium, copayments, and 
types of services covered.  A level is a value that an attribute might take.35   For example, in the 
simple example depicted  in Table 1-1, levels for monthly premiums of  health insurance could 
hypothetically include $500, $750, or $1,000.   Each of the different levels carries a unique 
value or part-worth for each respondent.  The influence of a particular level depends on how 
important the attribute is to the respondent.  Some individuals may believe that the premium is 
the most important attribute and the hospital copayment could be least important, while the 
importance’s are reversed for someone else.  Ultimately, conjoint analysis is able to simulate  
the process which consumers use in choosing products in the actual marketplace where they 
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Table 1-1. Part worths for hypothetical study  
 
Attributes  Utility 
Premium  
     $500 0.45 
     $750 0.08 
     $1000 -0.24 
Physician copayment  
     $15 0.32 
     $25 0.11 
     $35 -0.12 
Hospital copayment  
     10% 0.66 
     20% 0.22 
     30% -0.31 
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consider all of the product features simultaneously and choose the product which maximizes 
their utility as a function of having the greatest combined part worth values.35   
 
In the terminology of conjoint analysis, an attribute is a feature that can vary from product to 
product or service to service.35   In the most popular forms of conjoint analysis used today, 
respondents are presented with a profile where at least two different products are depicted.35   
These profiles are called choice tasks.35  Each profile will have the same attributes, but the 
levels will vary from one profile to another.35   Respondents are then asked to choose which 
product they prefer.35  In this example, one product may have a premium of $500, a physician 
copayment of $15, and hospital copayments of 30%, whereas another product may have 
premium of $750 physician copayments of $25, and hospital copayments of 10%.   When 
using conjoint analysis, one can derive the part-worth values that the sampled population has 
for each level.35  In addition, when the sample size is large enough or advanced techniques are 
used, the part-worth values for each individual respondent may be estimated accurately.35   In 
such cases, it is possible to estimate the products that each individual person would purchase.35 
This allows one to avoid false assumptions that may occur when one looks at the sample as an 
aggregate sample and avoids some heterogeneous preferences that may occur.35   
 
Conjoint analysis has been used several times in order to analyze consumers decision 
making process in choosing health insurance as well as long term private insurance and 
dental insurance.36-42  These research studies have demonstrated several benefits of using 
conjoint analysis in evaluating consumer preferences in choosing health plans.  For 
example,  these studies have demonstrated that some of the most important attributes 
consumers consider when choosing health care plans include premiums, freedom in 
choosing physicians, copayments for physicians vists, copayments for medications,  
freedom in choosing hospitals, and inclusion or exclusion of vision and dental coverage 
and strongly prefer plans which have high maximum liability.36,37,39   
 
After finding out the most important attributes in plans and their relative importance, 
decision makers can make practical applications with this information.  They can devise 
health plans which have an ideal blend of attributes and levels by figuring out which 
combination of proposed levels would be more successful in the marketplace.36  For 
example, in the example shown in Table 1-1 a plan with a premium of $500, physician 
copayments of $15, and hospital copayments of 30% would have a utility of .46 after 
adding up the part-worths associated with each level.  Alternatively,  plans with 
premiums of $750, physician copayments of $25, and hospital copayments of 10% would  
have a utility of 0.85.  However, conjoint analysis can also allow one to adjust for 
heterogenous preferences within the population.35  Researchers can repeat the same 
procedure performed on the aggregate sample for each individual.  In the “first choice” 
rule, one assumes that each individual will purchase the specific plan offering them the 
greatest utility so that one can simulate the proportion of patients who would purchase a 
given product.35  Simulation procedures have been performed in several cases to simulate 
both current and hypothetical health plans performance in the market place.36,42   
Studies have shown that the data gathered from conjoint analysis studies is reliable in 
predicting the market share of different types of insurance plans which are currently on 
the market when used in simulations.36,42   Subgroup analysis on secondary variables can 
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also be performed so that differential preferences in between groups which are moderated 
by demographic variables may be analyzed.36,37,39  The data derived from these studies 
also can allow decision makers to identify which specific demographic groups place more 
importance on certain features, so that plans may be tailored to these individuals 
preferences to obtain a higher yield.  For example, elderly individuals have been shown 
to place more importance on freedom of choice with doctors and hospitals when 
compared to the younger population.37   
 
Consumer Choice in Prescription Drug Markets 
 
Although conjoint analysis has been applied successfully several times in evaluating 
health insurance plans, it has only been used twice in evaluating prescription drug 
plans.43,44  Although these studies helped to demonstrate the feasibility of using conjoint 
analysis to evaluate prescription drug  plans, neither of these studies evaluated the 
preferences for Medicare Part D prescription drug plans.  The relative lack of conjoint 
analysis studies in prescription drug plans alludes to the general scarcity of studies 
focusing on consumer choice in prescription drug plans.  
 
Frakt and Pizer published the only study to date where the main focus was determining 
benficiaries sensitivity to premiums in the Medicare prescription drug plan market.45  
They concluded that the premium elasticity in the prescription drug plan market of -1.45 
was greater in magnitude than that seen in the Medicare Advanatage market, for several 
reasons.45  Namely that seniors may have to sever relationships with their physicians in 
order to switch plans in the Medicare Advantage market, and patients may have 
established brand loyalty with a Medicare Advantage plan.45  There have been studies 
which have evaluated seniors whether seniors would enroll in a prescription drug plan or 
whether they would remain without coverage.46-48  However these studies do not provide 
information on what factors are most important in the decision of seniors to choose one 
plan over other selections.   
 
In addition, there have also been studies published before the actual implementation of 
Medicare Part D which examined the issues of whether seniors would be able to choose 
prescription drug plans which would minimize their expected cost.49,50  However these 
may not be applicable to the Medicare Part D plan as it stands in the market as these 
studies do not feature the coverage gap or tiered copayments as is the case in the actual 
Medicare Part D plans.  Heiss and colleagues study evaluated consumer’s choices of 
health care plans in the current Medicare Part D market.51  They found that senior citizens 
tended to choose plans with lower premiums when it might have actually been more 
favorable for them to select plans which had higher premiums, but offered more 
comprehensive benefits.51  Accordingly, senior citizens were not selecting plans which 
minimized their expected annual out of pocket costs, a measure of  “..the sum of all out-
of-pocket beneficiary expenditures that are expected to occur during the year.”52  
Abaluck and Gruber had similar conclusions, asserting that seniors tended to place to 
much value on premiums at the expense of other out of pocket cost components such as 
copayments on medications.  They were able to demonstrate that if each senior had 
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chosen the plan which minimized costs, senior’s expenditures in the program could have 
been nearly 30% lower.53   
 
It is apparent that  as a group, seniors tend to place more emphasis on premiums, even at 
the expense of greater overall cost sharing. However, it is not clear whether this 
generalization can be applied to the senior population as a whole, or whether there are 
heterogenous preferences within the population.  Indeed, in their qualitative study of 
important attributes that seniors consider when considering drug plans, Cline and Gupta 
identified three distinct groups.54  Within one of these groups, mail order pharmacy was 
one of the two most important factors in selecting a drug plan.54  This alludes to the 
premise that just as with health insurance plans, their may be secondary variables which 
moderate ones preferences for certain components of a prescription drug plan.18  
Furthermore,  the context in which the medical services are delivered, in this case 
prescription medicines, may also be important.16  The premise that these principles would 
be important is not surprising, as previous reviews on health plan choice indicate the 
importance of secondary variables as well as the significance of the setting in which 
services are delivered.16,18    
 
 
Statement of Problem 
 
To date there is a significant gap in the literature.  Although previous research has 
demonstrated the considerable benefits of studies utilizing conjoint analysis in the area of 
marketing research for health care plans,35-41 these techniques have not yet been 
employed in a comprehensive manner in prescription drug plans, specifically with regard 
to the Medicare Part D prescription drug plan.  Studies conducted in this area have the 
potential to yield valuable information, such as what specific attributes of the plans do 
consumers place the most value on, and also will allow market simulations in order to 
predict if newly developed plans will be successful.35  This will not only allow insurance 
companies to have valuable insight in developing new plans, but will also save them 
wasted resources in marketing new plans which may not be in agreement with the 
Medicare Part D population’s consumer preferences.  Moreover, prospectively devising 
plans which are in alignment with consumer preferences is more important than ever now 
that health care reform is a major political topic.55  Many of these changes will 
specifically affect the Medicare Part D prescription drug program.  For example, under 
recently passed legislation, the doughnut hole will be progressively reduced so that it is 
phased out by 2020.10   This will require insurance companies to make changes to their 
most popular Medicare Part D plans, as over 90% of patients in stand alone prescription 
drug programs are enrolled in plans which have little or no gap coverage.10   
 
In addition, more information is needed in regards to whether there are any 
heterogeneous preferences in the senior population for Medicare Part D drug plans.  
There may be some seniors who place emphasis on factors in prescription drug plans 
which do not deal solely with cost.  
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Conceptual Models 
 
The conceptual model for this study is a modified version of Cline and Mott’s Model for 
choosing a prescription drug plan,49 which is in turn derived from Berki and Ashcraft’s 
Model for choosing a health care plan.16  Although the model for this study is largely 
based upon Cline and Mott’s model for prescription drug plans, it is helpful to examine 
Berki’s and Ashcraft’s model of Health Care Plan Choice16 depicted in Figure 1-1 in 
order to gain greater understanding of the general theory underlying all of these models.   
 
 
Berki and Ashcraft’s Model of Health Care Plan Choice 
 
Berki and Ashcraft proposed that there are several factors which directly influence the 
amount of health care services an individual or family will use.16  These include 
economic characteristics which influence the amount of financial capital that the unit 
(either family or individual) will be able to apply towards health care services.16  Certain 
risk factors such as the number of people in the unit, their age, and general health are also 
expected to influence the amount of health care services utilized.16  Finally, the beliefs 
about the efficacy of medicine will also serve to influence utilization, as those people 
which have greater confidence in the effectiveness of medicine will utilize it more 
often.16  The expected utilization patterns in turn influence the financial loss hypothesis 
and risk perception hypothesis.16   
 
As explained before, the financial loss hypothesis essentially states that, if all other 
factors are held constant, individuals or families will attempt to choose plans that 
minimize their expected financial outlays based upon the amount of services they believe 
will be incurred.16  The risk perception hypothesis proposes that when purchasing health 
insurance, if other factors are held the same, decision makers will avoid plans that do not 
have services that they believe they will utilize.16 Taken together, the financial loss 
hypothesis and risk perception hypothesis influence the characteristics of the insurance 
plan chosen by consumers.16 
 
The insurance plan characteristics are a function of what services are available, and how 
much the beneficiary will have to pay for these services.16 Therefore, the insurance 
characteristics consist of the benefit package, and the premium price as well as out-of- 
pocket payments.16  The Berki and Ashcraft Model acknowledges that the choice of 
consumers in deciding upon a health plan is influenced not only by the expected financial 
outlays, but also the context in which those services are delivered.16  The beneficiary’s 
personal attribute preferences are a set of preferences which describe how strongly the 
consumers feel about who, how, where, and in what setting the services are delivered.16 
The personal attribute preferences directly influence how consumers feel about the 
delivery system characteristics of different plans.16  The delivery system characteristics 
are concerned with questions such as from what providers (e.g. physicians and/or 
hospitals) the beneficiary will be able to obtain coverage, and how many services will 
they be able to obtain in one setting.16  Finally, the Berki and Ashcraft model proposes 
that the insurance characteristics and the delivery system characteristics taken together 
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Figure 1-1.   Berki and Ashcraft Model of Health Plan Choice 
 
Modified with permission.  Berki SE, Ashcraft ML.  HMO enrollment:  who joins what  
and why:  a review of the literature.  The Milbank Memorial Fund Quarterly, Health and  
Society 1980;58(4):588-632.16  
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help consumers to decide on their choice of a health care plan.16   
 
 
Cline and Mott’s Model of Prescription Drug Plan Choice 
 
As stated previously, the proposed model for this research is actually a modified version 
of Cline and Mott’s Model of Prescription Drug Plan Choice,49 depicted in Figure 1-2.  
Although the Cline and Mott Model49 and the Berki and Ashcraft Model16 are very 
similar for the most part, there are a few substantive differences which are noted here.  
The most obvious difference between the two models is that the Cline and Mott model 
deals with  the choice of a prescription drug plan,49 whereas the Berki and Ashcraft 
Model was developed for choice of health care plans.16  From this, it naturally follows 
that the Cline and Mott model does not deal with expected utilization of health care 
services such as physician or hospital visits, but rather anticipated consumption of 
prescription medications.  Moreover, within the context of insurance characteristics, the 
benefit package in the Cline and Mott model is not concerned with the breadth of services 
covered, but rather the range of medicines which is covered by the beneficiary’s plan.49  
Therefore, Cline and Mott replace the “benefit package” in the Berki and Aschraft model 
with “control mechanisms.”  The control mechanisms are a measure of the amount of 
restrictions placed upon a beneficiary’s formulary.49   
 
These two models also differ with regards to how they describe the delivery of their 
respective goods.   Within the attribute preferences, the Berki and Aschcraft Model is 
concerned with aspects of the consumer’s preferences in regards to patient-physician 
relationships, choice of physician, the breadth of services that may be obtained in a 
setting, and the perceived quality.16  Because these factors are not relevant within the 
context of prescription drug plans, the Cline and Mott models is concerned with patient’s 
attribute preferences in relevant areas such as their relationship with their pharmacist, and 
their experience with formularies.49  Finally, whereas the Berki and Ashcraft model 
describes the delivery system characteristics of hospitals and physicians in terms of 
access, continuity, comprehensiveness, quality of care, and social quality,16 the Cline and 
Mott Model evaluates the delivery system characteristics of access and continuity with 
respect to pharmacists and pharmacies.49  Continuity in the Cline and Mott Model refers 
to whether one is able to continue their relationship with their current pharmacy.48   
 
 
Conceptual Model for Prescription Drug Plan Choice in Medicare Part D 
 
The proposed model for this study is depicted in Figure 1-3.  This model follows the 
Cline and Mott Model closely with two notable exceptions.  Within the benefit plan 
characteristics, the deductible and doughnut hole coverage have been added, as these are 
prominent features of the Medicare Part D prescription drug plans.2  Moreover, as seen in 
the attribute preferences and delivery system characteristics, this study will include a 
measure of the accessibility for comprehensive pharmaceutical care available to the 
patient.   This is accomplished by including the restrictiveness of eligibility requirements 
for Medication Therapy Management Services (MTM) as an attribute.  This is a set of 
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Figure 1-2.   Conceptual model of prescription drug plan choice 
 
Modified with permission.  Cline RR, Mott DA. Demand for a Medicare prescription  
drug benefit: exploring consumer preferences under a managed competition framework.  
Inquiry 2003;40(2):169-183.49  
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Figure 1-3.        Conceptual model for prescription drug plan choice in dissertation 
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services with the goals of providing education, improving adherence, or detecting adverse 
drug events in the Medicare population and legislation concerning the provision of these 
services was also a part of the Medicare Modernization and Improvement Act of 2003.56 
These services can be provided by a pharmacist on site at a pharmacy, or alternatively 
they may be provided over the phone.56  As will be discussed later, insurance 
organizations have a considerable degree of latitude in determining patient’s eligibility 
for MTM services.56  
 
 
Specific Aims and Hypotheses 
 
The specific aims and hypotheses for this study are presented as follows: 
 
Specific Aim 1:   The first specific aim is to determine which drug benefit plan 
characteristics exert a significant influence on senior citizens preferences in choosing a 
Medicare Part D Prescription Drug Plan. 
 
 Hypothesis 1:   The premium price will be a significant attribute in determining 
consumer’s preferences when deciding on a Medicare Part D plan whereby higher 
premiums will be associated with a lower probability in a plan being selected, all 
else being equal. 
 
 Hypothesis 2:  The copayment amount will be a significant attribute in 
determining consumer’s preferences when deciding on a Medicare Part D plan 
whereby higher copayments will be associated with a lower probability in a plan 
being selected, all else being equal. 
 
 Hypothesis 3:  The deductible amount will be a significant attribute in 
determining consumer’s preferences when deciding on a Medicare Part D plan 
whereby higher deductibles will be associated with a lower probability in a plan 
being selected, all else being equal. 
 
 Hypothesis 4:  The amount of coverage in the doughnut hole will be a significant 
attribute in determining consumer’s preferences when deciding on a Medicare 
Part D plan, whereby seniors will be willing to pay more for plans which offer 
doughnut hole coverage, all else being equal. 
 
 Hypothesis 5:  The control mechanisms (formulary restrictiveness) will be a 
significant attribute in determining consumer’s preferences when deciding on a 
Medicare Part D plan, whereby more restrictive formularies will be associated 
with a lower probability in a plan being selected, all else being equal. 
 
Specific Aim 2:   The second specific aim is to determine which delivery system 
characteristics will exert a significant influence on senior citizens preferences in choosing 
a Medicare Part D prescription Drug Plan. 
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 Hypothesis 6:  The amount of access to pharmacy services will be a significant 
attribute in determining consumer’s preferences when deciding on a Medicare 
Part D plan, whereby more restricted pharmacy access will be associated with a 
lower probability in a plan being selected, all else being equal. 
 
 Hypothesis 7:  The restrictiveness of eligibility requirements in obtaining 
Medication Therapy Management Services will be a significant attribute in 
determining consumer’s preferences when deciding on a Medicare Part D plan, 
whereby more restricted eligibility requirements will be associated with a lower  
associated with a lower probability in a plan being selected, all else being equal.  
 
Specific Aim 3:  The third specific aim is to determine which of the demographic 
characteristics in the conceptual model for this study exert a significant effect on senior 
citizens preferences in choosing a Medicare Part D Prescription Drug Plan. 
 
 Hypothesis 8:  Individuals with higher incomes will be willing to pay higher 
premiums for prescription drug insurance in the Medicare Part D Prescription 
Drug Plan.   
 
 Hypothesis 9:  Older individuals will be willing to pay higher premiums for 
prescription drug insurance in the Medicare Part D Prescription Drug Plan. 
 
Specific Aim 4:  The fourth specific aim is to determine which of the explanatory 
variables in the conceptual model for this study exert a significant effect on senior 
citizens preferences in choosing a Medicare Part D Prescription Drug Plan.   
 
 Hypothesis 10:  Individuals with a greater number of chronic conditions will be 
willing to pay higher premiums for prescription drug insurance in the Medicare 
Part D Prescription Drug Plan. 
 
 Hypothesis 11:  Individuals taking a higher number of prescription medications 
will be willing to pay higher premiums for prescription drug insurance in the 
Medicare Part D Prescription Drug Plan. 
 
 Hypothesis 12:  Individuals with a stronger preference for Medical Care will be 
willing to pay higher premiums for prescription drug insurance in the Medicare 
Part D Prescription Drug Plan. 
 
 Hypothesis 13:  Individuals with a stronger relationship with their pharmacist will 
place greater importance on being able to have Medicare Part D Prescription Drug 
Plans with less stringent restrictions placed on being eligible for Medication 
Therapy Management Services. 
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Definition of Terms  
 
The following is a list of terms utilized throughout this study: 
 
 Attribute:  A characteristic of a product or service such as price or speed.  Every 
attribute must have at least two levels when used in the context of conjoint 
analysis.35  
 
 Adaptive Choice-Based Conjoint Analysis:  Also known as ACBC.  As one of the 
newest techniques used in conducting conjoint analysis studies, ACBC is 
available exclusively through Sawtooth Software (Sequim, WA).  With ACBC, 
purchase intentions at the individual level can be determined.35  
 
 Coinsurance:  A designated percentage of the health care costs which an insured 
individual is responsible for paying after meeting a deductible.57,58  
 
 Conjoint Analysis:  A quantitative technique with origins in marketing research 
designed to elicit consumer preferences for products or services.  In contrast to 
many other marketing techniques, conjoint analysis asks respondents to choose 
products by making tradeoffs simultaneously among the varying levels of 
characteristics (attributes) presented to them.35  
 
 Copayment:  A flat dollar copayment which designates the amount of health care 
expenses an insured party is responsible for paying after meeting a deductible.57,58   
 
 Creditable Coverage:  Insurance coverage which is at least as good as or 
actuarially superior to prescription drug coverage offered under Medicare Part D.  
Seniors citizens who do not have creditable coverage and fail to enroll in 
Medicare Part D are assessed a penalty of 1% of the Part D national base 
Beneficiary Premium for each month they delay enrollment.  This was 32 cents 
for each month in 2010.10,58  
 
 Deductible:  The amount of health care related expenses that must be incurred by 
the beneficiary or any covered parties before the insurer assumes coverage for 
medical services, products, and/or care provided to the insured party. This amount 
could be up to $310 for Medicare Part D prescription drug plans in 2010.57,58 
 
 Doughnut Hole:  A feature of many Medicare Part D plans wherein the 
beneficiary is responsible for 100% of the coinsurance of their prescription drugs 
after obtaining a certain amount of prescription drugs.  In 2010, coverage gap 
began at $2,830 in total drug costs and ended once there was $6,440 in total drug 
costs.10,58   
 
 Estimated Annual Cost:  Also known as EAC.  A measure of all estimated out of 
pocket expenses related to prescription drugs for a Medicare beneficiary in a year.  
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This includes premiums, copayments, coinsurance, deductibles, and costs for 
medications which are not included in a Part D formulary.52 
 
 Formulary:  An updated list of medications that is covered by an insurance plan.  
A closed or restrictive formulary generally covers fewer medications than an open 
formulary.57   
 
 Importance Score:  In conjoint analysis, a measure used to denote the relative 
significance of a given attribute in relation to other attributes in helping to 
determine the choice of the products or services being considered.35  
 
 Medicare Advantage:  Sometimes designated as Medicare Part C.  An optional 
program whereby seniors may obtain coverage for medical expenses through 
private companies which contract with Medicare.  Most often, these are managed 
care organizations which also confer coverage of prescription medications as part 
of the plan.15,58 
 
 Medicare Part D:  An optional program in Medicare which subsidizes the cost of 
outpatient prescription drugs for beneficiaries who choose to enroll.  It was 
established with the passage of the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003, and instituted on January 01, 2006.10,58    
 
 Medication Therapy Management Services:  Also known as MTM.  This is a set 
of services delivered by health care professionals with the goals of providing 
education, improving adherence, or detecting adverse drug events for medications 
in the Medicare population.56  
 
 Premium:  A designated amount of money which an insured party pays to an 
insurer in exchange for coverage of designated medical expenses.57,58  
 
 Prescription Drug Plan:  Also known as a PDP.  Within Medicare, a private health 
plan which contracts with Medicare solely for the purpose of providing coverage 
for prescription drugs.10,58 
 
 Prior Authorization:  A utilization management tool or control mechanism used 
by PDPs to control seniors use of prescription medications by requiring the 
prescriber of a medication to provide documentation to show why a particular 
medication is medically necessary for a patient.58  
 
 Quantity Limit:  A utilization management tool or control mechanism used by 
PDPs to control seniors use of prescription medications by specifying a limit on 
how much medication can be obtained at one time.58  
 
 Step Therapy:  A utilization management tool or control mechanism used by 
PDPs to control seniors use of prescription medications by stipulating seniors try 
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to use similar, lower cost medications before they use more expensive prescribed 
medications.58  
 
 Utility:  An economic term for the measurement of an individual’s overall 
preference for a certain state, product, or service.  Utility measures a respondent’s 
overall preferences for a product, while the part-worths are used to designate an 
individual’s preferences for separate levels composing the product.35 
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CHAPTER 2.    LITERATURE REVIEW 
 
 
Introduction 
 
The goal of this study is to determine the relative importance of different attributes and 
secondary characteristics in senior citizen’s choice of prescription drug plans as guided 
by a proposed model of prescription drug plan choice in Medicare Part D.  This chapter 
provides a review of literature pertinent to the study of consumer choice in Medicare Part 
D prescription drug plans.  The chapter is divided into two broad sections.  The first 
section provides a synopsis of specific studies relevant to consumer choice in prescription 
drug plans, while the second section evaluates the literature in the context of the variables 
featured in the proposed model of prescription drug plan choice in Medicare Part D.     
 
 
Overview of Studies on Prescription Drug Plan Choice 
 
This section provides a concise overview of specific studies which have examined 
consumer choice within the context of prescription drug plans.  This section is not only 
valuable in helping to show the benefit of conducting research on prescription drug plan 
choice, but it also helps to demonstrate which areas need further study.   
 
 
Prescription Drug Plan Choice in Seniors before Medicare Part D 
 
Cline and Mott conducted a study which asked seniors to choose from among 4 
hypothetical plans which varied with regard to the formulary, required use of a mail order 
pharmacy, the copayment amounts, and the monthly premiums.49  A sample of 1,194 
seniors in Wisconsin was surveyed.49  Characteristics which were associated with 
enrollment into a more comprehensive plan featuring higher premiums were a college 
education, a higher number of medical conditions, greater drug expenditures, poor health 
status, higher income and previous exposure to formulary provisions.49  Higher premiums 
and higher projected out of pocket costs were associated with a lower probability of a 
given prescription drug plan being selected.49  Individuals who reported using a mail 
order pharmacy seemed to be more comfortable with plans featuring mail order, however 
seniors who placed a strong preference on their relationship with their pharmacist tended 
to stay away from plans which featured mail order.49  This research suggests that benefit 
plan characteristics, delivery system characteristics, and some secondary characteristics 
may be important in determining choice of a prescription drug plan.49  However, this 
study  obviously has limited applicability to the Medicare Part D landscape as it lacks 
relevant features such as the doughnut hole, deductibles, and tiered cost sharing which 
are a prominent part of the Medicare Part D plans being offered.49 
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Conjoint Analysis in Prescription Drug Plan Choice 
 
The first study to utilize conjoint analysis in assessing consumer preferences for 
prescription drug programs was published by Holdford and Carroll in 2002.43  In 
evaluating a convenience sample of 130 individuals, the researchers attempted to measure 
the tradeoffs that consumers of prescription drug plans make in regards to three different 
areas:  copayments on medications, restrictiveness in the formulary, and restrictiveness in 
the choice of pharmacy.43  Three levels were used in the access to pharmacy attribute:  
able to use any pharmacy, having a restricted network of pharmacies while having the 
usual pharmacy included, and having a restricted network of pharmacies in which the 
patient’s usual pharmacy is not included.43  Within the cost-sharing attribute, there were 
also three levels specified:  no copayment, $8 for each prescription, or $15 for each 
prescription.43  The final attribute related to formulary provisions.  The first level within 
the formulary provisions stated that the plan would cover any medication without 
restrictions, while the second level stipulated that the plan would not cover brand 
medications if generics were available.43  The final level within the formulary provisions 
stated that the plan would only cover a limited number of drugs on the formulary, and the 
patient would have to pay full cost for drugs other than these.43   
The importance scores for formulary provisions (42%) were highest among the 
respondents, followed by copayment levels (32%) and pharmacy access (26%).43  A 
market segmentation analysis demonstrated that the respondents could be divided into 
four major categories based upon what attributes determined their preference of drug 
coverage.43  The largest group of respondents (44%) based their preferences primarily on 
formulary provisions, 23% based their decisions primarily on copayments, 23% based 
their preferences on a mixture of these attributes, and 10% based their decisions primarily 
on pharmacy access.43   
 
While this study demonstrates the feasibility of using conjoint analysis to assess attributes 
within prescription drug programs, the applicability of these results to Medicare Part D 
PDPs is limited.  Less than 6% of the respondents were over 65 years old.43  Furthermore, 
the plans described within this study lack features intrinsic to Medicare Part D such as 
premiums, the doughnut hole, and deductibles.43  However, the study does allude to the 
possibility that features other than limiting the out of pocket cost may help to determine 
one’s choice of a prescription drug plan.  For example, the difference in utility between 
no copayments and $8 copayments (0.218) was much smaller than the change in utility 
(1.09) when going from mandatory generics to having a restricted drug list.43  One may 
be tempted to conclude that there may be a portion of the market, particularly those 
which base their choice of a prescription drug plan primarily on the formulary provisions, 
which may be willing to trade off higher estimated annual costs for an open formulary.43  
However that conclusion cannot be drawn from this study, as this study does not include 
premiums or deductibles.43    
 
Wellman and Vidican published the most comprehensive study to date using conjoint 
analysis in the analysis of prescription drug plans.44  They obtained a sample of 143 
respondents from a mailing list.44  After consulting previous literature in the area of 
beneficiaries choice of prescriptions drug plans, they decided to use four attributes:  
23 
 
copayments (coinsurance), pharmacy access, formulary provisions, and premiums.44  In 
addition they attempted to study the importance which beneficiaries placed on interaction 
with their pharmacist.44  The levels for formulary in this study were similar to that used 
by Holdford and Carroll, and the pharmacy access variable was nearly identical with the 
exception of an additional level that stated beneficiaries must use a mail order 
pharmacy.44  Six levels were used for the copayment/coinsurance attribute: $2, $10, $20, 
$30, 10% or 25% for each medications.44  The premiums used were no premiums, $10 
per month, $25 per month, $100 per month, or $200 per month.44  The pharmacy 
interaction attribute featured three levels:  the pharmacist does not discuss the 
medications with beneficiaries, the pharmacist reviews the medications at the time of 
dispensing, and the pharmacist conducts comprehensive mediation reviews on a regular 
basis.44  It is important to note that the pharmacy interaction attribute was included as a 
measure of how much consumers would value the inclusion of coverage for medication 
therapy management services.44 
 
The importance scores were highest for monthly premium (37%), followed by copayment 
levels (25%), pharmacy access (16%), formulary control (14%) and interaction with the 
pharmacist (8%).44  Particularly strong preferences were shown for $2.00 copayments, 
being able to retain use of the current pharmacy, having all drugs covered even if generic 
medications were used, the ability to have a pharmacist regularly conduct comprehensive 
medication reviews, and premiums below $10 per month.44  In addition the authors 
performed market simulations which demonstrated that covering medication therapy 
management services could lead to a modest increase in the market share for a 
participating plan, while excluding one from their current pharmacy or telling them to use 
mail-order pharmacy would result in marked decreases in market share.44    
 
Several important points can be gleaned from examining the studies on prescription drug 
plan choice which utilize conjoint analysis.  This research as a whole substantiates the 
significance of using copayments, pharmacy access, and formulary control as attributes in 
studies involving conjoint analysis.43,44  In addition, the Wellman and Vidican study helps 
to establish the significance of using premiums as an attribute when studying prescription 
drug plans using conjoint analysis.44  Furthermore, this research alludes to the importance 
of including mail order pharmacy and contact with pharmacist in studies which examine 
prescription drug plans.43,44  However, the results of these studies are not entirely 
generalizable to the Medicare Part D population as the general adult population was 
surveyed, and they do not include deductibles, the presence of the doughnut hole, or    
tiered copayments.44   
 
 
Prescription Drug Plan Choice in Medicare Part D 
 
Frakt and Pizer’s analysis of prescription drug plan choice was published in 2010.45  
Their study analyzed data from all Medicare Beneficiaries in 2007 after excluding those 
with creditable coverage, those enrolled in Medicare Advantage plans, and those enrolled 
in low income subsidy plans.45  Their data sources were all publicly available files from 
CMS and included the PDP landscape source file, the annual enrollment by plan file, and 
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the prescription drug formulary and pharmacy network file.45  In focusing exclusively on 
the Medicare PDP market, their two-stage least squares regression model was designed to 
model the probability of a particular Medicare Part D plan being chosen.45  Several 
covariates were included such as the premium amount, the deductible amount, the 
minimum preferred copay, the maximum preferred copayment, the presence of generic 
gap coverage, the presence of brand name gap coverage, the number of formulary plans, 
and a designation of whether a plan was actuarially equivalent to a plan with standard 
benefits.45  The authors demonstrated a premium elasticity of -1.45.45  Variables which 
were inversely associated with choice of prescription drug plans included higher 
deductibles, greater minimum preferred copays, and an increased number of formulary 
tiers.45  Factors which were positively associated with the probability of a prescription 
drug plan being chosen were a higher maximum preferred copayment, coverage for brand 
name medications in the coverage gap, and the plan being actuarially equivalent to the 
standard plan.45  Coverage for generic medications in the doughnut hole was not 
significantly associated with a plan being selected.45  Many of these findings are intuitive 
such as lower premiums, deductibles, and minimum copayments being associated with 
higher enrollment as these would lead to lower out of pocket costs.  However the finding 
that basic benefits would be associated with greater probability of a plan being selected is 
puzzling, as plans have the option of offering superior enhanced coverage.  However, the 
authors speculate that this may be due to these plans having lower cost.45  The authors 
conclude that their premium elasticity is greater than that seen in the Medicare 
Advanatage Market primarily due to three reasons:   
 
1. Medicare HMOs have a higher cost to enter the market because they need to 
establish a network of providers.45 
    
2. In 2007, beneficiares did not have enough time to establish loyalty to a particular 
PDP, in contrast to the Medicare HMO market where beneficiaries had several 
years to establish loyalty to a particular company.45  
 
3. Beneficiaries could choose a PDP without having to worry about breaking their 
relationship with their primary care physician.45 
 
Heiss and colleagues used data collected from the 2005-2007 waves of the Retirement 
Perspectives Survey to analyze seniors perceptions and choices of Medicare Part D 
plans.51  The Retirement Perspectives Survey is conducted by the researchers and surveys 
a random group of seniors chosen to be a  representative sample of the non-
institutionalized U.S. population.51  In order to construct measures on the respondents 
projected and actual out of pocket medication costs, the researchers utilized the Medicare 
Current Beneficiary Survey along with median retail prices of drugs obtained from 
internet sites.51  They concluded that the senior’s amount of drug expenditures in 2005 
was a very good predictor of determining which seniors without credible coverage would 
enroll in Medicare Part D plans and that most of the seniors who would benefit from 
enrollment in a Medicare Part D plan had in fact enrolled.51  When choosing between 
different plans, seniors tended to choose ones with lower premiums, even if the actuarial 
value was less than another plan which may have been more comprehensive and actually 
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resulted in lower EAC.51  The authors also explored beneficiaries willingness to pay for 
various plan features such as doughnut hole coverage and no deductibles.51  Seniors were 
willing to pay significantly more to have plans with no deductible and doughnut hole 
coverage for brand name drugs when holding other features constant.51  The use of drug 
tiers and restrictive formularies were associated with lower prices with which 
beneficiaries were willing to pay for plans.51  This may be the most comprehensive study 
as of yet to look at seniors choice of prescription drugs, but like the Frakt and Pizer study, 
it ignores the potential impact of delivery system characteristics on prescription drug plan 
choice.45,51   
 
Abaluck and Gruber used secondary data obtained from the prescription drug records of    
the Wolters Kluwer company which processes approximately 31% of all third party 
prescription claims in the United States.53  The researchers had access to 2005 and 2006 
data.53  Variables which were associated with a lower probability of a prescription drug 
plan being chosen were higher premiums, the total out of pocket costs incurred with a 
plan, and higher deductibles.53   Any type of doughnut hole coverage, a higher proportion 
of drug costs covered, and a greater number of drugs included on the formulary were 
associated with a greater probability of a plan being selected.53  The authors concluded 
that premiums were far more important than other cost sharing characteristics in helping 
to determine seniors choice of a prescription drug plan, and seniors also had little 
appreciation for plans which would minimize their variability in spending.53  According 
to their analysis, if seniors had done an optimal job of selecting plans which minimized 
their expected annual cost, then they could have saved approximately 27% in annual drug 
expenditures.53   This paper contributes to the literature regarding the relationship of drug 
benefit plan characteristics to prescription drug plan choice, but it contributes little in 
regards to understanding the influence of delivery system characteristics and the 
influence of secondary variables.53   
 
In summary, the research on choice of PDPs in the Medicare Part D population has shed 
variable information on the importance of benefit plan characteristics in determining the 
choice of prescription drug plans.  However, much is left to be desired in the way of 
information regarding delivery system characteristics and how secondary variables may 
interact with primary variables in helping to determine prescription drug plan choice. 
 
 
Conceptual Model Variables in the Literature 
 
The second section evaluates the literature in the context of the variables featured in the 
proposed model of prescription drug plan choice in Medicare Part D.   This section helps 
to provide guidance on how these variables fit into the context of Medicare Part D as well 
as give guidance on how these variables may affect choice of Medicare PDPs.   
 
 
Premiums 
In 2006, the national weighted average for PDP premiums was approximately $26 per 
month.59  In 2009, this figure had increased to $35 per month, and it was projected to be 
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approximately $39 per month in 2010.59  There is considerable variation in the range of 
premiums offered to beneficiaries.  For example, in the Shelby county area of Tennessee, 
the range of premiums offered was $22-$100.70 during 2010, while the national range in 
premiums during 2011 was $14.80-$133.40.58,59  The premiums are normally set so that 
they cover 25.5% of the average expenditures in PDPs, while the government subsidizes 
the remaining 74.5%.60  However with the passage of the Patient Protection and 
Affordable Care Act of 2010, individual seniors making above $85,000 annually or 
couples making over $170,000 annually will be required to pay higher copayments.60  
Depending upon their income, these seniors will now have to pay 35%-85% of the total 
cost of their prescription drug program.60  Whereas the average premium offered for Part 
D plans was $32.34 in 2011 for most beneficiaries, the premiums offered to high income 
seniors ranged between $44.34-$101.44 in 2011.60  This law will affect over 4 million 
seniors by 2019, as approximately 11% of all newly eligible beneficiaries will be affected 
by this law in upcoming years.60 
Several studies have demonstrated the significance of premium as a factor in determining 
the choice of a prescription drug plan.  Cline’s study showed that higher premiums were 
inversely associated with the choice of a prescription drug plan in his study of senior’s 
choices among hypothetical drug plans.49  In their secondary analysis of consumer’s 
selection of Medicare Part D plans, Abaluck and Gruber demonstrated that a $100 
increase in the annual premiums of a plan would lead to a 50% reduction in the 
probability that a particular Medicare PDP would be chosen, corresponding to a an 
elasticity of -1.17.53  Frakt and Pizer found a premium elasticity of -1.45 in PDPs when 
using secondary data analysis of 2006 Medicare Part D plans.45  Finally, Wellman and 
Vidican concluded that premiums were the single most important attribute in prescription 
drug plans from their study which utilized conjoint analysis on the general population.44 
 
 
Doughnut Hole Coverage 
 
Much of the range in premiums is due to gap coverage or other enhanced benefits.11,12  In 
2010, the average national premium for a PDP which was actuarially equivalent to the 
standard benefit was $36.70, but for plans with any type of doughnut hole coverage this 
figure was nearly $79.12  Over 80% of the plans offered to beneficiaries have little or no 
gap coverage so that 94% of beneficiaries were enrolled in plans without gap coverage in 
2010.12  This is a decrease from that seen during the initial implementation of Medicare 
Part D as nearly 10% of patients were enrolled in plans with gap coverage during both 
2006 and 2007.61  The overwhelming majority of plans offer coverage for only generic 
medications during the coverage gap; in 2010 every state but Wisconsin had only one 
PDP which covered brand name prescription medications, and this one covered less than 
10% of brand medications.61  Before 2009, more plans were offering coverage for both 
generic and brand medications in the coverage gap as in 2006, nearly 5% of beneficiaries 
were enrolled in plans which offered gap coverage for brand and generic medications,61  
yet adverse selection has led to fewer and fewer of these plans being offered.12   
 
Even though only a small number of beneficiaries enroll in Medicare Part D plans with  
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gap coverage, this feature has been the subject of great controversy and a large amount of 
research.62-73  In general, approximately 6%-16% of those using Medicare Part D reach 
the coverage gap, but this percentage is higher for those with chronic conditions.68,71,73  
Approximately a quarter of individuals with diabetes and nearly 40% of individuals with 
dementia enter the coverage gap.68  During the coverage gap, seniors entering the 
coverage gap experience a 9%-16% decrease in their drug usage, while their medication 
costs increase up to 89% during this period.62  It is not surprising that these pressures may 
lead to acute health care exacerbations as seniors who enter the coverage gap are 60% 
more likely to utilize emergency room services.73  Moreover, seniors who enter the 
coverage gap may often sacrifice food or rent money in order to be able to purchase 
medications.67,72  For many Medicare beneficiaries, having plans which offer coverage 
for only generic medications in the coverage gap offers no appreciable benefit.  Diabetic 
patients entering the coverage gap with coverage for only generic medications are no 
more likely to be compliant to their medications when compared to patients with no 
doughnut hole coverage.66,69  In addition, seniors with coverage for only generic 
medications are just as likely as those with no gap coverage to have to split pills, skip 
days of medication, stop taking it altogether, or use over the counter medications instead 
of their prescription medications.67 
 
The doughnut hole has also been targeted for healthcare reform under The Patient 
Protection and Affordable Care Act of 2010.74,75  In 2010, seniors reaching the doughnut 
hole were given a $250 rebate.74  The doughnut hole will be effectively phased out by 
2020 so that seniors have 25% coinsurance after meeting any deductibles until they reach 
catastrophic coverage.74  This will be accomplished in different ways for brand drugs and 
generics drugs.74  Beginning in 2011, Medicare began subsidizing 7% of the cost of 
generic medications in the coverage gap, and will assume progressively greater cost 
sharing so that by 2020 it will subsidize 75% of the cost of generic medications in this 
period.74  Under the Patient Protection and Affordable Care Act, drug manufacturers will 
be required to provide a 50% discount on the cost of brand name medications when 
seniors reach the coverage gap.74  Medicare will began subsidizing 2.5% of the cost of 
brand name medications in this period during 2013, and will assume progressively 
greater cost sharing so that by 2020 it will subsidize 25% of the cost so that seniors will 
be responsible for 25% of the cost.74,75   
 
There has been a scarce amount of studies conducted on prescription drug plan choice 
which include the doughnut hole and none which use conjoint analysis.  In their 2010 
data, using secondary data analysis, Frakt and Pizer found that there was no association 
between doughnut hole coverage for generic medications and the probability of enrolling 
in a prescription drug plan when all other factors were held constant.45  However, plans 
which had coverage for brand name drugs in the doughnut hole were more likely to be 
selected when holding all other factors constant.45  Abaluck and Gruber’s study of a 
national Medicare sample concluded that after controlling for other cost related expenses, 
seniors would be willing to pay $50 annually to have generics covered in the donut hole 
and $300 annually to have brands covered in the donut hole.53  The study of Heiss et al.  
indicated that seniors were willing to pay approximately $2.72 per month to have gap a  
coverage for generics and $20.25 per month to have gap coverage for brand name 
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medications.51    
 
The research conducted by Abaluck and Gruber and Heiss et al. may help to explain why 
Frakt and Pizer found no association between generic doughnut hole coverage and why 
coverage for brand drugs during the doughnut hole is associated with a greater 
probability of plans being selected, as all of these studies evaluate Medicare Part D plans 
as they appear in the marketplace.45,51,53  In every year between 2006-2008 plans offering 
doughnut hole coverage had premiums which were at least $11 higher on average per 
month than plans with no gap coverage.51  This is higher than the price that seniors in 
general are willing to pay for generic doughnut hole coverage as demonstrated by the 
studies of Abaluck and Gruber52 and Heiss et al.51  Conversely, plans with doughnut hole 
coverage for generic and brand name drugs had premiums which were at least $16 higher 
on average per month than plans with no gap coverage.51  This is within the willingness 
to pay thresholds cited by Abaluck and Gruber53 and Heiss et al.51  This also helps 
explain why so few seniors are currently enrolled in plans with gap coverage, because the 
majority of them only provide coverage for generic medications. 
 
 
Deductibles 
 
The number of Medicare PDPs with a deductible has increased in recent years.  Less than 
half of PDPs featured a deductible each year from 2006-2009.55  However in 2010, 60% 
of plans featured a deductible with, 36% of plans featuring the maximum allowed 
deductible of $310, and 24% of plans featuring a deductible beneath this amount.11  Plans 
with no deductible or reduced deductibles tend to have higher premiums than plans with 
the standard deductible.11  One study indicated that the premiums for plans which were 
actuarially equivalent to the standard benefit were $30.75, $27.70, and $28.41 
respectively in 2006-2008 while plans without gap coverage and no or reduced 
deductibles offered premiums of $37.92, $31.93 and $33.12 during the same years.51  No 
or reduced deductible plans are very attractive to seniors.  One study found that in 2006 
and 2007, more than half of half of seniors were enrolled in plans with no or reduced 
deductibles and gap coverage.51   
 
There is a sparse amount of literature regarding deductibles and prescription drug plan 
choice.  As expected, Frakt and Pizer demonstrated that the amount of the deductible in 
Medicare PDPs was inversely associated with prescription drug plan choice.45  Abaluck 
and Gruber demonstrated that seniors would be willing to pay approximately $8 more per 
month for plans which had no deductible as opposed to the standard $250 deductible 
offered in 2006.53   In another study, Heiss and colleagues found that seniors were willing 
to pay just over $14 more per month in 2006 and 2007 to have no deductible in lieu of the 
$265 and $275 standard deductibles offered during this time frame.51  These studies are 
consistent in demonstrating that seniors are willing to pay some amount of money in 
order to avoid deductibles, although it may vary. 
 
 
 
29 
 
Copayments 
 
There is great variability in the copayment structure of Medicare Part D plans.  One 
distinct feature is that most plans do not use the 25% coinsurance as proposed under the 
standard benefit.  Instead most plans (89%) used some type of tiered structure in 2010 
with the most popular being one generic tier and 2 tiers for brand name medications.  In 
2010 median copayments were $7, $42, and $76 for generic, preferred brand, and non-
preferred brand medications respectively.11  By offering copayments which are less than 
the 25% coinsurance under the standard benefit, plans may offer enhanced coverage 
which is actuarially superior to the standard benefit, even in the absence of reduced 
deductibles or gap coverage.  In general, seniors in Medicare Part D plans have higher 
copayments than retirees with employer sponsored insurance, but this is not associated 
with a lower quantity of medication use in the Medicare Part D population, instead 
seniors with coverage through Medicare Part D tend to use generic drugs more frequently 
than their counterparts with employer sponsored insurance.76 
 
Copayments have been discussed frequently in the literature regarding prescription drug 
plan choice.  Cline and Mott found that the expected out-of-pocket costs were inversely 
associated with the probability of a prescription drug plan being selected by seniors in a 
survey of hypothetical drug plans administered to seniors before the implementation of 
Medicare Part D, although their measure for copays was simplistic as it included only $5 
and $10 copayments.49  Seniors were less sensitive to out of pocket costs than they were 
to premiums however.49  Holdford and Carroll’s conjoint analysis study elicited the 
preferences for the general adult population in regards to copayments of $0, $8, or $15.43  
They found that consumers preferred lower copayments, and the copayment attribute had 
an importance of 32% when considered alongside formulary provisions and pharmacy 
access.43  In their conjoint analysis study of the general population, Wellman and  
Vidican used copays or coinsurance rates of $2, $10, $20, $30, 10% or 25%.44  They 
found that copayments carried a 25% importance rating in the context of other attributes 
such as premiums, pharmacy access, formulary control, and interaction with the 
pharmacist with premiums being the most important attriubute.44  Frakt and Pizer 
demonstrated that lower minimum preferred copays were associated with a greater 
probability of a plan being selected while higher maximum preferred copays were 
associated with a lower probability of a plan being selected in the secondary data analysis 
of a national sample of Medicare Part D plans.45  Alabuck and Gruber indicated that 
seniors are willing to pay approximately $80 annually to go from a plan with 65% cost 
sharing to one with 25% cost sharing.53   
 
 
Control Mechanisms 
 
A considerable amount of latitude is given in regards to the number of drugs which must 
be included in a PDP’s formulary under Medicare.  Regulations stipulate that at least two 
medications must be covered within each therapeutic class.77  However there are six 
therapeutic classes where essentially all medications must be covered:  antidepressants, 
antipsychotics, anticonvulsants, oncology agents, immunosuppressants, and  medications 
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used in the treatment of HIV/AIDS.77  All plans at a minimum cover these medications, 
but there are some plans which cover essentially all Medicare approved medications 
without restrictions, while other plans cover as few as 62% of all approved medications.55  
On average, PDPs cover approximately 87% of all mediations approved for use by 
Medicare.55  
 
Covered medications may be subject to some type of utilization management which serve 
as control mechanisms for medication use.  The three primary types of utilization 
management tools are prior authorization, quantity limits, and step therapy.58  Nearly 
30% of covered medications operated under some type of control mechanism in 2010, 
with the most common tool being quantity limits (16% of medications), followed by prior 
authorization (15% of medications) and step therapy (3% of medications).55   
 
Formulary management has been evaluated in the context of it’s effect on prescription 
drug plan choice.  In their conjoint analysis of the general population, Holdford and 
Carroll concluded that the restrictiveness of the formulary was the most important 
attribute in determining prescription drug plan choice when considered along with 
copayment amounts and pharmacy access.43  They found a stronger preference for more 
open formularies.43  Wellman and Vidican concluded that formulary provisions ranked 
behind premiums, copayments, and pharmacy access in importance for determining 
choice of a prescription drug plan in their conjoint analysis survey of the general 
population.44  Abalcuck and Gruber concluded that a higher proportion of the most 
popular medications being covered is associated with a greater probability of a given 
Medicare PDP being selected, but the emphasis is placed on drugs which are currently 
prescribed with little regard for medications which may be prescribed in the future.53  
Leaving popular medications off of a formulary led to a 0.95 cents reduction in the price 
which seniors were willing to pay for a given plan after holding other cost related factors 
constant.53  Heiss et al. found that leaving one of the 100 medications uncovered in a 
Medicare PDP would lead to a $1.40 decrease in the amount that seniors would be 
willing to pay for a plan.51  They also found that having a top 100 drug covered, but with 
utilization management would lead to a $1.01 decrease in the amount seniors would be 
willing to pay for a Medicare PDP.51 
 
 
Pharmacy Access 
 
Medicare Part D acceptance is not universal within pharmacies.  While 97% of retail 
pharmacies accept at least one Medicare Part D plan, only seven out of ten pharmacies 
have contracts with every PDP available in their region.77  In particular, there is a 
shortage of independent pharmacies which contract with every PDP;  only 44% of retail 
pharmacies have contracts with every PDP in their area.77  This presents the greatest 
difficulty in rural areas where 30% of seniors must travel further than 15 miles to find a 
retail pharmacy which participates in Medicare Part D.78  Plans have also been given the 
option to implement mail order pharmacy within Medicare Part D at lower cost sharing, 
however beneficiaries must still be given the option of using a retail pharmacy.77,78   
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The role of pharmacy access in prescription drug plan choice has been evaluated in the 
general population, but not in the context of Medicare Part D.  Seniors who are not 
currently using mail order are less likely to enroll in plans which feature mail order.49  In 
their conjoint analysis study of the general population, Holdford and Carroll found that 
the general adult population had a strong aversion for being forced to use prescription 
drug insurance at a different pharmacy than their usual one, as their pharmacy access 
variable had an importance of 26% when considered alongside formulary provisions and 
copay stipulations.43  In their conjoint analysis study, Wellman and Vidican also 
demonstrated that the general adult population had a strong aversion for being forced to 
switch pharmacies, but there was an even greater dislike towards being forced to use mail 
order pharmacy.44   
 
 
Medication Therapy Management Services 
 
Medication therapy management services (MTM) are a set of services provided by health 
care professionals with the goals of providing education, improving adherence, and 
detecting adverse drug events in medications for the Medicare population.56  Medicare 
Part D PDPs have considerable freedom in determining the eligibility criteria for MTM.56  
These services are targeted towards beneficiaries who have more than one chronic 
disease, are taking at least two drugs which are covered by Medicare Part D plans, and 
are likely to have annual costs for their Part D drugs that are higher than a preset amount 
(initially $4,000).56  Senior citizens who take part in MTM programs have superior 
clinical outcomes when compared to seniors who do not participate in MTM services.79-82  
For example, participation in these programs is associated with better control of lipid 
levels and blood pressure among other conditions while decreasing medication related 
costs due to finding generic medications where applicable or discontinuing duplicate 
therapy.79-82  One study demonstrated that seniors undergoing medication therapy 
management services were over 12 times as likely to achieve goal blood pressure when 
compared to senior citizens who were eligible but chose not to participate.79 
 
MTM has not been studied extensively in the literature regarding choice of prescription 
drug plans.  However, in their conjoint analysis study of the general population, Wellman 
and Vidican demonstrated that the general population had a strong positive preference for 
greater pharmacist interaction where a pharmacist would offer those services similar to 
medication therapy management services.44 
 
 
Expected Utilization Patterns 
 
The implementation of Medicare Part D has been associated with increased drug use in 
the senior population while decreasing costs.  A recent review published on the changes 
in drug utilization and out-of-pocket costs associated with Medicare Part D concluded 
that implementation of Medicare Part D was associated with a 6%-13% increase in 
utilization and a 13%-18% decrease in prescription drug costs among the senior 
population.63  However, many of these studies used the data from one pharmacy chain, or 
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compared the decrease in costs of the Medicare population with the change in costs of the 
general adult population.63  For example one study using data from a pharmacy chain 
demonstrated that Medicare Part D had saved seniors approximately $9 per month on 
medication expenses while they took on average 14 pill more per month.83  A more recent 
study not included in the review and using data from a national government database 
demonstrated that the program was particularly effective in helping alleviate the cost 
burden for low income seniors without prior insurance.84  Seniors with Medicare Part D 
were found to have 4.2-5.5 prescriptions on average.84   Another study found that 
Medicare beneficiaries who did not have prescription drug insurance in either 2005 or 
2006 experienced a 31.6% decrease in their annual medication costs, as the annual 
expenditures dropped from $1116 in 2005 to $763 in 2006.85  However seniors without 
prior drug coverage enrolling in Medicare Part D during this time experienced an even 
greater 48.8% reduction in their medication cost during this time period as their annual 
medication costs went from $1533 to $784 during this time.85  These results suggest that 
while seniors enrolling in Medicare Part D did experience an approximately 13%-18% 
reduction in out-of-pocket drug costs relative to the general population, the absolute 
reduction in out-of-pocket drug costs may have been even greater due to a surprising 
decrease in out-of-pocket drug costs expenses for the general population.85   
 
There is sufficient data to indicate that seniors without creditable coverage who take 
many medications or have high medication expenses are more likely to enroll in 
Medicare Part D when compared to seniors without creditable coverage who take few 
medications or have low medication expenses.  In fact, seniors medication expenses prior 
to becoming eligible for Medicare Part D is the best predictor in determining whether 
they will enroll in Medicare Part D once they become eligible and do not have creditable 
coverage.46  It is also logical to deduce that seniors who have high medication expenses 
may be willing to pay more for plans, presumably in order to obtain better coverage.  
However, this has not been studied exhaustively in the literature.  This line of thinking 
may not prove to be entirely correct, as only a small minority (6%) of seniors enroll in 
plans with gap coverage which tend to be the most expensive plans, and enhanced 
coverage is not necessarily associated with higher premiums.12,13  One study suggests that 
seniors who would have high medication expenses without prescription insurance tend to 
stay away from the most inexpensive plans offered, and a study of hypothetical drug 
plans presented to seniors demonstrated that seniors taking a higher number of 
medications with a greater number of chronic diseases may be willing to pay more for 
generous prescription coverage.49,51  
 
 
Economic Characteristics 
 
The seniors enrolled in Medicare represent a diverse group in terms of income.  
Approximately 50% have household incomes of more than 200% of the federal poverty 
level while 38% have incomes below 150% of the federal poverty level.84  Observational 
data of enrollment in actual Medicare PDPs does not indicate that there is any association 
between income and choice of whether to enroll in a plan or the choice of a particular 
plan.46,51  However, there is some  evidence from research prior to the implementation of 
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Medicare Part D which suggests that seniors with high incomes may be willing to pay 
more for plans which offer better benefits, consistent with the literature on health plan 
choice and income.16,49 
 
Risk Factors 
Age has been shown to have an inverse relationship with enrollment in Medicare Part D 
plans where younger seniors without prior insurance coverage are more likely to enroll in 
a Medicare PDP.46,51  However, there is currently no information on how age influences 
the choice of a particular type of plan.  On average senior citizens have approximately  
1.4–2.9 conditions for which they some type of medication.46,85  A greater number of 
conditions for which one takes medications has been shown to be associated with a 
greater probability of enrolling in Medicare Part D, but the relationship with the type of 
plan chosen is unclear although preliminary evidence suggests that a greater number of 
chronic conditions may be associated with a willingness to pay higher costs for more 
generous prescription drug coverage.46  Approximately 87%-91% of seniors take some 
type of prescription medication on a regular basis.46,84  As stated in the expected 
utilizations pattern section, there is inconclusive evidence in regards to how much the 
medication burden affects the choice of a Medicare Part D plan.63,84,85   
 
 
Beliefs about Medicine 
 
The relationship between Medical Care Preferences and prescription drug plan choice has 
not been studied extensively.  A study of hypothetical prescription drug plans presented 
to seniors concluded that the preferences for receiving medical care had no appreciable 
effect on choice of a prescription drug plan.49  
 
 
Attribute Preferences 
 
The relationship between the patient-pharmacist relationship and prescription drug plan 
choice has not been investigated thoroughly.  A study of hypothetical prescription drug 
plans presented to seniors concluded that the preferences for receiving medical care had 
no obvious association with choice of a prescription drug plan.49  Preliminary evidence 
also indicates that seniors who have prior experience with a formulary which restricts 
their use of medications tend to avoid prescription drug plans which limit their use of 
medications.49 
 
 
Summary 
 
In summary, the research on choice of PDPs in the Medicare Part D population has shed 
variable information on the importance of benefit plan characteristics in determining the 
choice of prescription drug plans.  However, much is left to be desired in the way of 
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information regarding delivery system characteristics and how secondary variables may 
interact with primary variables in helping to determine prescription drug plan choice.  
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CHAPTER 3.    METHODS 
 
 
Overview 
 
This chapter provides a detailed description of the methods undertaken in this study.  A 
brief description is provided for the rationale behind using Adaptive Choice-Based 
Conjoint Analysis (ACBC) for this survey.  In addition, the operationalization of the 
variables is discussed as well as the techniques and processes used to collect the data.  
Finally, the data evaluation plan is presented.  
 
 
Rationale of Adaptive Choice-Based Conjoint Analysis as Survey Technique 
 
Conjoint analysis has been used to evaluate consumer’s preferences for multiple 
attributes of products and services in various fields such as psychology, decision theory, 
and economics ever since the early 1970’s.86  There are many different types of conjoint 
analysis techniques.  The theoretical foundation for conjoint analysis was laid by Luce in 
1964 and others followed soon thereafter.87  Over time, several different approaches to 
conjoint analysis have evolved.88 
 
 
Full Profile Conjoint Analysis 
 
One of the earliest methods for collecting data which became popular was known as the 
full profile or conjoint value analysis approach.  During the 1970s this approach was 
often used in lieu of the “two-factor-at-a-time procedure” approach or trade off procedure 
where only two factors were considered at a time.86  The respondents were then asked to 
rank the combinations so that the most desirable combination was most preferred and the 
least desirable combination was least preferred.86  In contrast, the full profile approach 
used the full set of attributes, and displayed all of them on a card simultaneously.86  
Experts within the field acknowledge that it may be hard for respondents to look at more 
than six attributes at a time.88  If more than six attributes are presented at a time, 
respondents may ignore attributes which they do not consider to be important, or ignore 
certain levels within important attributes due to information overload.88  The full profile 
approach has different formats for presenting the data.86,89  For example, all of the 
attributes may be presented for one product or service and the respondent may be asked 
how likely they are to purchase the product on a continuous scale.86 The scale could have 
different lengths such as 1-10 or 1-100.89  This approach is particularly good for new 
products that have not yet come onto the market.86  Another option is for respondents to 
be presented with a full set of product profiles, and to rank the profiles from their most 
desirable to their least desirable.89   Finally, respondents can be presented with two 
profiles at a time, known as pairwise presentation, and asked to evaluate which one they 
would purchase and the strength of their preference for that product.86  For example, a 
respondent would have the option of saying they strongly prefer product A, somewhat 
prefer product A, have no preference for either product A or B, somewhat prefer product 
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B, or strongly prefer product B.86  Some researchers believe that the ranking system may 
be more reliable, citing the premise that it may be harder for consumers to accurately 
express the magnitude of their preference for a product than simply stating which product 
they prefer.86   
 
 
Adaptive Conjoint Analysis 
 
As stated previously, one of the main limitations of full profile conjoint analysis is that a 
limited amount of attributes may be used.88  Adaptive conjoint analysis was developed by 
Richard Johnson of Sawtooth Software in the mid 1980s, principally as a means to 
bypass this limitation.90  In adaptive conjoint analysis, the respondent’s previous answers 
within a section are used by a computer in order to select the next question so as to 
provide the most information.90   
 
While the number of maximum attributes to be analyzed under full profile conjoint 
analysis was six, the number of attributes that can be used in adaptive conjoint analysis 
can be up to 24.91  In reality most studies using adaptive conjoint analysis have between 
8-15 attributes.91  This is accomplished by taking the respondent through a set of partial 
profiles where only a few of the attributes are displayed at one time.88    
 
The adaptive conjoint analysis interview potentially goes through several stages.  The 
first stage, the “adaptive conjoint analysis rating” question type is designed to find out 
which levels of an attribute the consumer prefers.91  This question is not used for 
attributes where it is obvious that one level is preferred above another, where for example 
a lower price is understood to offer greater utility than a higher price.91  The next stage in 
adaptive conjoint analysis involves the “adaptive conjoint analysis importance” 
question.91  This set of questions is designed to find out which attributes are most 
important to the respondent.91  The next stage involves the “adaptive conjoint analysis 
pairs” question which is comprised of questions which use conjoint analysis principles.91  
This is similar to the full profile pairwise presentation where the respondent is asked to 
choose between two products and services and indicate how strong their preference is for 
the product or service they choose.91  However only a part of the full number of attributes 
is usually presented in a scenario, and the next question is chosen by the computer to find 
the most information possible about the attributes.91   
 
Although Adaptive Conjoint Analysis has several advantages, it also has distinct 
limitations.  One obvious limitation is that it requires the use of a computer.91  It is also 
difficult to account for interactions with Adaptive Conjoint Analysis because it is a main 
effects model where the utilities for each attribute are measured in the context of other 
attributes being equal.88  The Adaptive Conjoint Analysis method also has a tendency to 
underestimate the importance of price when it is included as an attribute, and this 
underestimation is more pronounced as the number of attributes increases.88   
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Choice-Based Conjoint Analysis 
 
Choice-Based Conjoint is relatively new, as it started to become popular in the early 
1990s, and is now the most popular method for conjoint analysis.88  Choice-based 
conjoint analysis does not ask respondents to rate or rank either one or two products;  
rather it asks respondents to choose one product or service from at least two.88  In fact, 
there have been cases where respondents have been presented with up to eight different 
products or services at one time and asked to choose which one they would purchase.92    
 
Choice-based conjoint analysis offers several theoretical advantages over ratings or 
ranking based systems.  The process of choosing one product is analogous to what 
consumers actually do in real life situations, so that people are able to understand this 
process quite readily.92  It is also possible to choose a none option.92  This option in 
particular contributes data about demand for price increases.92  Choice-based conjoint 
analysis is also capable of exploring interactions between different attributes, which has 
been cited as a limitation in full profile and adaptive conjoint analysis.92  
 
However choice-based conjoint analysis does have limitations.  Each question answered 
by a respondent offers less information because little information is gained about the 
products which were not chosen.88  There is no data gathered on how strongly the chosen 
product was preferred or the rank order of the products which were not chosen.88,92  
Therefore, the choice-based conjoint analysis method may require more questions per 
respondent or a larger sample size.92  Another limitation associated with conjoint analysis 
is the fact that it analyzes responses at the aggregate or group level and inferences may 
not always be made about individual level utilities as is possible when using rating or 
ranking systems.92  However with newer methods such as hierarchial Bayesian 
estimation, individual level utilizes can be gathered from choice-based conjoint 
analysis.92  In addition, the limitation of attribute levels in choice-based conjoint analysis 
is even more pronounced than in full profile conjoint analysis.88  Because more than two 
products or services may be presented at once, it is improbable that respondents will be 
able to process information for more than six attributes.88,92  In fact, even this number of 
attributes may be too many when there are many complex levels within attributes.92 
With choice-based conjoint analysis, there is a lot of information to consider as all 
attributes are typically presented for each service.92        
 
 
Potential Problems with Using Traditional Conjoint Analysis Methods 
 
With this dissertation, there were several factors that dictate what would be the most 
appropriate method to use.  One of the most important factors was the fact that this study 
had eight attributes.  Furthermore, the respondents were senior citizens who may have 
cognitive limitations.   As stated earlier, the maximum number of attributes 
recommended for a full profile study and a choice-based conjoint analysis study is six.  
Therefore, this seemed to preclude the full panel analysis or the choice-based method 
from being used in this study.  As stated previously, adaptive conjoint analysis is able to 
handle more than seven attributes.91  This seemed to make adaptive conjoint analysis a 
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viable choice as the method to use in this study.  However, this method has the limitation 
of being inaccurate as relates to price data.88  Therefore, adaptive conjoint analysis was 
not without major flaws as a method to use in this study as this study had attributes which 
related to cost such as the premium price and the copayment amounts.   
 
 
Adaptive Choice-Based Conjoint Analysis 
 
Fortunately, there is a method which combines features of both choice-based and 
adaptive conjoint analysis which is known as adaptive choice-based conjoint analysis 
(ACBC).93  This form of conjoint analysis was developed in response to the fact that 
many respondents seemed to be answering choice-based conjoint analysis items too 
quickly in order to be able to fully evaluate all of the attributes and levels presented for 
each scenario.93  Therefore it was proposed that many respondents have a “must have” 
feature which they look for and select no matter what other options are available, or they 
may have features which they attempt to avoid at all costs.93  ACBC analysis has several 
stages just as adaptive conjoint analysis does.93  The first stage is a “build your own” 
question where the respondent chooses their preferred levels for each attribute.93  Where 
it is obvious that certain levels will be preferred for a particular attribute they are left out 
of this question.93  This would include attributes such as price where it is obvious that a 
lower price would be preferred.93  Based upon responses to this question, a pool of 
variations of the product or service being offered is created where all of the attributes and 
levels are included, but ones which are closer to the preferred levels of the respondent 
occur more often.93   The subsequent stage is called the screening section.93  In this 
section, approximately four variations of the product or service being evaluated are 
presented to respondents at a time.93  Respondents are asked to indicate which of these 
they think are possibilities for them to buy.93  Based upon the responses to the screening 
section, the respondent may be presented with the option of selecting a certain feature 
(level) which they believe is a must have.93  Also, the respondent may be presented with 
the option of selecting a feature which they would always like to avoid.93  The next stage 
is the choice tasks section.93  The respondent is presented with multiple variations of the 
product of the service being offered and asked to choose which one they prefer, just as in 
choice-based conjoint analysis.93  However, all of the choices presented have any feature 
which was identified as a must have, and they omit any feature that was identified as one 
the respondent must avoid.93  In addition, any attributes which are the same among the 
products are highlighted so that the respondent can concentrate only on those features 
which are dissimilar.93  Even though all attributes are presented, this helps reduce the 
amount of information which the respondent must process.93  Because of this, one can 
measure more than six attributes, with recommendations that no more than a dozen are 
measured.93  Furthermore, ACBC is recognized as being a good method to analyze price 
attributes, and is able to produce estimates for part worth values at the individual level.93   
 
For the aforementioned reasons, ACBC represented the most reasonable approach for this 
study.  There are potential limitations to ACBC.  ACBC does tend to take more time to 
compete as respondents may take twice as long to complete an adaptive conjoint analysis 
survey as they do with choice-based conjoint analysis.93  In addition the administration of 
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ACBC requires a computer.93  When all factors were taken into consideration, the 
benefits of using ACBC outweighed any problems that may be associated with it’s use in 
this study.   
 
 
Operationalization of Variables 
 
This section describes the operationalization of the variables used in this study.  Separate 
sections are used to describe the variables that are in the conceptual model as well as 
variables included in the study that are not a part of the conceptual model.   
 
 
Variables outside of Conceptual Model 
 
Although some variables such as gender, education, and race are not part of the 
conceptual model for this study, they are standard sociodemographic variables.  These 
variables may be useful in helping to identify certain demographic segments of the 
market which may have unique preferences.   In addition the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) recommends that these variables 
be included in the study, and in addition their interaction with the attribute levels may be 
studied as recommended in the review by Scanlon and colleagues.18,94   In addition, 
seniors will be asked whether they selected their own current plan, or if they received 
assistance from physicians, pharmacists, their family, or another source.  This question is 
important to implement because many times seniors may receive assistance in selecting 
their Medicare Part D plans.95  These variables are described in Table 3-1. 
 
 
Explanatory Variables within Conceptual Model 
 
The economic characteristics were evaluated by asking seniors about their household 
income.  This question took the form of a categorical variable, and income ranges were 
included which were appropriate for seniors.  It was explicitly stated to the respondents to 
include their social security and retirement benefits in their estimation of income as it is 
expected that few, if any of them, will be working.   
 
Several questions were asked to evaluate the use of risk factors.  Seniors were asked to 
provide their self reported age.  The number of acute and chronic Medical Conditions 
was evaluated by asking patients whether they have the conditions which are listed in the 
2005 Medicare Current Beneficiary Health Status and Functioning Survey (MCBHFS).96  
This survey asks about several conditions such as arteriosclerosis, hypertension, 
myocardial infarctions, angina, congestive heart failure, arrthymias, strokes, various 
cancers, rheumatoid arthritis, osteoporosis, a broken hip, chronic obstructive pulmonary 
disease, asthma, benign prostatic hypertrophy, or diabetes.96  The patient’s use of 
prescription medications was ascertained be asking them to self report the number of 
prescription medications they have been taking for the previous 30 days and the out of 
pocket cost for these medications.  Thus, this question was also used in determining the 
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Table 3-1. Operationalization of variables outside conceptual model 
 
Variable Possible response 
Gender Male 
 Female 
Race/ethnicity Non Hispanic white 
 Non Hispanic black 
Education Less than high school 
 High school graduate 
 Some college 
 Bachelor’s degree or 
higher 
Who helped select Medicare Part D plan Primarily self 
 Family members 
 Physician 
 Pharmacist 
 Other source 
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respondents expected utilization patterns.  The patient’s preferences for medical care 
were evaluated by using a validated scale developed by Ganther and colleagues for the 
express purpose of measuring patient’s preferences for self care as opposed to formal 
medical care.97  A version of the survey was graciously provider by Doctor Julie Ganther 
(Ganther, Personal Communication, 04-26-2011) as seen in Appendix A. 
 
The strength of the respondent’s relationship with their pharmacist was evaluated using a 
3 item scale by Worley and Schommer.98  This scale included three questions:    
 
1. It is important for me to take my prescription to the same pharmacist or group of 
pharmacists whenever I need a prescription filled. 
 
2. If I had a general health related question that did not require me to obtain a 
prescription, I would still rely on my pharmacist for advice related to these 
questions. 
 
3. If a less expensive pharmacy opened near my present pharmacy, I would change 
pharmacies. 
 
The patient’s experience with formularies was evaluated by asking them to state whether 
they thought they were in an unrestrictive (open) formulary or a closed formulary and 
measured on a Likert scale.  The respondents were be asked to evaluate their satisfaction 
with their formulary on a 5 point Likert scale.   The operationalization of the explanatory 
variables is included in Table 3-2 for quick reference. 
 
Operationalization of Premiums, Deductibles, and Doughnut Hole  
The drug benefit plan characteristics, including the premium, deductibles, and doughnut 
hole were all included as attributes within the conjoint analysis survey.  In general, it is  
recommended to include 3 to 5 levels for each attribute.56  The levels chosen should 
represent what a consumer would see in the actual market place, and be mutually 
exclusive.56,99  Therefore, in order to ensure that the presented attributes were realistic, 
the cost sharing features of the 2010 PDPs were consulted. 
 
These cost sharing features were derived after consulting the Medicare Part D plans 
available in Shelby County during 2010 using Medicare Part D’s Drug Plan Finder 
website and the Medicare and You 2010 publication. 58,100-102  The website displays each 
of the plans which are offered to seniors in a region during each year, and also offers 
them the opportunity to see their EAC after they input their medications and pharmacy  
preferences.102  Although information on the 2010 plans is no longer available on the 
Medicare Drug Plan Finder website, this information is available through the Q1 
Medicare organization which provides educational materials and decision support tools 
for the Medicare community.100-102  Previous studies using conjoint analysis to analyze 
prescription drug insurance did not include a deductible or doughnut hole.42,43  The 
premium was used as an attribute in one previous study which used levels of $10, $25, 
$100, and $200.44       
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Table 3-2. Operationalization of explanatory variables in conceptual model 
 
Variable Description 
Household income Less than $10,000 
 $10,001-$15,000 
 $15,001-$20,000 
 $20,001-$30,000 
 $30,001-$40,000 
 $40,001-$50,000 
 More than $50,000 
  
Age Self reported age 
  
Chronic and acute 
conditions 
Respondents indicated which conditions on the 2005 
MCBHFS they have.96 
  
Current Rx 
use/expected 
utilization 
patterns 
Respondents were asked to indicate the number of prescription 
medications they take and the out of pocket cost associated 
with these. 
  
Medical care 
preferences 
Respondents were administered a 9 item scale developed by 
Ganther and colleagues. (See Appendix A for details).97 
  
Patient 
pharmacist 
relationship 
Respondents were administered a 3 item scale developed by 
Worley and Schommer.98 
  
Formulary 
exposure 
Respondents answered two 5 point Likert scales, one designed 
to measure the restrictiveness of their current formulary, and 
another designed to assess their satisfaction with their current 
formulary. 
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Characteristics of plans with the maximum $310 deductible and no gap coverage are 
displayed in Table 3-3. There was wide variation in the premium for these types of plans 
as they ranged from $22 to $63.58  The average premium for these types of plans was 
$31.66, however after taking out the plan with a $63 premium, the average premium was 
$29.42.58  The median premium was $31.30.58  However after taking out the plan with a 
premium of $63, the median premium was $30.10.58  The premium does not necessarily 
seem to be related to the patients out of pocket costs for their medications.  For example, 
the lowest premium for a plan with the standard 25% coinsurance rate is $22 while there 
is a plan with the same coverage which has a premium of $33.60.58  However, it is 
important to remember that some plans may have more expensive medications included 
on their formulary that other plans do not offer coverage for. 
 
Table 3-4 shows characteristics of plans with intermediate deductibles and no gap 
coverage.  The premiums for these plans were generally higher than those plans with 
maximum deductibles, yet the premiums for some of these plans were lower than some of 
those found in the plans which featured maximum deductibles.58  The average premium 
for these plans was $38.40, while the median premium was $37.20.58  The average 
deductible in these plans was $138 with a median deductible of $150.58  As with the 
maximum deductible plans, there was no discernable pattern in regards to the deductibles 
and copayment amounts.   
 
Table 3-5 shows the characteristics of plans with no deductible and no gap coverage.  
The average premium of these plans was $45.76 and the median premium was $45.40.58  
There was no obvious correlation between the premiums and the copayment amounts.   
 
The copayment features of plans with no deductible and gap coverage are featured in 
Table 3-6.  The average premium within these types of plans was $72.24 with a median 
of $68.30.58  However, after a plan with a premium of $100.74 was removed, the average 
premium and median premium were approximately $68.58 
 
Most of the differences in the range of premiums were determined by the plans 
deductibles and doughnut hole coverage, which was as expected based upon the 
information discussed in the literature review concerning the doughnut hole and 
deductible.12,61  In order to present realistic prices, the summed pricing approach of 
Sawtooth Software’s Adaptive Choice-Based Conjoint Analysis Program was used.103 
This feature allows the price, in this case the premium, to function as a continuous 
variable by allowing random variation around a price that is based upon the components 
intrinsic to the product which may affect price.103  In this study, the price was allowed to 
fluctuate from between 30% below or 30% above the “average” price of the prescription 
drug plan package based upon the deductible and gap coverage it contained.  This 30% 
variation allowed the investigator to have enough variation in price to cover most of the 
premiums that were being offered in the market in 2010, and also represented the 
recommended levels to be used with the Adaptive Choice-Based Conjoint Analysis 
Software.103                                                                                                                                                                                 
 
Generally it was found that plans with the maximum allowed deductible of $310 and no 
44 
 
Table 3-3. Plans with maximum deductible and no gap coverage in 2010 
 
Premium Generic copay       Brand copay 
 One 
tier 
Preferred Non 
preferred
One 
tier 
Preferred Non 
preferred 
$22.00  25%   25%   
$23.50 $0    30% 65% 
$25.10  $5 45%  20% 45% 
$26.40 $3    $30 $79 
$26.50 $6    $25 $71.50 
$30.00  25%   25%   
$30.20  25%   25%   
$31.20  $6 25% 25%   
$31.50  25%   25%   
$32.40  $3.50 45%  25% 45% 
$32.80 $4    $38 $95 
$33.00 $7    $19.75 $95 
$33.60  25%   25%   
$33.70 $4    $33 $65 
$63.00 $9   $31   
 
 
 
 
Table 3-4. Plans with intermediate deductible and no gap coverage in 2010 
  
Premium Generic copay       Brand copay 
 One 
tier 
Preferred Non 
preferred
One 
tier
Preferred Non 
preferred 
$27.80  $5 $35 $35 33% 
$28.50  $3 $5 $35 $60 
$30.00  $4 52% 20% 52% 
$30.70  $7 43% 11% 43% 
$32.30  $0 $8 $37 $84 
$35.80 $6   $43   
$38.60 $5   $35 $65 
$39.10  $7 62% 20% 62% 
$40.30 $4   $45 $90 
$43.80 $6   $39 75% 
$51.30  $2.50 $7.50 $25 $35 or 
$90 
$62.60  $4 $30 $25 25% 
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Table 3-5. Plans with no deductible and no gap coverage in 2010 
 
Premium Generic copay       Brand copay 
 One 
tier 
Preferred Non 
preferred 
One 
tier 
Preferred Non 
preferred 
$37.90  $7 $85  $43 $85 
$40.90  $7 $63.25  $42 $63.25 
$43.60  $8 $40  $40 $75 
$44.00 $0    $42 $85 
$46.80  12% 49%  16% 49% 
$48.10 $8.00    $37 $74 
$48.60  $2.50 $5 33%   
$56.20  $0 $95  $42 $95 
 
 
 
 
Table 3-6. Plans with no deductible featuring gap coverage in 2010 
 
Premium Generic copay Brand copay 
 One tier Preferred Non preferred Preferred Non preferred
$60.50 $6   $35 $60 
$61.10  $2 $4 $35 $60 
$63.20  $2.50 $7.50 $39 $98 
$64.30  $5.00 $25 20% 75% 
$72.30  $6  $35 $65 
$76.60 $7   $42 $90 
$79.20 $6   $40 75% 
$100.70  $7 $45 $45 $75 
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doughnut hole coverage had an average premium of approximately $30 per month.  
Those plans with an intermediate deductible lower than $310 had an average premium of 
approximately $38 per month, so that the price in this survey was on average $8 higher in 
a plan with an intermediate deductible when compared to a plan with the maximum 
allowed deductible when holding the gap coverage constant. It was decided to use $150 
as the intermediate deductible in this study because it was easy to comprehend and would  
allow for linear relationships to increase statistical efficiency when used with a $300 
deductible.103  Plans with no deductible had premiums that were on average 
approximately $46 per month.  Accordingly, plans with no deductible in this survey had 
premiums that were on average $16 higher than plans with a $310 deductible when 
holding gap coverage constant.  This fits along well with data from Heiss et al. which 
shows that when smaller deductibles were offered in 2006 and 2007, seniors were willing 
to pay approximately $14 to go from maximum deductible plans to no deductible plans.   
 
There were differing amounts of doughnut hole coverage offered:  no gap coverage at all, 
few generics (less than 65%) covered in the doughnut hole, many (65%-99%) generic 
drugs covered within the gap, or essentially all generic drugs covered within the gap.99-101   
These same levels were utilized within this study.  As noted before in the literature 
review, only a few customers choose plans with gap coverage indicating that demand for 
these plans may be low.  Furthermore, Heiss et al. noted that the willingness 
to pay for plans with generic doughnut hole coverage was lower than the  implicit price   
insurers use for these products.  Therefore, the researcher used a slightly more 
conservative estimate, where $20 was added to the premium if it included full doughnut 
hole coverage, even though the average premium was on average $22 higher for these 
plans in comparison to plans with no doughnut hole coverage.  Plans with some generics 
covered in the doughnut hole had $15 added to the base price, and plans with few 
generics covered in the doughnut hole had $10 added to the base price.  Once again, this 
allowed for a linear relationship so that demand for different levels of gap coverage could 
be evaluated.  The base prices and potential price ranges for the price attribute are 
depicted in Table 3-7.  This framework allowed the researcher to capture all premium 
prices with the exception of one offered in the Shelby County PDP market during 2010. 
 
 
Operationalization of Copayments 
In previous studies conjoint analysis studies of prescription drug payment, the most 
comprehensive copayment structure presented to respondents was levels of $2, $10, $20, 
$30, 10% or 25%.44  While this structure has wide variation in the copayment range and 
encompasses a broad array of values, it fails to encompass the tiered structure which 
predominates in the Medicare Part D market.  Therefore, for this study the decision was 
made to use two attributes to capture copayment levels, one for generic medications and 
one for brand medications.  As seen in Tables 3-3 through 3-6, there is a wide range of 
copayment structures in Medicare Part D Prescription Drug Plans currently being offered 
in these plans with no standard copayment amounts.   
                                                                                                                                       
When looking at coverage for generic drugs within these plans, many plans only use one 
tier level for generics, while some plans make a distinction between a preferred group of 
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Table 3-7. Summed pricing for premium  
 
Deductible Gap coverage Average 
premium
Minimum 
premium 
Maximum 
premium 
$300 None $30 $21 $39 
$300 Few generics $40 $28 $52 
$300 Some generics $45 $32 $59 
$300 All generics $50 $35 $65 
$150 None $38 $27 $49 
$150 Few generics $48 $34 $62 
$150 Some generics $53 $37 $69 
$150 All generics $58 $41 $75 
$0 None $46 $32 $60 
$0 Few generics $56 $39 $73 
$0 Some generics $61 $43 $79 
$0 All generics $66 $46 $86 
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generic drugs and a non-preferred group of generic drugs.  In those plans with one tier for 
generics, the copayment amount ranges from $0 to $9.58  In plans with two tiers for 
generic drugs, the copayment amount ranges from $0 to $8 for preferred generics, and 
from $45 to $95 for non-preferred generics.58  In addition there are various coinsurance 
amounts, with several plans using the standard benefit plan 25% coinsurance rate for all 
generics, while several plans use a percentage coinsurance rate for non-preferred 
generics.58  The copayments for generic medications are depicted in Table 3-8.  The zero 
dollar and seven dollar copayment amounts were chosen to capture copayments on the 
low and high end for plans which use one tier copayments for generic medications.  The 
25% coinsurance rate was used to represent a coinsurance rate, and evaluate how 
respondents react to variable copayments.  Finally, the $7 and 50% copayment was 
chosen in order to evaluate how respondents felt about two tier generic plans. 
When looking at coverage for brand name drugs, there are only two plans which employ 
one copayment level for brand name drugs, while all of the rest have either preferred 
brands and non-preferred brands, or a coinsurance rate.58  The lowest copayment on a 
preferred brand is one plan with an amount of $19.75, while there are three plans with 
preferred copayments of $25 and six with preferred copayments of $35.58  There are nine 
plans which have preferred copayments of $45.58  Copayments for non preferred brands 
were $35 to $95.58  Finally, there were six plans which included the 25% coinsurance 
amount.58  Accordingly, the levels for brand copayment as depicted in Table 3-8 were 
chosen in order to form a representative range of copayments.   
 
 
Operationalization of Control Mechanisms 
The inclusion of control mechanisms has been incorporated in prior studies through the 
inclusion of formulary provisions.43,44  One study acknowledged that a formulary has 
restrictions only in the sense that it requires use of generics when they are available, 
while another study stated that the formulary was limited in the sense that it covers a 
more limited set of drugs.  While these definitions do address the issue of a formulary in 
some sense, they do not speak to the utilization management tools used by some of the 
Medicare Part D plans such as prior authorization, stepped care, and quantity limits.55,58  
An attempt to include these provisions were made in this study.   The utilization 
management tools, along with the requirement that patients use generic medications if 
they were available fall up under the term “some restrictions.”  It was explicitly stated to 
patients what the term some restrictions meant when they were taking the survey.  
Furthermore, the levels within the survey stated whether prescription drug plan covered 
all or some of the patient’s medications.   
 
In this study, four levels were used for control mechanisms as seen in Table 3-8.  Level 
one was the most unrestrictive level where the plan covered any medication the physician 
prescribed with no type of control mechanism.  This level was stated as “all drugs 
covered and no restrictions on covered drugs.”  Level two also covered all drugs but 
some types of control mechanisms were imposed.  This was termed as “all drugs covered 
but some restrictions on covered drugs.”  In level three, there were some drugs which the  
physician prescribes that would not covered by the plan.  However for those drugs which 
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Table 3-8. Attributes and levels used in conjoint analysis survey   
 
Attributes Level 
Premium  Summed pricing approach ($21-$86) 
Brand copayment  
     Level 1 $25 or $40 
     Level 2 25% 
     Level 3 $35 or $60 
     Level 4 $45 or $95 
Generic copayment  
     Level 1 $0 
     Level 2 $7 
     Level 3 25% 
     Level 4 $7 or 50% 
Doughnut hole coverage  
     Level 1 None 
     Level 2 Few generics covered in doughnut hole 
     Level 3 Some generics covered in doughnut hole 
     Level 4 All generics covered in doughnut hole 
Formulary coverage  
     Level 1 All of your drugs are covered with no restrictions. 
     Level 2 All of your drugs are covered with some restrictions. 
     Level 3 Some of your drugs are covered with no restrictions. 
     Level 4 Some of your drugs are covered with some restrictions. 
Pharmacy access  
     Level 1 You can use all pharmacies. 
     Level 2 You can only use some pharmacies including your current 
one. 
     Level 3 You can only use some pharmacies not including your 
current one. 
     Level 4 You must use mail order for best benefits. 
Deductible  
     Level 1 $0 
     Level 2 $150 
     Level 3 $310 
MTM  eligibility  
     Level 1 2 diseases and 3 drugs required 
     Level 2 2 diseases and 6 drugs required 
     Level 3 3 diseases and 6 drugs required 
     Level 4 4 diseases and 9 drugs required 
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were covered, no utilization management tools were used, although respondents were 
instructed that they may be required to use generics if they were available.  This level 
was stated as “some drugs are covered but there are no restrictions on covered drugs.”  In 
level four, there were also some drugs which the plan does not cover.  Moreover, for 
some of those drugs which the plan covered, utilization management tools may have been 
used.  This level was stated as “some of your drugs are covered and there are some 
restrictions on covered drugs.”   
 
Operationalization of Delivery System Characteristics 
 
One key component of the delivery system characteristics is concerned with the access 
that beneficiaries have to the health care professionals themselves so that the services 
and/or medications may be rendered to them.  This feature was included as an attribute in 
the conjoint analysis survey.  Within the framework of prescription drug plans, previous 
studies have examined access from the standpoint of whether beneficiaries were able to 
use their plans at all pharmacies, or even whether the beneficiary is restricted to using 
mail order pharmacies.43,44  This study proposed to look at all these factors as a measure 
of access to pharmacies.  Other conjoint analysis studies have looked at delivery system 
characteristics from a point of continuity by exploring whether it is important to 
consumers if they will be able to use their benefits at the pharmacies which they have 
patronized in the past.43,44  This feature was also incorporated within this study so that 
this question in the conjoint analysis survey had levels that examine this feature from 
both the number of pharmacies that patrons were able to use, and also whether they were 
able to continue with their current pharmacy.   
 
As depicted in Table 3-8, the first level of pharmacy access was one where the patient 
was able to use any pharmacy.  Within the survey, this level was stated as “you can use 
all pharmacies.”  The second level of access was one where patients were not able to use 
all pharmacies, but they could continue to use their current pharmacy with the PDP.  In 
this survey, this level was stated as one where patients were not able to use all 
pharmacies and their current pharmacy or pharmacies were not included in the covered 
network.  In the survey this level was stated as “you can use some pharmacies, but not 
including your current one.”  The fourth level of access addressed the fact that some 
prescription drug plans like to encourage mail order pharmacy.  Within the conjoint 
analysis survey, this level was stated as “you must use mail order for full benefits.”   It 
was not stated that patients had to use mail order pharmacy as previous surveys stated, 
because within Medicare Part D, plans must provide some type of retail pharmacy 
coverage.43,44,77,78 
 
In addition, there has been some research which has looked at the pharmacies and the 
pharmacist from the point of comprehensiveness, or the degree of interaction the patient 
has with their pharmacist.44  Although, this was not a part of Cline and Mott’s Model on 
Prescription Drug Plan Choice,49 it was included in this model.  This study proposes to 
examine consumer preferences for the restrictiveness in being eligible to obtain 
Medication Therapy Management Services (MTM).  These are a set of services which 
can be provided by pharmacists, and are available to beneficiaries enrolled in Medicare 
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Part D plans in order to ensure optimal use of medications and reduce the risk of adverse 
drugs events.56   
 
At the time when this study was being constructed, Medicare Part D Prescription Drug 
Plans had considerable freedom in determining the eligibility criteria for MTM.56  MTM 
was targeted towards beneficiaries who had more than one chronic disease, were taking at 
least two drugs which were covered by Medicare Part D plans, and were likely to have 
annual costs for their Part D drugs that were higher than a preset amount (initially 
$4,000).56  Recent data demonstrated that approximately 55% of national Medicare Part 
D plans required patients to have only 2 chronic diseases to meet the requirement 
pertaining to multiple chronic diseases.56  Approximately a quarter of plans required 
patients to have at least three chronic diseases, 11.7% required patients to have at least 4 
chronic diseases, and 6.8% required patients to have at least 5 chronic diseases in order to 
be eligible for MTM.56  When looking at the minimum drug requirement, the data 
demonstrated that over 60% of plans required patients to have 5-8 drugs in order to meet 
this requirement.56  Just over 20% of plans required patients to have only 2-4 drugs in 
order to meet the requirement of having multiple drugs.56  The remainder of plans 
required patients to take at least 9 drugs in order to be eligible for MTM.56  These 
eligibility criteria are important in determining who participates in MTM, as over 75% of 
those who are eligible for MTM choose to participate.56  
 
This study used 4 different levels to access the restrictiveness of eligibility requirements 
for MTM as depicted in Table 3-8.  The first level was the least restrictive and required 
patients to have only 2 chronic diseases and take only 3 drugs in order to be eligible for 
MTM.  The next level was slightly more restrictive in that patients had to have at least 2 
chronic diseases and take at least 6 drugs in order to be eligible for MTM.  The third level 
required patients to have three chronic diseases and take at least 6 drugs in order to be 
eligible for MTM.  Finally, the fourth level required patients to have 4 chronic diseases 
and take at least 9 drugs in order to be eligible for MTM. 
 
 
Survey Instrumentation 
The survey was administered to seniors via Sawtooth Software’s ACBC.103  
Representative screens from the survey are shown in Appendix B.  The first part of the 
adaptive choice-based conjoint analysis instrument consisted of the build your own 
section.  In the first part of this section, respondents indicated which of the following they 
would prefer, holding all other factors constant:  
1. A PDP with a $310 deductible and a $30 monthly premium; 
2. A PDP with a $150 deductible and a $38 monthly premium; 
3. A PDP with a $0 deductible and a $46 monthly premium. 
After indicating their preference for this section, respondents were given the option to 
add doughnut hole coverage to their preferred plan.  Plans with a few generics covered 
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added $10 to the monthly premium, plans with many generics covered added $15 to the 
monthly premium, and plans with all generics covered added $20 to the monthly 
premium.   
After completing the Build-Your-Own section, the survey consisted of alternating 
sections of three types:  a screening task, an unacceptable section, or a must have section.  
In the screening tasks section, respondents were presented with four concepts and asked 
to indicate whether each one was a possibility or whether they would not consider each 
one in real life.  After completing the first three screening tasks, respondents were taken 
to the “unacceptables” section.  The features presented in this section involved levels 
where the respondent had not chosen a concept which included the level.  For example, if 
the respondent had not chosen any plans with a $45 or $95 copay for brand name 
medications, or any plans where the deductible was $310, then these levels could be 
presented in the unacceptables section.  After a respondent designated a level as 
unacceptable, it would not appear in the remainder of the survey.  Respondents were only 
allowed to mark one feature as unacceptable at a time, and there was no more than one 
level presented for an attribute at a time.  The “must have” section gave respondents a 
chance to select levels which they considered essential to have in a PDP.  For example if 
they felt that they would only select plans which had no deductible, they were given the 
opportunity to select a $0 deductible as a must have.  From this point on, all plans 
presented would have $0 deductibles.   The flow of this section was as follows:  3 
screening tasks, unacceptable #1, one screening task, unacceptable #2, must have #1, one 
screening task, unacceptable #3, must have #2, one screening task,  unacceptable #4, 
must have #3, two screening tasks.   
After completing the screening tasks, unacceptable, and must have sections in their 
entirety, the respondent was directed to complete the choice task tournament.  This 
section included the concepts which the respondent had indicated that they considered a 
possibility in the screening tasks.  Three concepts at a time were presented to 
respondents, and they were asked indicate which PDP they would select in real life.  
“winning” concepts were retained for subsequent rounds in the choice tournament so that 
respondents would have to select from among the concepts which they had chosen in 
previous rounds.   
 
 
Study Design  
 
This study focused on seniors who are Medicare members or eligible for Medicare, as 
this is the population that eligible for enrollment in Medicare Part D Prescription Drug 
Plans.  People who are over the age of 65, or younger individuals with permanent 
disabilities are eligible for enrollment in Medicare.1  During 2010, there were over 47 
million people enrolled in Medicare, and over 39 million of these were enrolled due to 
their age.1  This study focused on the elderly population as they comprise the bulk of the 
Medicare population.  Therefore, seniors who were at least 65 and currently enrolled in 
any form of Medicare were included in this study.  An informed consent form approved 
by the University of Tennessee Institutional Review Board was administered to 
participants in order to ensure that they understand the purpose of the study.  This 
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document is presented in Appendix C. Due to time constraints and limited financial 
resources, this analysis will be restricted to the Shelby County area of Tennessee.  In 
2007, there were just over 110,000 individuals on Medicare in Shelby County, and nearly 
87,000 of these individuals were eligible for enrollment in Medicare based on their  
age.104  Within Medicare, approximately 56% of the population is female, and over 52% 
of the population in Shelby County is female.105,106  Therefore, the proposed sample for 
this study was approximately 55% female. Also, within Shelby County, approximately 
52% of the population is African American, and approximately 45% of the population is 
white.106  People derived from other ethnic groups were not included in this study due to 
inadequate sample size.  Therefore, the proposed sample composition for this research 
was approximately 52%-55% black and 45%-48% white.  Accordingly, the inclusion 
criteria for this study was Non-Hispanic Black or Non-Hispanic White seniors over the 
age of 65 currently enrolled in Medicare who attended or resided at one of the sites where 
the study was conducted.  
 
Patients who had mental conditions such as retardation, Alzheimer’s disease or other 
psychiatric conditions which may preclude them from answering the questions correctly 
were excluded from the study.   In addition, the respondents had to be able to read and 
understand English.  Therefore, the exclusion criteria for this study included any 
cognitive challenges that precluded the respondent from accurately being able to respond 
to the questions such as psychiatric conditions and the inability to comprehend written or 
spoken English.   
 
 
Sample Size 
 
The computation of sample size within conjoint analysis studies is an unsettled issue.35  
Previous studies using conjoint analysis in the analysis of prescription drug plans have 
used 150 respondents or less.43,44  However there are some “rules of thumb” which may 
be helpful in deciding the sample size for a conjoint analysis study.  For example one 
formula used in traditional choice-based conjoint analysis suggests that nta/c>500.35  In 
this formula, n is the number of respondents, t is the number of tasks or questions which 
each respondent answers, a is the number of alternative choices presented to a patient in 
each question, and c is equal to the number of attributes in the study multiplied by the 
number of levels in the attribute with the greatest number of levels.35  If this study were 
done using traditional choice-based conjoint analysis, a good figure for the number of 
proposed tasks for each participant would be approximately 15, and the number of 
proposed alternatives presented for each task would be 4.  The number of attributes in 
this study was 8, and the highest number of levels within any attribute was limited to 4.  
Therefore, a good sample size for this study using traditional choice-based conjoint 
analysis would be approximately 267 participants.  However, this study used Adaptive 
Choice-Based Conjoint Analysis which actually requires a smaller sample size.103   
However in order to obtain accurate estimates for individual level estimates, a larger 
sample size was used and ensure adequate numbers for each of the genders and races in 
this group a sample size of 500 was targeted. 
 
54 
 
Study Setting 
 
The conjoint analysis survey was piloted among a small sample of students and staff at 
the University of Tennessee Health Science Center.  The survey was then piloted among 
15 seniors at the Bartlett Senior Center to refine clarity of questions and ensure that there 
were not too many attributes, and that the seniors were able to understand all of the 
material presented to them.  Initially, an attribute was included in order to define the 
quality of the plan, but in general seniors indicated that this attribute was not relevant.   
 
The original proposal was for this study to be conducted exclusively at senior centers 
located within Shelby County.  The investigator obtained the phone numbers of local 
senior centers and called the directors to enquire about the possibility of administering 
the survey, and also to find out how many senior citizens attend the facilities.107  The 
senior centers with which the investigator established contact and which gave verbal 
consent to allow the investigator to come in and administer the survey included the 
Raleigh-Frayser Senior Center, the J.K. Lewis Senior Center, the Bartlett Senior Center,  
the McWherter Senior Center, and the Orange Mound Community Service Center.  These 
senior centers represent diverse populations in Memphis.  The director of the Raleigh-
Frayser Senior Center estimated that they have a “couple hundred” seniors on any given 
day, and approximately 90% of them are over the age of 65.  The director of the J.K. 
Lewis Senior Center related that their daily census is approximately 100 seniors each day, 
and she estimates that 98% of them are at least 65 years old.  The McWherter Senior 
Center has approximately 90-100 seniors each day, and approximately 60% of them are 
estimated to be over the age of 65.  The director of the Orange Mound Community 
Service Center stated that there are approximately 200-250 seniors at the center daily, and 
approximately 65% are over the age of 65.   
 
The investigator worked with each director to set up times to come by the senior center 
and administer the survey to those seniors who are willing to participate.  Flyers were 
posted to inform seniors of the times and dates where the survey would be conducted at 
the respective center.  The director of the senior center and/or the service coordinator 
helped to inform seniors of the availability of the survey and kept records of who had 
taken the survey so that seniors would not take the survey more than once.   
 
After administering the survey at these senior centers for at three months, the investigator 
reached a saturation point at approximately 220 patients whereby most of the seniors 
encountered at these locations had either taken the survey or declined to take the survey.  
Accordingly, the investigator sought out alternative sites to conduct the study.  The 
investigator was able to establish contact with several senior homes which exclusively 
housed a senior population.108  These included apartments such as Latham Terrace, 
Magnolia Terrace, John Exum Towers, Linden Camilla Towers, Wesley Highland 
Meadows and Wesley Graceland Gardens.108   While working with resident coordinators, 
the investigator was able to interview as many as 15 patients in one day.  This 
represented a dramatic increase in the rate of interviews obtained by going to senior 
centers so that the investigator was able to obtain 497 completed interviews.  The data 
collection took place over a time period of six months. 
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The investigator sat down with participants and administered all materials to participants 
so that they were able to ask questions and gain clarification on items which they did not 
understand clearly.   This leads to better data quality as the investigator can explain the 
information to respondents so that they make a well informed decision.  The conjoint 
analysis portion itself took approximately 15 minutes per respondent, with some 
respondents completing this section in as little as 10 minutes and some taking as long as 
25 minutes.  The additional questions of the survey which were not attributes such as 
demographic information were also included in the survey.  On average, it took 
respondents about 10 minutes to complete these questions, so that the total survey took 
approximately 25 minutes to administer. 
 
 
Data Analysis 
 
This section discusses the analysis of the data gathered during the study.  Descriptions are 
provided in regards to the methods used to evaluate the three major outcomes produced 
as a result of conducting this study:  the part worth values, the importance scores, and the 
willingness to pay. 
 
 
Part Worth Values 
 
The utility values for the sample were derived using hierarchial bayes (HB) estimation 
through the use of Sawtooth Software’s CBC/HB software.109  Hierarchical bayes has 
lower and upper level models used in estimating the part worth values.110  A lower level 
model is used in estimating part worths at the individual level, and an upper level model 
is used in measuring population parameters.110  The lower model assumes that the 
individual’s partworths for each attribute which ultimately determine their probability for 
choosing a plan with specified characteristics conform to a multinomial logit model.110  
The lower model is described mathematically by the following equation: 
 
pk = exp(xk' ßi )/∑exp(xj' ßi).110 
 
The probability of choosing a particular product in comparison to other products is 
designated by pk.110  Several factors help to determine the probability in selecting a 
specific product or service, Xk.110  More specifically, this probability is a function of Xi, 
the levels which make up the product or service, and βi, the individual’s part worths for 
those specific levels.110  As the equation shows, the total utility derived by an individual 
from a given product is obtained by adding up the respondents part worths for each level 
presented in the specified product.110  The total utility is then exponentiated.110  After 
these same functions have been performed for all other alternatives presented to the 
respondent, the probability that the respondent will choose a given product is derived by 
dividing that product’s exponentiated utility by the total exponentiated utility of all 
alternatives presented.110  For example, consider product A with a total utility of 5, 
product B with a total utility of 7, and product C with a total utility of 8.  Raising e to the 
fifth power yields 148, while raising e to the sixth power yields 1097, and raising e to the 
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eighth power yields 2981.  In order to find the probability that any particular product will 
be chosen, one simply divides that products exponentiated utility by the sum of the total 
exponentiated utilities.110  In this example, the probability that product B will be chosen 
is 1097/4,226 or 26%.   
 
The upper model in HB is described by the mathematical formula Bi ~Normal (α,D).110  
Once again βi represents the part worths for an a specific respondents, while α is used to 
describe the estimate for the average part worth for the specified level across all 
respondents taking the survey.110  The distribution of the variances and covariances 
across all of the respondents is described by D.110  The HB model assumes that α and D 
can be approximated by a normal distribution.110        
 
The estimates for βi, α, and D are obtained using an iterative process called Gibbs 
Sampling.110  During this process, the program borrows information from the population 
parameters to influence the individual estimates so that they roughly conform to a normal 
distribution.110   In particular, when individual responses are uncharacteristic of the 
population’s responses as a whole, information is borrowed from the population 
characteristics in order to bring these responses more in line with population 
parameters.110  In this way, the utility estimates for each individual are stabilized by the 
population estimates.110  This process is repeated thousands of times until the estimates 
are assumed to converge to a set of values that fits the data well.110  After convergence is 
assumed, the program makes thousands of estimates of each respondent’s utilities using 
the data derived from the previous section.110  A point estimate of the respondent’s utility 
is produced after averaging all of these estimates.110  An estimate of α is obtained by 
taking the mean value of the thousands of estimates produced after convergence has been 
assumed.110 
 
The covariate feature of Sawtooth Software’s CBC/HB software was used in determining 
if the part worth values differed significantly between segments.110,111  For each covariate 
examined the software produces a point estimate of the magnitude of the difference in 
between the part worth being examined and the reference level examined.110,111  For 
example in examining race, the reference group of Caucasians may have a part worth 
0.787 for zero dollar copayments on generic medications.  However, the program also 
reports that blacks on average have a part worth value which is 0.165 higher than whites.  
In order to determine statistical significance, one examines the estimates of the added 
values in part worth due to the covariate after convergence has been assumed.110,111  In 
this study, 20,000 iterations were performed to allow for convergence, and an additional 
20,000 iterations were performed to allow for stable estimates of the α parameter.  The 
parth-worth estimates from the covariate of interest were examined at the 2.5% percentile 
and the 97.5%  percentile in order to obtain a 95% confidence interval and evaluate 
whether they were statistically significant.110,111  If the values crossed zero then they were 
not assumed to be significant.  So in this example, the value of the added part worth due 
to being black may be -0.031 at the 2.5% percentile and 0.293 at the 97.5% percentile, so 
it can not be termed significant because it includes zero. This process is explained in 
detail in a technical paper.110   
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After the part worth values were obtained using covariates in Sawtooth Software’s 
CBC/HB, the respective utility runes were imported into  Software’s SMRT program  and 
the utility runs were utilized with the appropriate group.112  For example, if the sample 
was divided into three groups based upon their pharmacy preference scores, the utility 
run obtained by using these preference scores as a covariate in CBC/HB were imported 
into SMRT and the sample was divided into these three segments in SMRT.  The SMRT 
program rescales the scores using a method known as zero centered diffs so that the total 
sum of the part worth between the least preferred and most preferred levels of each 
attribute across attributes is equal to the number of attributes times 100.112 
 
 
Importance Scores 
 
The importance scores for each attribute were determined to assess the relative 
importance consumers placed on each attribute.  Within each attribute the difference in 
utilities between levels holding the highest utility and the lowest utility were calculated to 
obtain the attribute utility range for that particular attribute.  These attribute utility ranges 
were summed to produce a utility range total.  The attribute utility ranges were divided by 
the utility range total to produce an importance score for the respective attribute.  These 
measures were performed using Sawtooth Software’s SMRT program.112 
 
 
Willingness to Pay 
 
The willingness to pay values were computed using standard methods in conjoint 
analysis.  The differences between the partworths values for the reference level and the 
level of interest were obtained and divided by the appropriate premium coefficient.113,114   
 
 
Protection of Human Subjects 
 
The study procedures were approved Institutional Review Board of the University of 
Tennessee Health Science Center in Memphis, TN.  A copy of the consent forms is 
available in the Appendix C.   All information was kept confidential and only the 
researcher had access to sensitive data. 
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CHAPTER 4.    RESULTS 
 
 
Description of Sample Characteristics 
 
A description of the sample’s demographic characteristics are provided in Table 4-1.   A 
total of 497 seniors were interviewed.  The sample had a mean age of approximately 74 
years.  Approximately 72% of the sample was female and approximately 28% was male.  
Most of the respondents (71%) were African American but there were also 144 
Caucasians interviewed.  Over 70% of the sample had graduated from high school, but 
just over 14% had obtained at least a bachelor’s degree.  Nearly a quarter (26%) of the 
respondents indicated they had completed some college without obtaining a four year 
degree.  A large portion of the seniors (53.5%) had incomes under $15,000, indicating 
that they were on relatively fixed incomes.  Only 7.6% of the respondents indicated that 
they had annual incomes in excess of $40,000 annually. Nearly four out of ten (38.8%) of 
the seniors interviewed had incomes of $15,000-$40,000 annually.  Less than half 
(42.3%) of the seniors indicated that they selected their prescription drug insurance plans 
on their own.   A few seniors reported receiving help from their family members (10.1%) 
or physician (2.2%) in helping to select a plan, but a sizable portion indicated that they 
received help from “other sources” such as service coordinators or social workers at their 
respective facilities or representatives from an insurance company.    
 
The characteristics of the study sample which are specific to their health status or their 
preferences for receiving health care are shown in Table 4-2.  On average, the sample 
had 2 comorbidities, although there was wide variation as the number of self reported 
comorbidities varied from 0-12.  There was also wide variation in the number of 
prescription medications utilized by the sample.  The mean number of medications 
utilized by respondents was 5.15, but there were some seniors who reported taking no 
prescription medications while some seniors reported taking as many as 20.  The study 
sample also had large differences in their monthly out of pocket expenditures on 
prescription medications.  While seniors reported spending over $38 per month on 
average, the range for this variable was $0 per month to $900 per month.  The 
respondent’s scores on the medical preferences ranged from 11-45 with a mean score of 
30.38 and a standard deviation of 8.30, indicating that there was also heterogeneity in the 
group regarding their medical preferences.  The pharmacy loyalty scores also had wide 
variation as the highest possible score was 15 and the lowest possible score was 3.  The 
mean score on this scale was 10.28 with a standard deviation of 2.41.  Some seniors were 
unable to respond to the questions designed to measure formulary generosity or 
formulary satisfaction, because they stated that may not have had to use the plan yet to 
obtain medications, they did not have a prescription insurance plan, or they had just 
recently obtained their current plan so that they had no experience with it yet.  In general, 
most of the seniors answering these questions indicated that their plan had an open 
formulary, and they were satisfied with their current insurance.  On a scale of 1-5 the 
mean score for the formulary generosity variables was 4.46 and the mean score on the 
formulary satisfaction variables was 4.41. 
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Table 4-1. Demographics of sample 
  
Variables (N=497) Number % 
Gender   
     Male 138 27.8 
     Female 359 72.2 
Race   
     White 144 29.0 
     Black 353 71.0 
Education   
     Less than high school 144 29.0 
     High school graduate  154 31.0 
     Some college  129 26.0 
     Bachelor’s or higher 70 14.1 
Income   
     $0-$10,000 113 22.7 
     $10,001-$15,000 153 30.8 
     $15,001-$20,000 87 17.5 
     $20,001-$30,000 78 15.7 
     $30,001-$40,000 28 5.6 
     $40,001-$50,000 14 2.8 
     More than $50,000 24 4.8 
How prescription drug insurance selected   
     Primarily on own 210 42.3 
     Family members 50 10.1 
     Physician 11 2.2 
     Pharmacist 0 0 
     No drug plan 6 1.2 
     Other source 219 44.1 
Note:  Mean age (SD)=73.93 (7.21). 
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Table 4-2. Medical care specific variables 
 
Variable (N=497) Minimum Maximum Mean SD 
Comorbidities 0 12 1.97 1.82 
Number of prescription medications 0 20 5.15 3.64 
Monthly cost of medications (dollars) 0 900 38.61 69.74 
Medical preference score 9 45 30.38 8.30 
Pharmacy loyalty score 3 15 10.28 2.41 
Formulary generosity score 1 5 4.46 0.86 
Formulary satisfaction score 1 5 4.41 0.89 
Notes:   Formulary generosity score computed from 460 valid responses and formulary 
satisfaction score computed from 467 valid responses. 
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Table 4-3 shows the average part worth values for the sample without using any 
covariates and before rescaling.  The premium had a strong effect on respondent’s utility 
as every marginal dollar increase above the average decreased a respondent’s utility for a 
plan by 0.551.  This lends strong support for study hypothesis number 1, so that the null 
hypothesis of stating that the premium has no effect on beneficiary’s choice of a plan 
could be rejected. Within brand copayments, the seniors who were surveyed displayed a 
strong preference for plans offering copayments of $25 or $50, as these copayment types 
had a part worth of 2.134.  The next level within copayments that was preferred most 
among the sample was copayments of $35 or $60 followed by copayments of 25%.  
However, there was relative indifference between 25% cost sharing levels and copayment 
levels of $35 or $60 as the upper 95% confidence interval for 25% costsharing plans is 
higher than the lower 95% confidence interval of $35 or $60 copayments.  The $45 or 
$95 copayment had the lowest part worth value.  These results support study hypothesis 
number 2 as it is clear that lower copayment amounts are associated with higher utility 
values, ultimately leading to a greater probability that a plan would be selected. 
 
Within generic copayments the most preferred level was $0 copayments, followed by 
copayments of $7.  The copayment structure of $7 or 50% was the third most preferred 
level, while 25% coinsurance was the least preferred level within this attribute.   
However, there was not a statistically significant difference between the 25% costsharing 
levels and the $7 or 50% copayment structure as the confidence intervals for these two 
levels crossed.  These results also help to support study hypothesis #2. 
 
Strong consumer preferences were displayed within the deductible attribute and followed 
a logical order.  The difference in part worth values from $0 to $150 (5.147) was nearly 
identical to the difference in part worth values in going from $150 to $310 (5.194).   
These results clearly support study hypothesis #3 so that the null hypothesis of the 
deductible amount having no effect on a senior’s choice of a PDP may be rejected. 
 
Within the attribute of doughnut hole coverage, the least preferred level was few generics 
covered followed by no generics covered in the doughnut hole.  However, there is no 
statistical significance in between these levels as the confidence intervals share common 
values.  With both of these levels, the part worth was approximately -2.  The most 
preferred level in this attribute was coverage for all generics in the doughnut hole, with a 
part worth over 4 followed by having some generics covered in the doughnut hole.  These 
results seem to support research hypothesis #4 but only to a certain degree.  In general the 
seniors seem to exhibit greater utility for having plans where all or most of the generics 
are covered within the doughnut hole, but only including a few generics covered during 
this period does not affect their utility in a way that is different from having no doughnut 
hole coverage whatsoever.  Within the attribute of formulary coverage, respondents 
indicated a rational order where they preferred to have all of their medications without 
restrictions.  The most preferred level was to have all drugs covered with no restrictions, 
followed by having all drugs covered with some restrictions.  However these measures 
are not statistically significant from each other as their confidence intervals share 
common values.  The level that was preferred the third most in this attribute was some 
drugs covered with no restrictions, level.  These results support research hypothesis #5. 
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Table 4-3. Part worths for aggregate sample 
 
Attributes  Part 
worth 
SE Lower 
95% CI 
Upper 
95% CI 
Premium (per dollar increase at average) -0.551 0.01 -0.600 -0.506 
Brand copayment     
     $25 or $40 2.134 0.05 1.899 2.342 
     25% 0.522 0.05 0.305 0.750 
     $35 or $60 0.845 0.05 0.628 1.103 
     $45 or $95 -3.502 0.10 -3.94 -3.073 
Generic copayment     
     $0 1.536 0.06 1.311 1.785 
     $7 -0.065 0.03 -0.313 0.127 
     25% -0.879 0.04 -1.130 -0.625 
     $7 or 50% -0.593 0.03 -0.835 -0.401 
Doughnut hole coverage     
     None -1.914 0.04 -2.343 -1.296 
     Few generics covered -2.133 0.07 -2.925 -1.285 
     Some generics covered -0.104 0.06 -0.354 0.184 
     All generics covered 4.151 0.08 3.397 5.020 
Formulary coverage     
     All drugs covered no restrictions 4.911 0.11 4.465 5.391 
     All drugs covered some restrictions 4.077 0.12 3.661 4.568 
     Some drugs covered no restrictions -2.123 0.11 -2.697 -1.600 
     Some drugs covered some restrictions -6.864 0.11 -7.637 -6.247 
Pharmacy access     
     All pharmacies available 3.071 0.08 2.625 3.385 
     Some pharmacies available including       
     current 
2.885 0.09 2.490 3.248 
     Some pharmacies available not including  
     current 
-3.986 0.14 -4.597 -3.359 
     Mail order used for best benefits -1.970 0.11 -2.466 -1.465 
Deductible     
     $0 5.163 0.14 4.724 5.646 
     $150 0.016 0.05 -0.211 0.251 
     $310 -5.178 0.12 -5.681 -4.747 
MTM  eligibility     
     2 diseases and 3 drugs required -0.090 0.03 -0.268 0.081 
     2 diseases and 6 drugs required -0.022 0.02 -0.167 0.150 
     3 diseases and 6 drugs required 0.105 0.03 -0.069 0.259 
     4 diseases and 9 drugs required 0.007 0.02 -0.160 0.171 
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Table 4-3.       (continued) 
 
   
Attributes Part 
worth 
SE Lower 
95% CI 
Upper 
95% CI 
None -9.300 0.43 -10.747 -7.397 
Notes:  SE indicates standard error and CI indicates confidence interval. 
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However, in general the seniors indicated no significant differences in between having all 
of their medications covered with no restrictions and all of their medications covered 
with some restrictions. 
 
Within the pharmacy access attribute the most preferred level was to have all pharmacies 
available, although it was not statistically different from having only some pharmacies 
available but being able to continue using the current one.  The least preferred level 
within this attribute was not being able to use the current pharmacy, while having to use 
mail order to obtain the best benefits was the third most preferred level and significantly 
different from other levels in this attribute.  These results clearly support research 
hypothesis 6. 
 
The part worth values for MTM eligibility do not reflect a logical order and have 
relatively small part worths.  This may indicate that this attribute was not clearly 
understood by the respondents despite the researcher’s efforts to explain them, or the 
respondents may not have placed great importance on this attribute when compared to 
other attributes.   Therefore, in this study we fail to reject the null hypothesis that the 
restrictiveness in MTM eligibility requirements affects beneficiary’s selection of a 
prescription drug plan.   
 
The value placed on the none parameter was -9.300 which represents the intercept for the 
purchaser’s decision threshold.  In order for a respondent to consider purchasing the 
product, the product must have a positive magnitude greater than the none threshold.  For 
the general sample, a Part D plan must have a utility greater than 9.300 for the consumer 
to consider purchasing it.  
 
The part worths are shown after they have been rescaled using the zero centered diffs 
method in Table 4-4.  The part worths were scaled so that the total sum of the part worth 
between the least preferred and most preferred levels of each attribute across attributes is 
equal to the number of attributes times 100 as specified by the Sawtooth SMRT system.  
Throughout the remainder of the results sections, part worth values will be presented 
using this method, as it facilitates easier interpretation of the results. 
 
The importance scores for the total sample are shown in Table 4-5.  The premium was 
overwhelmingly the most important factor with an importance score of 50.3%.  the 
second most important attribute was formulary coverage with a score of 12.1% followed 
closely by the deductible with an importance score of 11.6%.  Pharmacy access was the 
fourth most important attribute with an importance score of 10.1% and the brand 
copayment was the fifth most important attribute with an importance score of 7.0%.  The 
generic copayment (3.7%) was slightly more important than doughnut hole coverage 
(3.5%), while MTM eligibility had an importance score of 1.7%. 
 
The marginal willingness to pay values are presented in Table 4-6.   In this study the 
marginal WTP represents the change in premiums that customers would need in order to 
have the characteristic in that level as opposed to the reference level within the specified 
attribute.  In general copayments had a relatively modest effect on this parameter,  
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Table 4-4. Part worths for aggregate sample rescaled 
 
Attributes (N=497) Part worth 
Premium (per dollar increase at average) -4.71 
Brand copayment  
     $25 or $40 20.09 
     25% 3.33 
     $35 or $60 7.81 
     $45 or $95 -31.23 
Generic copayment  
     $0 14.16 
     $7 -0.11 
     25% -8.57 
     $7 or 50% -5.49 
Doughnut hole coverage  
     None -2.81 
     Few generics covered -10.11 
     Some generics covered -2.21 
     All generics covered 10.70 
Formulary coverage  
     All drugs covered no restrictions 46.95 
     All drugs covered some restrictions 38.09 
     Some drugs covered no restrictions -38.52 
     Some drugs covered some restrictions -46.52 
Pharmacy access  
     All pharmacies available 28.90 
     Some pharmacies available including   
     current 
26.83 
     Some pharmacies available not including    
     current 
-38.08 
     Mail order used for best benefits -17.65 
Deductible  
     $0 45.52 
     $150 0.70 
     $310 -46.22 
MTM  eligibility  
     2 diseases and 3 drugs required -0.80 
     2 diseases and 6 drugs required -0.03 
     3 diseases and 6 drugs required 0.77 
     4 diseases and 9 drugs required 0.06 
None  -73.06 
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Table 4-5. Importance scores for total sample 
 
Attributes Importance  
 scores 
Premium 50.3% 
Formulary coverage 12.1% 
Deductible 11.6% 
Pharmacy access 10.1% 
Brand copayment 7.0% 
Generic copayment 3.7% 
Doughnut hole coverage 3.5% 
MTM eligibility 1.7% 
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Table 4-6. Marginal WTP for aggregate sample rescaled 
 
Attributes Marginal WTP 
Premium (per dollar increase at average) -4.71 
Brand copayment  
     $25 or $40 $4 
     25% Reference 
     $35 or $60 $1 
     $45 or $95 -$7 
Generic copayment  
     $0 $5 
     $7 $2 
     25% Reference 
     $7 or 50% $1 
Doughnut hole coverage  
     None Reference 
     Few generics covered & 
     Some generics covered $0 
     All generics covered $3 
Formulary coverage  
     All drugs covered no restrictions $2 
     All drugs covered some restrictions Reference 
     Some drugs covered no restrictions -$16 
     Some drugs covered some restrictions -$18 
Pharmacy access  
     All pharmacies available $0 
     Some pharmacies available including   
     current 
Reference 
     Some pharmacies available not including    
     current 
-$14 
     Mail order used for best benefits -$9 
Deductible  
     $0 $10 
     $150 Reference 
     $310 -$10 
MTM  eligibility  
     2 diseases and 3 drugs required & 
     2 diseases and 6 drugs required & 
     3 diseases and 6 drugs required & 
     4 diseases and 9 drugs required & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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although respondents indicated that they would have to be paid approximately $7 in order 
to accept a brand copayments of $45 or $95 when compared to the reference of 25% cost 
sharing.  Including free generics increased the marginal WTP by $4 from the reference of 
25% cost sharing.  Having all generics covered in the doughnut hole increased the 
marginal WTP by $3 from the reference of having no drugs covered within the doughnut 
hole.  Due to the illogical part worth values in the study, where many seniors seemed to 
indicate a greater preference for having no generics covered at all in the doughnut hole as 
opposed to having a few generics covered in the doughnut hole, no marginal WTP values 
were presented for comparing the preference level of a few generics in comparison to 
none at all.  Within formulary coverage, the attribute level of only covering some drugs 
without any restrictions decreased the marginal WTP by $16 from the reference of having 
all drugs covered with some restrictions.  Seniors indicated that they would have to be 
paid $18 to accept plans which covered some drugs with some restrictions in comparison 
to the reference of having all drugs covered with some restrictions. Within the pharmacy 
access attribute, plans which did not contract with the respondent’s current pharmacy had 
a marginal WTP $14 lower than the reference level of covering some pharmacies 
including the respondent’s current pharmacy.  On average, seniors indicated that they 
would have to be paid $9 in order to accept having to use mail order for the best benefits.   
With regards to the deductible, seniors indicated that they would be willing to pay 
approximately $10 more in premiums to have no deductibles in comparison to a $150 
deductible.  Likewise, the study sample demonstrated that including a $310 deductible in 
a plan would lower their WTP in premiums by approximately $10 per month when  
compared to a similar plan with a $150 deductible.   
 
 
Results by Age 
 
The parts worths by age are presented in Table 4-7.  The seniors were divided into two 
groups according to their age, those who were 65-75 years old, and those over the age of 
75.  In general, the younger senior citizens between the ages of 65-75 had similar 
preferences to those over the age of 75.  However, seniors between 65-75 had a greater 
aversion to having few generics covered in the doughnut hole and stronger preferences to 
having all generics covered in the doughnut hole.  In addition, the part worth values for 
older senior citizens was significantly higher for having some drugs covered with no 
restrictions and also some drugs covered with some restrictions.  However, in these 
particular cases the seniors still displayed logical preferences for plans which would offer 
greater drug coverage.  Another noteworthy feature of this table is the fact that the none 
parameter is nearly 20 points higher for the seniors above the age of 75 as it is for those 
seniors between the age of 65-75 although this value is not statistically significant.  This 
is probably due to the relatively large standard error of this parameter, but it is a 
difference that stands out nevertheless.  In addition, it is important to note that these 
results do not support study hypothesis number 9 as there is no statistically significant 
difference in between these two groups in regards to the part worth value for the 
premium.  The importance scores by age are shown in Table 4-8.  In both of these 
groups, the premium is the most important factor, although it seems to take on slightly 
greater importance for the older seniors.  Within both groups, the amount of drugs 
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Table 4-7. Part worth values by age rescaled   
 
Attributes 65-75 Over 75 
Premium (per dollar increase at average) -4.64 -4.83 
Brand copayment   
     $25 or $40 21.83 17.96 
     25% 3.73 3.42 
     $35 or $60 8.95 6.40 
     $45 or $95 -34.51 -27.78 
Generic copayment   
     $0 15.52 10.66 
     $7 -0.56 0.36 
     25% -9.34 -6.58 
     $7 or 50% -5.62 -4.43 
Doughnut hole coverage   
     None -4.70 -2.96 
     Few generics covered -10.16 -8.99* 
     Some generics covered 2.45 3.70 
     All generics covered 12.41 8.25* 
Formulary coverage   
     All drugs covered no restrictions 49.02 42.83 
     All drugs covered some restrictions 39.91 35.70 
     Some drugs covered no restrictions -43.24 -35.01* 
     Some drugs covered some restrictions -45.39 -43.52* 
Pharmacy access   
     All pharmacies available 27.73 28.71 
     Some pharmacies available including current 27.14 25.40 
     Some pharmacies available not including current -38.29 -33.96 
     Mail order used for best benefits -16.59 -20.15 
Deductible   
     $0 46.25 44.16 
     $150 3.21 0.83 
     $310 -49.47 -44.98 
MTM  eligibility   
     2 diseases and 3 drugs required 0.15 -1.55 
     2 diseases and 6 drugs required 0.13 0.44 
     3 diseases and 6 drugs required -0.59 2.11 
     4 diseases and 9 drugs required 0.31 -1.01 
None  -66.42 -85.34 
Note:  * indicates significant difference from age 65-75 at P=0.05 level. 
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Table 4-8. Importance scores by age 
 
Attributes 65-75 Over 75 
 importance scores importance scores 
Premium 49.4% 52.4% 
Formulary coverage 12.1% 11.5% 
Deductible 12.0% 11.6% 
Pharmacy access 9.9% 9.7% 
Brand copayment 7.5% 6.6% 
Generic copayment 3.9% 3.3% 
Doughnut hole coverage 3.6% 3.1% 
MTM eligibility 1.7% 1.8% 
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covered in the formulary and the deductible amount are nearly equivalent in importance 
and similar to that seen in the aggregate group.  In the 65-75 year old group and the group 
with ages over 75, the degree of pharmacy access was the fourth most important factor in 
decisions of purchasing a prescription drug plan with an importance score of 
approximately 9.8%.  The copayments on brand medications were the fifth most 
important factor in determining choice of a prescription drug plan.     
 
The marginal WTP values by age are presented in Table 4-9.  The stronger preference for 
younger seniors in having comprehensive generic doughnut hole coverage is reflected by 
a slightly higher marginal WTP when compared to older individuals.   Younger senior 
citizens were willing to pay $4 for full doughnut hole coverage while older senior citizens 
were only willing to pay $2 for full doughnut hole coverage.  The slightly greater 
decrease in part worths for having only some drugs covered in younger senior citizens is 
reflected in the WTP for measures.  In addition, the WTP was decreased by $16 for 
having some drugs covered with restrictions for seniors over the age of 75 and $22, for 
seniors ages 65-75, reflecting the fact that younger seniors had lower utilities for this 
attribute level.  The seniors under the age of 65 as well as the seniors over the age of 65 
indicated that they would have be paid at least $12 monthly in order to accept plans 
which did not feature coverage with their current pharmacy, and they also demonstrated 
that they would have to be paid $9 per month in order to accept plans where mail order 
was used in order to obtain the best benefits. 
 
 
Results by Gender 
 
The parts worths are presented by gender in Table 4-10.  The preferences levels within 
each attribute are consistent with what is observed in the general sample.  However, the 
part worths for no doughnut hole coverage and a $150 deductible were significantly 
lower in females than males.  The part worth for having all generics covered in the 
doughnut hole was significantly higher for males than males.  Within the brand 
copayments, the female senior citizens had stronger preferences for the $25 or $40 level 
in brand copayments, but this difference was not statistically significant.  Similarly, they 
displayed greater preferences for $0 generic medications but this difference was not 
statistically significant.  The female senior citizens also had a greater aversion to the 
higher priced brand medications priced at $45 for preferred brand medications and $95 
for non preferred brand medications, although once again this was not statistically 
significant.  Males did not seem to place quite as great as a preference on being able to 
retain their current pharmacy.  The part worth values for being able to use all pharmacies, 
and being able to use some pharmacies including the current one were lower for males in 
comparison to females.  Moreover, the part worth value for females was lower when only 
some pharmacies were covered in a plan but the respondent’s current pharmacy was not 
one of those covered.  In general, these results do not indicate a considerable degree of 
difference in between males and females in regards to their preferences for different 
attributes within PDPs. 
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Table 4-9. Marginal WTP by age rescaled 
 
Attributes 65-75 Over 75 
Premium (per dollar increase at average) -4.64 -4.83 
Brand copayment   
     $25 or $40 $4 $3 
     25% Reference Reference 
     $35 or $60 $1 $1 
     $45 or $95 -$8 -$6 
Generic copayment   
     $0 $5 $4 
     $7 $1 $1 
     25% Reference Reference 
     $7 or 50% $1 $0 
Doughnut hole coverage   
     None Reference Reference 
     Few generics covered & & 
     Some generics covered $2 $1 
     All generics covered $4 $2 
Formulary coverage   
     All drugs covered no restrictions $2 $1 
     All drugs covered some restrictions Reference Reference 
     Some drugs covered no restrictions -$18 -$15 
     Some drugs covered some restrictions -$18 -$16 
Pharmacy access   
     All pharmacies available $0 $1 
     Some pharmacies available including  
     current 
Reference Reference 
     Some pharmacies available not including  
     current 
-$14 -$12 
     Mail order used for best benefits -$9 -$9 
Deductible   
     $0 $9 $9 
     $150 Reference Reference 
     $310 -$11 -$9 
MTM  eligibility   
     2 diseases and 3 drugs required & & 
     2 diseases and 6 drugs required & & 
     3 diseases and 6 drugs required & & 
     4 diseases and 9 drugs required & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
 
73 
 
Table 4-10.   Part worth values by gender rescaled 
 
Attributes Males Females 
Premium (per dollar increase at average) -4.80 -4.67 
Brand copayment   
     $25 or $40 18.13 20.58 
     25% 2.34 4.27 
     $35 or $60 7.58 7.74 
     $45 or $95 -28.05 -32.59 
Generic copayment   
     $0 11.52 14.07 
     $7 2.36 -0.71 
     25% -8.73 -7.81 
     $7 or 50% -5.15 -5.55 
Doughnut hole coverage   
     None -4.50 -2.69* 
     Few generics covered -13.14 -8.10 
     Some generics covered 2.88 1.57 
     All generics covered 14.76 9.22* 
Formulary coverage   
     All drugs covered no restrictions 48.37 47.40 
     All drugs covered some restrictions 35.58 40.32 
     Some drugs covered no restrictions -36.54 -38.99 
     Some drugs covered some restrictions -47.42 -48.73 
Pharmacy access   
     All pharmacies available 25.19 29.32 
     Some pharmacies available including current 21.15 27.31 
     Some pharmacies available not including  
     current 
-33.99 -38.96 
     Mail order used for best benefits -12.35 -17.66 
Deductible   
     $0 40.33 47.17 
     $150 5.72 -0.47* 
     $310 -46.06 -46.70 
MTM  eligibility   
     2 diseases and 3 drugs required -0.84 -1.14 
     2 diseases and 6 drugs required -0.58 0.89 
     3 diseases and 6 drugs required 0.05 0.08 
     4 diseases and 9 drugs required 1.37 0.17 
None  -82.85 -70.68 
Note:  * indicates significant difference from males at P=0.05 level. 
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The importance scores are presented by gender in Table 4-11.  In general, the importance 
scores are similar and are consistent with results seen in the aggregate sample.   However 
there are some features of note.  In particular, the premium appeared to be marginally 
more important to males where the value was 51.7% in males and 50.0% in females.  The 
slightly higher value of doughnut hole coverage to males is reflected in this table as the 
value of doughnut hole coverage is 4.1% in males and 2.9% in females.  The pharmacy 
access attribute was marginally more important in females as it carried a value of just 
over 10% in females while it was 9.1% in males.    
 
The marginal WTP for attribute levels by gender are shown in Table 4-12.  In general, 
these results are very similar to each other and follow the same trends as seen in the 
general sample.  The biggest differences in between the groups are in the formulary 
coverage and pharmacy access components.  Females had to be paid more in order to 
accept plans with limited drug coverage.  In order to accept plans with some drugs 
covered but no restrictions, females indicated that they would have to be paid $17 per 
month as opposed to $15 monthly for males.  In addition, the female senior citizens 
demonstrated that they would have to be paid $19 per month in order to accept plans 
were only some drugs were covered with some restrictions, while this value was $17 
monthly for males.  There also seemed to be slight differences in between the groups with 
regards to their willingness to pay for in regards to pharmacy access.  Female senior 
citizens indicated that they would have to be paid $14 monthly to accept plans which 
offered coverage at some pharmacies, but not their current one.  Males demonstrated that 
they would have to be paid $12 per month in order to take a plan where their current 
pharmacy was not covered.   
 
 
Results by Race 
 
The parts worths by race are presented in Table 4-13.  Whites were significantly less 
sensitive to increases in premiums than blacks.  In addition whites displayed relative 
higher part worths to having a copayment of $45 or $95 on a brand name medication, and 
also in regards to having greater amounts of doughnut hole coverage, and these values 
were significantly different at the P=0.05 level.  Whites had significantly lower part 
worth values for plans which lacked doughnut hole coverage.  Blacks had higher utility 
values for a zero deductible and lower utility values for a $310 deductible.  In addition, 
the value of the none parameter was significantly higher for blacks when compared to 
whites.  Moreover there were some results which were not statistically significant, but 
may be noteworthy.  Whites had higher part worth values for having all of their 
medicines covered with no restrictions, and also having all of their medicines covered 
with some restrictions.  In addition, the part worth value was lower for whites when only 
some drugs were covered with some restrictions, although this value was not statistically 
significant.  Finally, the white seniors demonstrated lower part worth values for having 
only some pharmacies included in the plan where their current pharmacy was not 
included.  Although there are some differences in between blacks and whites, the 
differences between these groups is not as great as the difference seen in other groups. 
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Table 4-11.   Importance scores by gender 
 
Attributes Males Females 
 importance scores importance scores 
Premium 51.7% 50.0% 
Formulary coverage 12.3% 12.5% 
Deductible 11.2% 11.8% 
Pharmacy access 9.1% 10.2% 
Brand copayment 6.6% 7.2% 
Generic copayment 3.3% 3.6% 
Doughnut hole coverage 4.1% 2.9% 
MTM eligibility 1.7% 1.7% 
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Table 4-12.   Marginal WTP by gender rescaled 
 
Attributes Males Females 
Premium (per dollar increase at average) -4.80 -4.67 
Brand copayment   
     $25 or $40 $3 $3 
     25% Reference Reference 
     $35 or $60 $1 $1 
     $45 or $95 -$6 -$8 
Generic copayment   
     $0 $4 $5 
     $7 $2 $2 
     25% Reference Reference 
     $7 or 50% -$1 $0 
Doughnut hole coverage   
     None Reference Reference 
     Few generics covered & & 
     Some generics covered $2 $1 
     All generics covered $3 $3 
Formulary coverage   
     All drugs covered no restrictions $3 $2 
     All drugs covered some restrictions Reference Reference 
     Some drugs covered no restrictions -$15 -$17 
     Some drugs covered some restrictions -$17 -$19 
Pharmacy access   
     All pharmacies available $1 $0 
     Some pharmacies available including  
     current 
Reference Reference 
     Some pharmacies available not including  
     current 
-$12 -$14 
     Mail order used for best benefits -$7 -$10 
Deductible   
     $0 $7 $10 
     $150 Reference Reference 
     $310 -$11 -$10 
MTM  eligibility   
     2 diseases and 3 drugs required & & 
     2 diseases and 6 drugs required & & 
     3 diseases and 6 drugs required & & 
     4 diseases and 9 drugs required & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-13.   Part worth values by race rescaled 
 
Attributes Blacks Whites 
Premium (per dollar increase at average) -4.93 -4.19* 
Brand copayment   
     $25 or $40 18.84 23.06 
     25% 5.22 -1.55* 
     $35 or $60 8.12 5.90 
     $45 or $95 -32.17 -27.40* 
Generic copayment   
     $0 14.34 11.71 
     $7 -0.31 0.54 
     25% -9.38 -6.78 
     $7 or 50% -4.65 -5.48 
Doughnut hole coverage   
     None -0.93 -8.69* 
     Few generics covered -6.30 -20.38* 
     Some generics covered 0.90 8.21* 
     All generics covered 6.33 20.87* 
Formulary coverage   
     All drugs covered no restrictions 43.60 55.64 
     All drugs covered some restrictions 36.30 53.43 
     Some drugs covered no restrictions -37.71 -40.89 
     Some drugs covered some restrictions -42.18 -58.18 
Pharmacy access   
     All pharmacies available 27.06 30.81 
     Some pharmacies available including current 25.37 27.73 
     Some pharmacies available not including current -35.20 -43.20 
     Mail order used for best benefits -17.23 -15.34 
Deductible   
     $0 46.65 42.40* 
     $150 1.38 2.08 
     $310 -48.02 -44.48* 
MTM  eligibility   
     2 diseases and 3 drugs required -1.18 1.03 
     2 diseases and 6 drugs required 0.35 0.42 
     3 diseases and 6 drugs required 0.47 -0.26 
     4 diseases and 9 drugs required 0.37 -1.19 
None  -86.28 -44.93 
Note:  * indicates significant difference from blacks at P=0.05 level. 
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The importance scores are presented by race in Table 4-14.  The higher value that 
African Americans place on the premium is reflected in this table as the value for this 
attribute is nearly 7 points higher in blacks than whites.   Caucasians place more 
emphasis on formulary provisions than blacks as reflected by the fact that this was the 
second most important attribute to Caucasians while it was the third most important 
attribute for African Americans.  The value for this attribute was over 14% in whites and 
11.2% in blacks.  The deductible was the second most important attribute for African 
Americans and the third most important for whites.  Another distinction in between the 
groups is that doughnut hole coverage was more important than generic copayments in 
the whites, a departure from the pattern seen in the aggregate sample.  In blacks, however 
the generic copayments were more important than doughnut hole coverage.  This alludes 
to the fact that doughnut hole carried a higher importance in whites at 5.5% compared to 
2.7% for blacks. 
 
The marginal WTP values are presented by race in Table 4-15.  The greater preferences 
by whites for lower brand copays are reflected in a marginal WTP of $6 for $25 or $40 
brand copays in comparison to blacks having a marginal WTP of $3 when using a 
reference of 25% costsharing.  In addition, the marginal WTP is decreased $2 more in 
blacks than in whites when a $45 or $95 copayment is imposed.  The greater emphasis 
that whites place on formulary coverage is demonstrated by their marginal WTP 
thresholds being decreased by greater amounts than blacks when plans cover some 
medications as opposed to the reference of covering all drugs with some restrictions.  On 
average, whites indicated that they would have to be paid at least $23 in order to accept 
plans where only some of their medications were covered, a contrast to the $15 figure for 
blacks.  One particular finding of note is that in general, whites were willing to pay $4 
more for some generics covered in the doughnut hole, and $7 more to have all generics 
covered in the doughnut hole. 
 
 
Results by Income 
 
Table 4-16 shows the part worths by income.  There were marked differences between 
these groups in premium sensitivity as both low (up to $15,000 annual income, and 
middle income ($15,000-$30,000 in annual income) were more sensitive to increases in 
premiums than high income seniors (above $30,000 annually).  Furthermore, both of the 
lower income groups tended to have a greater aversion to being required to use mail order 
for the best benefits when compared to the high income group.  In addition, the middle 
and lower income groups placed greater utility on being able to use all pharmacies or 
their current pharmacy.  In regards to the level some pharmacies available but not 
including the current one, the low income group demonstrated significantly lower part 
worth values in comparison to the high income group.  There were also differences 
between the high income group and the other groups in their part worths for deductible 
levels.  The middle and low income groups had significantly higher part worths for zero 
dollar incomes and significantly lower part worths for the $310 deductible.  Finally, both 
the middle and low income groups had a greater magnitude on the “none” parameter in 
comparison to the high income group.   
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Table 4-14.   Importance scores by race 
 
Attributes Blacks   Whites 
 importance scores importance scores 
Premium 52.5% 45.3% 
Formulary coverage 11.2% 14.1% 
Deductible 11.9% 11.0% 
Pharmacy access 9.7% 10.9% 
Brand copayment 6.9% 7.3% 
Generic copayment 3.5% 4.0% 
Doughnut hole coverage 2.7% 5.5% 
MTM eligibility 1.6% 1.9% 
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Table 4-15.   Marginal WTP by race rescaled 
 
Attributes Blacks Whites 
Premium (per dollar increase at average) -4.93 -4.19 
Brand copayment   
     $25 or $40 $3 $6 
     25% Reference Reference 
     $35 or $60 -$1 $2 
     $45 or $95 -$8 -$6 
Generic copayment   
     $0 $4 $4 
     $7 $1 $2 
     25% Reference Reference 
     $7 or 50% $1 $0 
Doughnut hole coverage   
     None Reference Reference 
     Few generics covered & & 
     Some generics covered $0 $4 
     All generics covered $1 $7 
Formulary coverage   
     All drugs covered no restrictions $1 $1 
     All drugs covered some restrictions Reference Reference 
     Some drugs covered no restrictions -$15 -$23 
     Some drugs covered some restrictions -$16 -$27 
Pharmacy access   
     All pharmacies available $0 $1 
     Some pharmacies available including  
     current 
Reference Reference 
     Some pharmacies available not including    
     current 
-$12 -$17 
     Mail order used for best benefits -$9 -$9 
Deductible   
     $0 $9 -$9 
     $150 Reference Reference 
     $310 -$10 -$11 
MTM  eligibility   
     2 diseases and 3 drugs required & & 
     2 diseases and 6 drugs required & & 
     3 diseases and 6 drugs required & & 
     4 diseases and 9 drugs required & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-16.   Part worth values by income rescaled 
 
Attributes Low Middle High  
Premium (per dollar increase at average) -5.11* -4.35* -3.34 
Brand copayment    
     $25 or $40 19.86 19.27 31.93 
     25% 6.97* 0.18 -10.46 
     $35 or $60 8.13* 10.84* -0.38 
     $45 or $95 -34.97* -30.29 -21.10 
Generic copayment    
     $0 14.38 11.87 15.11 
     $7 -2.44 1.25 10.62 
     25% -7.38 -9.12 -9.22 
     $7 or 50% -4.56 -4.00 -16.51 
Doughnut hole coverage    
     None 1.57* -7.11* -12.72 
     Few generics covered -4.45* -15.74* -20.04 
     Some generics covered -0.90* 6.84* 4.00 
     All generics covered 3.78 16.01* 28.77 
Formulary coverage    
     All drugs covered no restrictions 42.02 48.74 68.29 
     All drugs covered some restrictions 36.07 38.63 55.46 
     Some drugs covered no restrictions -37.22 -39.58 -49.95 
     Some drugs covered some restrictions -40.87 -47.79 -73.80 
Pharmacy access    
     All pharmacies available 26.93* 31.16* 22.33 
     Some pharmacies available including current 25.84* 29.29* 15.05 
     Some pharmacies available not including  
     current 
-33.70* -44.99 -32.92 
     Mail order used for best benefits -19.07* -15.45* -4.46 
Deductible    
     $0 48.35* 41.93* 40.31 
     $150 -1.85 4.46 6.04 
     $310 -46.50* 46.39* -46.35 
MTM  eligibility    
     2 diseases and 3 drugs required -0.79 1.04 -7.48 
     2 diseases and 6 drugs required -0.38 1.84 2.15 
     3 diseases and 6 drugs required 1.09 -2.23 6.17 
     4 diseases and 9 drugs required 0.09 -0.65 -0.83 
None  86.99* 61.93* -12.15 
Note:  * indicates significant difference from high income group at P=0.05 level. 
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The importance scores are presented by income in Table 4-17.  Although premium is the 
most important attribute within each group, the magnitude of the value is 9.1 percentage 
points higher in the middle income group and 15.6% points higher in the low income 
group.  These values, along with the part worth of the premiums support hypothesis #8 in 
demonstrating that high income seniors are willing to pay higher premiums after holding 
all other factors constant.  Formulary coverage is relatively more important in the high 
income group and the middle income group in comparison to the low income groups, as it 
is the second most important attribute in the middle income and high income groups, but 
the third most important attribute in the low income groups.  In addition, copayments 
carry greater importance in the high income group in comparison to the low and high 
income groups.  There is also a trend of doughnut hole coverage becoming more 
important as income increases.  
 
The marginal WTP values are presented by income in Table 4-18.  The high income 
group had noticeably higher marginal WTP values for low copayments.  The greater 
emphasis that the high income group places on formulary provisions is reflected by the 
larger relative decrease in marginal WTP for having only some medications covered 
when compared to the groups with lower incomes.  Having to use mail order for the best 
benefits also decreased marginal WTP by a smaller amount in the high income group 
when compared to the middle and low income groups.  The effect of the $310 deductible 
on marginal WTP was also greater in the high income groups than in the lower income 
groups, yet this was largely a consequence of the smaller magnitude of the premium 
attribute in higher income senior citizens as the magnitude of their utility values for 
deductibles was actually smaller than the other two groups.   Finally the differences in 
preferences in doughnut hole coverage between the groups is reflected in this table as 
high income groups were willing to pay $12 for full generic doughnut hole coverage 
compared to $5 and $0 respectively for middle and low income groups.  When looking at 
these results, one should keep in mind that higher income seniors may have more 
disposable income to spend, so that $10 for a high income senior may represent a lower 
percentage of the income which they receive than $10 for a low income senior.  Overall, 
these results along with the importance scores and part worth values show important 
distinctions between low income seniors and high income seniors. 
 
 
Results by Medical Preferences 
 
Table 4-19 shows the part worths by medical preferences.  There were no significant 
differences in between these groups in their sensitivity to premiums as was hypothesized.  
Therefore, we are unable to reject the null hypothesis of study hypothesis #12 and cannot 
say that higher preferences for medical care are associated with greater willingness to pay 
more for Medicare Part D PDPs.  Interestingly, the group with higher medical 
preferences had lower part worth for the attribute level of using some pharmacies 
including the current one and a higher relative utility for using mail order benefits in 
comparison to the group with low medical preferences.  In general these groups appear to 
be similar to one another. 
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Table 4-17.   Importance scores by income 
 
Attributes Low  Middle  High  
 importance importance importance 
 scores  scores scores 
Premium 54.1% 47.6% 38.5% 
Formulary coverage 10.9% 12.7% 17.2% 
Deductible 11.9% 11.3% 11.4% 
Pharmacy access 9.5% 10.9% 9.7% 
Brand copayment 6.8% 7.0% 8.5% 
Generic copayment 3.4% 3.7% 5.2% 
Doughnut hole coverage 2.0% 5.0% 6.8% 
MTM eligibility 1.4% 1.9% 2.7% 
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Table 4-18.   Marginal WTP by income rescaled 
 
Attributes Low Middle High 
Premium (per dollar increase at average) -5.11 -4.35 -3.34 
Brand copayment    
     $25 or $40 $3 $4 $13 
     25% Reference Reference Reference
     $35 or $60 $0 $3 $3 
     $45 or $95 -$8 -$7 -$3 
Generic copayment    
     $0 $4 $5 $7 
     $7 $1 $2 $6 
     25% Reference Reference Reference
     $7 or 50% $1 $1 -$2 
Doughnut hole coverage    
     None Reference Reference Reference
     Few generics covered & & & 
     Some generics covered $0 $3 $5 
     All generics covered $0 $5 $12 
Formulary coverage    
     All drugs covered no restrictions $1 $2 $4 
     All drugs covered some restrictions Reference Reference Reference
     Some drugs covered no restrictions -$14 -$18 -$32 
     Some drugs covered some restrictions -$15 -$20 -$38 
Pharmacy access    
     All pharmacies available $0 $0 $2 
     Some pharmacies available including  
     current 
Reference Reference Reference
     Some pharmacies available not including  
     current 
-$17 -$17 -$14 
     Mail order used for best benefits -$12 -$10 -$6 
Deductible    
     $0 $10 $9 $10 
     $150 Reference Reference Reference
     $310 -$9 -$10 -$16 
MTM  eligibility    
     2 diseases and 3 drugs required & & & 
     2 diseases and 6 drugs required & & & 
     3 diseases and 6 drugs required & & & 
     4 diseases and 9 drugs required & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-19.   Part worth values by medical preferences rescaled 
 
Attributes Low Middle High 
Premium (per dollar increase at average) -4.63 -4.79 -4.54 
Brand copayment    
     $25 or $40 19.85 20.60 21.26 
     25% 3.61 3.42 3.64 
     $35 or $60 6.08 10.19 7.33 
     $45 or $95 -29.54 -34.21 -32.23 
Generic copayment    
     $0 15.56 14.00 12.15 
     $7 -3.51 0.29 1.65* 
     25% -8.37 -8.53 -8.58 
     $7 or 50% -3.68 -5.76 -5.23 
Doughnut hole coverage    
     None -1.52 -4.14 -0.63 
     Few generics covered -6.12 -11.06* -13.19 
     Some generics covered 0.67 3.71* 2.22 
     All generics covered 6.96 11.49* 11.60 
Formulary coverage    
     All drugs covered no restrictions 48.81 43.76 49.76 
     All drugs covered some restrictions 39.04 34.49 42.55 
     Some drugs covered no restrictions -35.54 -35.82* -43.92 
     Some drugs covered some restrictions -52.30 -2.42 -48.39* 
Pharmacy access    
     All pharmacies available 31.65 25.82* 29.24 
     Some pharmacies available including  
     current 
30.16 24.84 24.71* 
     Some pharmacies available not including  
     current 
-36.63 -35.70 -40.39 
     Mail order used for best benefits -25.17 -14.92 -13.56* 
Deductible    
     $0 46.95 43.37 45.60 
     $150 1.13 0.83 1.29 
     $310 -48.08 -44.20 -46.89 
MTM  eligibility    
     2 diseases and 3 drugs required -1.76 -0.79 0.56 
     2 diseases and 6 drugs required 1.86 -0.23 -0.46 
     3 diseases and 6 drugs required 0.38 0.94 0.66 
     4 diseases and 9 drugs required -0.49 0.08 -0.75 
None  -71.17 -78.17 -61.65 
 Note:  * indicates significant difference from low medical preferences at P=0.05 level. 
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Table 4-20 presents the importance scores by medical preferences.  The trends for all 
three of these groups closely mimic that seen in the aggregate sample, although doughnut 
hole coverage is slightly more important than brand copayments in the group which has 
high preferences for medical care.  
 
Table 4-21 presents the marginal WTP by Medical Preferences.  The largest difference in 
between the groups is that the group with low medical preferences has their marginal 
WTP decreased by a greater amount when having to use mail order to obtain the best 
benefits. 
 
 
Results by Number of Prescription Medications 
 
Table 4-22 shows the part worths by number of prescription medications.   An obvious 
trend occurs which demonstrates that as the number of medications increases, the 
premium sensitivity decreases.  However, this difference is only statistically significant 
when comparing the group with at least 7 medications with the group which takes no 
prescription medications at all.  Therefore, we cannot say that hypothesis #11 is true for 
most seniors.   For this study, this was only found to be true when comparing seniors 
taking at least seven medications with seniors taking no medications at all.  This makes 
intuitive sense as individuals who have no medications may perceive that they do not 
need to purchase prescription insurance.  
 
In addition, although it is not statistically significant, this table shows a trend where 
seniors who have more medications place more value on having lower copayments for 
the medications.  For example, seniors taking at least 7 medications placed greater value 
on having brand medications at $25 or $40 when compared to seniors taking no 
medications at all, and the same comparison holds true as well when looking at $0 
copayments for generic medications.   
 
Moreover, a trend is apparent where higher medication costs seem to cause a greater 
decrease in utility for those taking more medications.   For example, seniors taking no 
medications at all had the highest relative part worth values for $45 and $95 brand 
copays.  This also makes intuitive sense, because some of these seniors may believe that 
they may not be exposed to these copayments at all.  However, seniors taking multiple 
medications probably have been or have reason to believe that there is a strong 
probability that they will be exposed to these types of copayments.  Furthermore, the 
group with no medications at all seems to have much lower preferences for having any 
type of substantive doughnut hole coverage in comparison to other groups as the results 
seemed to indicate that they actually have greater preferences for no doughnut hole 
coverage of all.  Of course, this may be a result of these seniors repeatedly choosing plans 
with the lowest premium which were associated with lower levels of doughnut hole 
coverage, although the software is supposed to evaluate components featured in the 
summed pricing independent of the price.  The number of medications appears to be one 
of the most important factors in determining senior’s preferences within Medicare Part D 
plans. 
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Table 4-20.   Importance scores by medical preferences score 
 
Attributes Low  Middle  High  
 importance importance importance 
 scores  scores scores 
Premium 50.1% 51.3% 49.3% 
Formulary coverage 12.2% 11.6% 12.7% 
Deductible 12.1% 11.3% 11.6% 
Pharmacy access 10.3% 9.8% 10.1% 
Brand copayment 7.1% 6.8% 7.2% 
Generic copayment 3.6% 3.7% 3.6% 
Doughnut hole coverage 2.9% 3.7% 3.7% 
MTM eligibility 1.7% 1.6% 1.8% 
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Table 4-21.   Marginal WTP by medical preferences rescaled 
 
Attributes Low Middle High 
Premium (per dollar increase at average) -4.63 -4.79 -4.54 
Brand copayment    
     $25 or $40 $4 $4 $4 
     25% Reference Reference Reference
     $35 or $60 $1 $1 $1 
     $45 or $95 -$7 -$8 -$8 
Generic copayment    
     $0 $5 $5 $5 
     $7 $1 $2 $2 
     25% Reference Reference Reference
     $7 or 50% $1 $1 -$1 
Doughnut hole coverage    
     None Reference Reference Reference
     Few generics covered & & & 
     Some generics covered $0 $2 $1 
     All generics covered $2 $3 $3 
Formulary coverage    
     All drugs covered no restrictions $2 $2 $2 
     All drugs covered some restrictions Reference Reference Reference
     Some drugs covered no restrictions -$16 -$15 -$19 
     Some drugs covered some restrictions -$20 -$16 -$20 
Pharmacy access    
     All pharmacies available $0 $0 $1 
     Some pharmacies available including  
     current 
Reference Reference Reference
     Some pharmacies available not including  
     current 
-$14 -$13 -$14 
     Mail order used for best benefits -$12 -$8 -$8 
Deductible    
     $0 $10 $9 $10 
     $150 Reference Reference Reference
     $310 -$11 -$9 -$11 
MTM  eligibility    
     2 diseases and 3 drugs required & & & 
     2 diseases and 6 drugs required & & & 
     3 diseases and 6 drugs required & & & 
     4 diseases and 9 drugs required & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-22.   Part worth values by number of prescription medications rescaled 
 
Attributes 0 1-3 4-7 Over 7 
Premium (per dollar increase at 
average) 
-5.45 -4.87 -4.65 -4.41* 
Brand copayment     
     $25 or $40 13.49 18.67 23.39 20.21 
     25% 2.76 2.46 4.08 4.42 
     $35 or $60 6.07 8.23 8.70 8.15 
     $45 or $95 -22.32 -29.36 -36.17 -32.77 
Generic copayment     
     $0 10.22 15.26 12.59 14.16 
     $7 -2.64 0.10 0.77 -1.30 
     25% -5.99 -7.67 -8.25 -8.49 
     $7 or 50% -1.59 -7.69 -5.11 -4.37 
Doughnut hole coverage     
     None 7.86 -1.69 0.93 -10.97* 
     Few generics covered -4.95 -3.47 -8.74 -29.69* 
     Some generics covered -2.32 0.56 0.03 13.59* 
     All generics covered -0.59 4.60 7.78 27.07* 
Formulary coverage     
     All drugs covered no  
     restrictions 
43.03 46.83 47.04 47.37 
     All drugs covered some  
     restrictions 
35.55 37.84 36.93 37.36 
     Some drugs covered no  
     restrictions 
-39.27 -40.81 -40.97 -38.50 
     Some drugs covered some  
     restrictions 
-39.31 -43.45 -43.00 -46.24* 
Pharmacy access     
     All pharmacies available 28.73 27.67 29.09 27.62 
     Some pharmacies available  
     including current 
24.96 25.53 29.94 22.27 
     Some pharmacies available  
     not including current 
-33.86 -35.09 -45.52 -39.43 
     Mail order used for best  
     benefits 
-19.83 -18.10 46.23 -10.45 
Deductible     
     $0 48.51 45.16 46.23 41.30 
     $150 -1.72 2.27 1.82 2.22 
     $310 -46.79 -47.44 -48.05 -43.51 
MTM  eligibility     
     2 diseases and 3 drugs required -0.41 -1.99 -1.44 0.34 
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Table 4-22.       (continued) 
 
    
Attributes 0 1-3 4-7 Over 7 
     2 diseases and 6 drugs  
     required 
-2.48 2.20 0.04 -2.14 
     3 diseases and 6 drugs  
     required 
-0.28 0.52 1.91 -0.70 
     4 diseases and 9 drugs  
     required 
3.18 -0.73 -0.51 2.50 
None  -95.93 -84.21 -67.65 -62.04 
 Note:  * indicates significant difference from group with no medications at P=0.05 level. 
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The importance scores by the number of medications are presented in Table 4-23.  This 
table helps to demonstrate that as consumers are taking more medications, they are less 
sensitive to premiums, as the importance score for premium for those taking over 7 
medications is more than 10% points lower than those who do not take any medications.  
This table also helps to demonstrate the fact that seniors who are taking any number of 
medications seem to place higher priority on copayments in comparison to seniors who 
are currently taking no medications as their importance scores in these respective 
categories are higher than for those who are taking no medications at all. However, it is 
interesting to note that these values are virtually equal amongst those who are taking any 
type of medication.   
 
With regards to the deductible amount, this table and  demonstrate that seniors who are 
taking no medications may prefer plans with no deductible more so than seniors that are 
taking many medications.  This makes sense as seniors who are taking no medications 
may feel that even if they do have to use their prescription insurance, they may not meet 
the deductible.  For example, if they have to take the medication for only acute 
conditions, then they may not meet the deductible if they do not have to take the 
medication on a recurring basis.  On the other hand, seniors taking multiple medications 
may believe that they will exceed the deductible during the year.    
 
There is also a trend towards formulary coverage becoming more important with 
increasing amounts of medication.   As seniors take more medications, it is important for 
them not to have multiple medications that are not covered so that they incur the full 
price of the medication. 
 
Table 4-24 shows the marginal WTP by the number of medications.  This table helps to 
demonstrate the greater value placed on lower copayments by seniors taking multiple 
medications.  As an example, seniors taking at least seven medications would be willing 
to pay $4 more per month in premiums for $25 or $40 brand name medications instead of 
the 25% cost sharing as stated in the standard benefit.  Meanwhile, seniors currently 
taking no medications indicated that they would be willing to pay $2 more per month for 
having the $25 or $40 brand copayments instead of the 25% cost sharing stipulated in the 
standard benefit. Likewise, seniors taking multiple medications are affected more 
negatively by higher copayments than seniors taking no medications.  The senior citizens 
taking over seven medications indicated that they would have to have premiums which 
were $8 lower in order to accept $45 or $95 brand name copayments instead of the 25% 
coapyments, while seniors taking no medications indicated that they would have to have 
premiums which were $5 lower in order to accept the $45 or $95 brand name 
copayments.   Similar trends are found when one examines the preferences in regards to 
copayments for generic medications.   
 
In addition, this table helps to demonstrate that seniors taking over 7 medications would 
be willing to pay approximately $9 more in premiums to have doughnut hole coverage, a 
greater amount than that seen in other groups.  Also, as alluded to in Table 4-22 and 
Table 4-23, seniors taking more medications also indicated that they would have to be 
paid more in order to accept plans with more restrictive formulary coverage. 
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Table 4-23.   Importance scores by number of prescription medications 
 
Attributes 0 
 importance 
scores 
1-3 
importance 
scores 
4-7 
importance 
scores 
Over 7 
importance 
scores 
Premium 57.6% 51.8% 50.2% 46.5% 
Formulary 
coverage 
10.8% 11.7% 11.9% 13.3% 
Deductible 12.0% 11.7% 11.9% 10.7% 
Pharmacy access 8.6% 9.9% 10.2% 10.3% 
Brand copayment 5.6% 7.0% 7.1% 7.1% 
Generic 
copayment 
2.6% 3.8% 3.6% 3.9% 
Doughnut hole 
coverage 
1.6% 2.4% 3.2% 6.4% 
MTM eligibility 1.2% 1.7% 1.7% 1.7% 
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Table 4-24.   Marginal WTP by number of prescription medications rescaled 
 
Attributes 0 1-3 4-7 Over 7 
Premium (per dollar increase at 
average) 
-5.45 -4.87 -4.65 -4.41 
Brand copayment     
     $25 or $40 $2 $3 $4 $4 
     25% Reference Reference Reference Reference
     $35 or $60 -$1 $1 $1 $1 
     $45 or $95 -$5 -$7 -$9 -$8 
Generic copayment     
     $0 $3 $5 $4 $5 
     $7 $1 $2 $2 $2 
     25% Reference Reference Reference Reference
     $7 or 50% $1 $0 -$1 -$1 
Doughnut hole coverage     
     None Reference Reference Reference Reference
     Few generics covered & & & & 
     Some generics covered -$2 $0 $0 $6 
     All generics covered -$2 $1 $1 $9 
Formulary coverage     
     All drugs covered no  
     restrictions 
$1 $2 $2 $2 
     All drugs covered some   
     restrictions 
Reference Reference Reference Reference
     Some drugs covered no  
     restrictions 
-$14 -$16 -$17 -$17 
     Some drugs covered some  
     restrictions 
-$14 -$17 -$17 -$19 
Pharmacy access     
     All pharmacies available $1 $0 $0 $1 
     Some pharmacies available  
     including current 
Reference Reference Reference Reference
     Some pharmacies available not  
     including current 
-$11 -$12 -$16 -$14 
     Mail order used for best    
     benefits 
-$8 -$9 -$4 -$7 
Deductible     
     $0 $9 $9 $10 $9 
     $150 Reference Reference Reference Reference
     $310 -$8 -$10 -$11 -$10 
MTM  eligibility     
     2 diseases and 3 drugs required & & & & 
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Table 4-24.       (continued) 
 
    
Attributes  0 1-3 4-7 Over 7 
     2 diseases and 6 drugs required & & & & 
     3 diseases and 6 drugs required & & & & 
     4 diseases and 9 drugs required & & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Results by Pharmacy Preferences 
 
Table 4-25 shows the part worths by pharmacy preferences.   There is no significant 
difference in between the groups in their premium sensitivity.  The insignificance of the 
requirements for MTM eligibility attribute prevents us from testing hypothesis #13 in this 
study.  In addition, although there are no statistically significant differences between part 
worth values in the pharmacy attribute, the results are counterintuitive in that lower levels 
of pharmacy preferences seem to be associated with higher utilities for more liberal 
access to pharmacy and lower part worth values for restricted access to pharmacies. No 
other significant details of note are found in this table. 
 
The importance scores are presented by pharmacy preferences in Table 4-26.   No 
outstanding features of note are presented within this table.  The marginal WTP is 
presented by pharmacy preferences in Table 4-27.  In general, these groups are similar to 
each other. 
 
 
Results by Education 
 
Table 4-28 shows the part worths by education level.   The premium sensitivity of those  
who have at least some college education is significantly lower than those who have no 
higher than a high school education.  Having higher levels of doughnut hole coverage 
was more important to those with higher levels of education.  Maintaining access to the 
current pharmacy and having lower deductibles were more important for seniors with 
lower levels of education.    There was also large difference in the none parameter 
between these two groups, but it was not statistically significant, presumably due to the 
large standard error of this particular parameter.   
 
Table 4-29 shows the importance scores by education.  This table reflects the higher 
importance that seniors without a college education place on the premiums. Those seniors 
with a college education place slightly more importance on formulary coverage and 
deductibles.  In addition, seniors with at least some college education had slightly more 
importance placed on doughnut hole coverage.   
 
Table 4-30 presents the marginal WTP by education.  One notable difference occurs in 
regards to doughnut hole coverage, where seniors with at least some college education 
were willing to pay $6 for doughnut hole coverage and seniors with no more than a high 
school education were only willing to pay $1 for doughnut hole coverage.  In addition, 
seniors with at least some college education would have to be paid $24 in order to accept 
plans where only some of their drugs were covered with some restrictions in comparison 
to $17 for seniors with no more than a high school education. There were also differences 
in WTP for mail order services.  Seniors with lower levels of education indicated that 
they would have to be paid $9 in order to have to use mail order for the best benefits, but 
seniors with at least some college education indicated that they would have to be paid $3 
in order to use mail order for the best benefits.   
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Table 4-25.   Part worth values by pharmacy preferences rescaled 
 
Attributes Low Middle High 
Premium (per dollar increase at average) -4.77 -4.66 -4.65 
Brand copayment    
     $25 or $40 21.68 20.71 19.37 
     25% 2.42 3.90 4.25 
     $35 or $60 6.40 7.45 10.40 
     $45 or $95 -30.50 -32.05 -34.02 
Generic copayment    
     $0 15.70 14.16 12.18 
     $7 -1.06 0.87* -0.47 
     25% -7.05 -8.32 -10.79 
     $7 or 50% -7.59 -6.71 -0.92 
Doughnut hole coverage    
     None -1.11 -2.17 -4.48 
     Few generics covered -2.20 -11.12* -11.55* 
     Some generics covered -0.68 4.03* 0.87* 
     All generics covered 3.99 9.27* 15.15* 
Formulary coverage    
     All drugs covered no restrictions 42.67 46.31 48.79 
     All drugs covered some restrictions 36.38 37.01 40.57 
     Some drugs covered no restrictions -37.12 -36.09 -39.79 
     Some drugs covered some restrictions -41.93 -47.22 -49.57 
Pharmacy access    
     All pharmacies available 29.47 28.40 29.19 
     Some pharmacies available including  
     current 
26.32 27.68 25.46 
     Some pharmacies available not including  
     current 
-35.06 -38.86 -38.61 
     Mail order used for best benefits -20.73 -17.21 -16.04 
Deductible    
     $0 46.62 47.23 39.65 
     $150 1.72 1.44 2.31 
     $310 -48.34 -48.67 -41.96 
MTM  eligibility    
     2 diseases and 3 drugs required 1.97 -2.06 -1.10 
     2 diseases and 6 drugs required 0.12 1.16 -0.88 
     3 diseases and 6 drugs required -0.33 0.13 0.40 
     4 diseases and 9 drugs required -1.76 0.78 1.58 
None  -79.34 -70.72 -67.06 
 Note:  * indicates significant difference from low pharmacy preferences at P=0.05 level. 
97 
 
Table 4-26.   Importance scores by pharmacy preferences 
 
Attributes Low  Middle  High  
 importance importance importance 
 scores  scores scores 
Premium 54.1% 47.6% 38.5% 
Formulary coverage 10.9% 12.7% 17.2% 
Deductible 11.9% 11.3% 11.4% 
Pharmacy access 9.5% 10.9% 9.7% 
Brand copayment 6.8% 7.0% 8.5% 
Generic copayment 3.4% 3.7% 5.2% 
Doughnut hole coverage 2.0% 5.0% 6.8% 
MTM eligibility 1.4% 1.9% 2.7% 
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Table 4-27.   Marginal WTP by pharmacy preferences rescaled 
 
Attributes Low Middle High 
Premium (per dollar increase at average) -4.77 -4.66 -4.65 
Brand copayment    
     $25 or $40 $4 $4 $3 
     25% Reference Reference Reference
     $35 or $60 $1 $1 $1 
     $45 or $95 -$7 -$8 -$8 
Generic copayment    
     $0 $5 $5 $5 
     $7 $1 $2 $2 
     25% Reference Reference Reference
     $7 or 50% -$0 $0 $2 
Doughnut hole coverage    
     None Reference Reference Reference
     Few generics covered & & & 
     Some generics covered $0 $1 $1 
     All generics covered $1 $2 $4 
Formulary coverage    
     All drugs covered no restrictions $1 $2 $2 
     All drugs covered some restrictions Reference Reference Reference
     Some drugs covered no restrictions -$15 -$16 -$17 
     Some drugs covered some restrictions -$16 -$18 -$19 
Pharmacy access    
     All pharmacies available $1 $0 $1 
     Some pharmacies available including  
     current 
Reference Reference Reference
     Some pharmacies available not including  
     current 
-$13 -$14 -$14 
     Mail order used for best benefits -$10 -$9 -$9 
Deductible    
     $0 $9 $10 $8 
     $150 Reference Reference Reference
     $310 -$10 -$11 -$10 
MTM  eligibility    
     2 diseases and 3 drugs required & & & 
     2 diseases and 6 drugs required & & & 
     3 diseases and 6 drugs required & & & 
     4 diseases and 9 drugs required & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-28.   Part worth values by education rescaled 
 
Attributes Low High 
Premium (per dollar increase at average) -4.98 -4.19* 
Brand copayment   
     $25 or $40 18.92 22.59 
     25% 4.93 2.94 
     $35 or $60 9.36 6.63 
     $45 or $95 -33.21 -32.17 
Generic copayment   
     $0 13.87 13.85 
     $7 -1.86 1.68 
     25% -7.75 -9.92 
     $7 or 50% -4.25 -5.60 
Doughnut hole coverage   
     None -1.056 -5.81 
     Few generics covered -4.82 -19.39* 
     Some generics covered 0.19 5.93* 
     All generics covered 3.59 19.28* 
Formulary coverage   
     All drugs covered no restrictions 44.57 54.51 
     All drugs covered some restrictions 38.20 42.65 
     Some drugs covered no restrictions -36.01 -40.45 
     Some drugs covered some restrictions -46.76 -56.71 
Pharmacy access   
     All pharmacies available 28.40 27.25* 
     Some pharmacies available including  
     current 
27.97 23.41* 
     Some pharmacies available not including  
     current 
-37.66 -38.43 
     Mail order used for best benefits -18.71 -12.23* 
Deductible   
     $0 45.16 44.10 
     $150 1.87 1.87 
     $310 -47.03 -45.90* 
MTM  eligibility   
     2 diseases and 3 drugs required 0.35 -2.72 
     2 diseases and 6 drugs required 0.51 0.73 
     3 diseases and 6 drugs required 0.68 0.04 
     4 diseases and 9 drugs required -1.54 1.95 
None  -84.30 -46.80 
 Note:  * indicates significant difference from low education group at P=0.05 level. 
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Table 4-29.   Importance scores by education 
 
Attributes Low importance scores High importance scores 
Premium 49.4% 45.0% 
Formulary coverage 12.1% 14.2% 
Deductible 12.0% 11.4% 
Pharmacy access 9.9% 10.2% 
Brand copayment 7.5% 7.5% 
Generic copayment 3.9% 4.1% 
Doughnut hole coverage 3.6% 5.5% 
MTM eligibility 1.7% 2.0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
Table 4-30.   Marginal WTP by education rescaled 
 
Attributes Low High 
Premium (per dollar increase at average) -4.98 -4.19 
Brand copayment   
     $25 or $40 $3 $5 
     25% Reference Reference 
     $35 or $60 $1 $1 
     $45 or $95 -$8 -$8 
Generic copayment   
     $0 $4 $6 
     $7 $1 $3 
     25% Reference Reference 
     $7 or 50% $1 $1 
Doughnut hole coverage   
     None Reference Reference 
     Few generics covered & & 
     Some generics covered $0 $3 
     All generics covered $1 $6 
Formulary coverage   
     All drugs covered no restrictions $1 $3 
     All drugs covered some restrictions Reference Reference 
     Some drugs covered no restrictions -$15 -$19 
     Some drugs covered some restrictions -$17 -$24 
Pharmacy access   
     All pharmacies available $0 $1 
     Some pharmacies available including  
     current 
Reference Reference 
     Some pharmacies available not including  
     current 
-$13 -$15 
     Mail order used for best benefits -$9 -$3 
Deductible   
     $0 -$9 $10 
     $150 Reference Reference 
     $310 -$10 -$11 
MTM  eligibility   
     2 diseases and 3 drugs required & & 
     2 diseases and 6 drugs required & & 
     3 diseases and 6 drugs required & & 
     4 diseases and 9 drugs required & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Results by Disease Burden 
 
Table 4-31 shows the part worth values by disease burden.  Although there is a tendency 
for the premium to increase as the disease burden increases, it is not statistically 
significant.  Therefore we cannot reject the null hypothesis of hypothesis #10.  The data 
also suggest that seniors with at least one comorbidity may place a greater value on 
having $0 generics.  Seniors with at least one comorbidity had lower relative part worths 
in regards to having all pharmacies available for use or at least their own compared to 
seniors without a comorbidity.   
 
Table 4-32 displays the importance scores by disease burden.  This table reflects the 
decreasing influence of the premium as the disease burden increases.  Copayments, 
doughnut hole coverage, and formulary provisions seem to take on increasing importance 
as seniors have higher disease burdens.  Table 4-33 shows the marginal WTP by disease 
burden.  This table demonstrates that seniors with a greater disease burden may be 
willing to pay slightly more for plans with doughnut hole coverage, and they are also 
particularly averse to having plans with only some drugs covered, and some restrictions 
on those covered drugs. 
 
 
Results by Out of Pocket Medication Cost 
 
Table 4-34 shows the part worths by monthly out of pocket medication cost.  The 
premium sensitivity of the groups which pay either at least $41 for their medications and 
those paying at least $80 per month is significantly lower than the group which pays at 
most $10 for their medications on a monthly basis.  The group which pays at least $80 
per month for their medications had significantly lower part worth values for lower levels 
of doughnut hole coverage and significantly higher part worths for higher levels of 
doughnut hole coverage when compared to the those spending the least amount of money 
on their medications. The deductible also was not as important of a factor for seniors with 
the highest medication costs.  In addition, the none parameter was significantly lower for 
seniors who spent at least $40 per month on their medications in comparison to seniors 
who spent no more than $10 monthly on their medications.    
 
Table 4-35 displays the importance scores by the monthly out of pocket medication cost.  
This table reflects the decreased relative importance of premiums for those spending at 
least $80 per month on their medications as the importance score for premium is highest 
for those who currently have no out of pocket medication cost and lowest for those who 
have out of pocket medication cost of at least $80.  The doughnut hole and formulary 
provisions are also most important for those who spend at least $40 per month on their 
medications.   
 
Table 4-36 displays the marginal WTP values by monthly out of pocket medication cost.  
Seniors spending more than $80 per month on their medications were willing to pay more 
per month for free generics and doughnut  hole coverage, and had to be paid more in 
order to accept plans where all of their medications were not covered.   
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Table 4-31.   Part worth values by disease burden rescaled 
 
Attributes None 1-2 >2 
Premium (per dollar increase at average) -4.84 -4.67 -4.29 
Brand copayment    
     $25 or $40 18.97 20.28 19.82 
     25% 1.82 4.99 3.45 
     $35 or $60 8.72 6.21 10.71 
     $45 or $95 -29.51 -31.47 -33.97 
Generic copayment    
     $0 10.27 14.77 15.61 
     $7 0.54 -0.17 -2.46 
     25% -6.74 -8.41 -11.29 
     $7 or 50% -4.08 -6.20 -1.86 
Doughnut hole coverage    
     None -0.44 -2.31 -7.94 
     Few generics covered -6.23 -8.18 -18.48* 
     Some generics covered 1.00 2.04 6.59* 
     All generics covered 5.67 8.46 19.83* 
Formulary coverage    
     All drugs covered no restrictions 47.65 48.00 46.93 
     All drugs covered some restrictions 36.03 40.55 39.04 
     Some drugs covered no restrictions -36.57 -37.16 -25.94* 
     Some drugs covered some restrictions -47.11 -51.39 -60.03 
Pharmacy access    
     All pharmacies available 35.75 24.72* 28.21* 
     Some pharmacies available including  
     current 
35.22 22.67* 22.47* 
     Some pharmacies available not including  
     current 
-50.59 -33.77* -35.72* 
     Mail order used for best benefits -20.38 -13.63 -14.96 
Deductible    
     $0 44.58 46.60 39.26 
     $150 1.96 1.43 3.79 
     $310 -46.86 -48.03 -43.05 
MTM  eligibility    
     2 diseases and 3 drugs required -0.78 -0.42 1.60 
     2 diseases and 6 drugs required 0.31 0.70 0.86 
     3 diseases and 6 drugs required 0.28 -0.34 -4.67* 
     4 diseases and 9 drugs required 0.19 -0.61 2.21 
None  -70.68 -74.71 -54.24 
 Note:  * indicates significant difference from no disease group at P=0.05 level. 
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Table 4-32.   Importance scores by disease burden 
 
Attributes Low  Middle  High  
 importance importance importance 
 scores  scores scores 
Premium 51.3% 50.3% 47.3% 
Formulary coverage 11.9% 13.0% 14.3% 
Deductible 11.5% 12.0% 11.1% 
Pharmacy access 11.8% 9.1% 10.1% 
Brand copayment 6.4% 7.2% 7.7% 
Generic copayment 3.2% 3.8% 4.2% 
Doughnut hole coverage 2.4% 3.0% 5.4% 
MTM eligibility 1.6% 1.7% 2.1% 
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Table 4-33.   Marginal WTP by disease burden rescaled 
 
Attributes Low 1-2 >2 
Premium (per dollar increase at average) -4.84 -4.67 -4.29 
Brand copayment    
     $25 or $40 $4 $3 $4 
     25% Reference Reference Reference
     $35 or $60 $1 $0 $2 
     $45 or $95 -$6 -$8 -$9 
Generic copayment    
     $0 $4 $5 $6 
     $7 $2 $2 $2 
     25% Reference Reference Reference
     $7 or 50% $0 $0 $2 
Doughnut hole coverage    
     None Reference Reference Reference
     Few generics covered & & & 
     Some generics covered $0 $1 $3 
     All generics covered $1 $2 $6 
Formulary coverage    
     All drugs covered no restrictions $2 $1 $2 
     All drugs covered some restrictions Reference Reference Reference
     Some drugs covered no restrictions -$15 -$17 -$15 
     Some drugs covered some restrictions -$17 -$20 -$23 
Pharmacy access    
     All pharmacies available $0 $0 $1 
     Some pharmacies available including  
     current 
Reference Reference Reference
     Some pharmacies available not including  
     current 
-$18 -$12 -$14 
     Mail order used for best benefits -$12 -$8 -$9 
Deductible    
     $0 $9 $10 $8 
     $150 Reference Reference Reference
     $310 -$10 -$11 -$11 
MTM  eligibility    
     2 diseases and 3 drugs required & & & 
     2 diseases and 6 drugs required & & & 
     3 diseases and 6 drugs required & & & 
     4 diseases and 9 drugs required & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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Table 4-34.   Part worth values by out of pocket medication cost rescaled 
 
Attributes $0-$10 $11-$40 $41-$79 >$80 
Premium (per dollar increase at 
average) 
-5.01 -4.86 -4.31* -3.60* 
Brand copayment     
     $25 or $40 17.64 21.11 19.93 24.40 
     25% 1.74 5.81 -0.73 0.22 
     $35 or $60 8.14 7.93 2.87 8.70 
     $45 or $95 -27.52 -34.86 -22.10 -33.32 
Generic copayment     
     $0 16.63 13.73 5.20* 14.57* 
     $7 0.01 -0.07 -2.95 -4.21 
     25% -8.15 -8.90 -3.69* -8.62 
     $7 or 50% -8.49 -4.76 -4.47 -1.74* 
Doughnut hole coverage     
     None 0.82 -0.19 -1.94 -23.99* 
     Few generics covered -7.44 -4.10 -11.50 -36.45* 
     Some generics covered 0.57 0.44 -1.49 21.11* 
     All generics covered 6.05 3.86 14.94 39.33* 
Formulary coverage     
     All drugs covered no  
     restrictions 
46.25 43.68 56.82 61.05 
     All drugs covered some  
     restrictions 
38.30 34.12 41.36 53.94 
     Some drugs covered no  
     restrictions 
-42.08 -37.82* -47.25* -44.92 
     Some drugs covered some  
     restrictions 
-42.47 -39.98 -50.94 -70.07 
Pharmacy access     
     All pharmacies available 29.14 26.94 34.73 26.14* 
     Some pharmacies available  
     including current 
24.90 25.66 33.12 24.98 
     Some pharmacies available  
     not including current 
-34.39 -38.02 -42.48 -40.83 
     Mail order used for best  
     benefits 
-19.65 -14.58 -25.38 -10.29* 
Deductible     
     $0 48.48 45.20 44.56 34.01* 
     $150 -0.91 4.65* 0.73 2.80 
     $310 -47.57 -49.85 -45.29 -36.81* 
MTM  eligibility     
     2 diseases and 3 drugs required -0.41 -1.99 -1.44 0.34 
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Table 4-34.       (continued) 
 
    
Attributes $0-$10 $11-$40 $41-$79 >$80 
     2 diseases and 6 drugs  
     required 
-0.24 0.70 2.10 -2.89 
     3 diseases and 6 drugs  
     required 
1.21 0.23 -3.10 1.48 
     4 diseases and 9 drugs  
     required 
1.83 -0.40 -3.87 0.64 
None  -80.10 -83.90 -52.04* -29.50* 
 Note:  * indicates significant difference from $0-$10 group at P=0.05 level. 
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Table 4-35.   Importance scores by out of pocket medication cost  
 
Attributes $0-$10 
importance 
scores 
$11-$40 
importance 
scores 
$41-$79 
importance 
scores 
>$80 
importance 
scores 
Premium 53.3% 52.3% 45.5% 39.0% 
Brand copayment 6.1% 7.4% 7.1% 7.6% 
Formulary 
coverage 
11.4% 10.9% 14.1% 16.7% 
Deductible 11.9% 12.2% 11.4% 9.3% 
Pharmacy access 9.3% 9.8% 11.6% 10.7% 
Generic 
copayment 
3.8% 3.6% 3.5% 4.3% 
Doughnut hole 
coverage 
2.5% 2.0% 4.5% 10.3% 
MTM eligibility 1.6% 1.8% 2.4% 2.1% 
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Table 4-36.   Marginal WTP by monthly out of pocket medicine cost rescaled  
 
Attributes $0-$10 $11-$40 $41-$79 >$80 
Premium (per dollar increase at 
average) 
-5.01 -4.86 -4.31 -0.376 
Brand copayment     
     $25 or $40 $3 $3 $5 $7 
     25% Reference Reference Reference Reference 
     $35 or $60 $1 $0 $1 $2 
     $45 or $95 -$6 -$8 -$5 -$9 
Generic copayment     
     $0 $5 $5 $2 $6 
     $7 $2 $2 $0 $1 
     25% Reference Reference Reference Reference 
     $7 or 50% $0 $1 $0 $2 
Doughnut hole coverage     
     None Reference Reference Reference Reference 
     Few generics covered & & & & 
     Some generics covered -$0 -$0 $0 $13 
     All generics covered $1 $1 $4 $20 
Formulary coverage     
     All drugs covered no    
     restrictions 
$2 $2 $4 $2 
     All drugs covered some  
     restrictions 
Reference Reference Reference Reference 
     Some drugs covered no  
     restrictions 
-$16 -$15 -$21 -$27 
     Some drugs covered some    
     restrictions 
-$16 -$15 -$21 -$34 
Pharmacy access     
     All pharmacies available $1 $0 $0 $0 
     Some pharmacies available 
     including current 
Reference Reference Reference Reference 
     Some pharmacies available not     
     including current 
-$12 -$13 -$17 -$18 
     Mail order used for best  
     benefits 
-$9 -$8 -$13 -$10 
Deductible     
     $0 $10 $8 $10 $9 
     $150 Reference Reference Reference Reference 
     $310 -$9 -$11 -$11 -$11 
MTM  eligibility     
     2 diseases and 3 drugs required & & & & 
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Table 4-36.       (continued) 
 
    
Attributes $0-$10 $11-$40 $41-$79 >$80 
     2 diseases and 6 drugs required & & & & 
     3 diseases and 6 drugs required & & & & 
     4 diseases and 9 drugs required & & & & 
Note:  & indicates willingness to pay not calculated due to irrational order. 
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CHAPTER 5.    DISCUSSION 
 
 
This study sought to evaluate the preferences for Shelby County seniors in regards to 
Medicare Part D drug plans using the guidance of a conceptual framework developed 
from previous research regarding beneficiaries selection of health plans and prescription 
drug plans.  The research indicated that several factors influence senior’s choice of 
prescription drug plans including drug benefit plan characteristics and delivery system 
characteristics.  The most important factors for the aggregate sample in selecting drug 
plans in decreasing order were premiums, formulary coverage, deductible amount, and 
pharmacy access.  
 
In terms of drug benefit plan characteristics, greater amounts of control mechanisms, 
higher premiums, and greater copayments were associated with lower utilities in a PDP, 
and hence a lower probability of a plan being selected.  These findings are not surprising 
as previous research has demonstrated this relationship.43-45,49,51,53  In addition as 
expected, higher deductibles were found to be associated with lower utility.  In general, 
doughnut hole coverage appeared to have a positive association with the probability of a 
plan being selected, but this was only true where plans had coverage for at least some 
generics within the doughnut hole.   
 
This study also indicated that access to the pharmacy is an important component in the 
selection of prescription drug plans.  While previous research on medication insurance 
had explored this issue,43,44 it had not been investigated within the context of Medicare 
Part D plans.  In most cases, there was not an appreciable difference between the part 
worth values for seniors being able to use all pharmacies with their prescription insurance 
or being able to use only some pharmacies as long as their current pharmacy was 
included in the insurance plan.  However, the part worth values were much lower when 
seniors were presented with plans which did not allow them to use their insurance within 
their current pharmacy.  Seniors also indicated that they preferred not to have to use mail 
order to get the best benefits from their prescription drug plan.  The results gathered from 
this study indicated that the eligibility requirements for MTM services are not an 
important component in seniors selection of prescription drug plans.  This may indicate 
that many of these seniors are not aware of these services, and that greater efforts must be 
put in place in order to ensure that seniors are aware of these benefits.   
 
This study also sought to analyze the impact of secondary factors, that is factors which 
are not characteristics of the drug plans themselves, on the choice of prescription drug 
plans.18  Exploring the impact of economic characteristics in senior’s choice of 
prescription drug plans demonstrated the role that income plays when they decide on a 
plan.   Out of all the sub groups analyzed within this study, seniors with high incomes 
demonstrated the smallest sensitivity to increases in premiums.  The importance score for 
premiums for this group was nearly 30% lower than that seen in low income seniors.  
These results suggest that although, the seniors with higher incomes are sensitive to 
changes in premiums, they probably would be willing to pay higher prices for 
prescription insurance as will be the case in the Affordable Care Act.60  The results 
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indicate that doughnut hole coverage is more important to seniors with higher incomes 
than lower income groups.  While lower income seniors did not indicate that they would 
be willing to pay any additional money for doughnut hole coverage, and middle income 
seniors indicated that they would be willing to pay $5 more for full generic coverage in 
the doughnut hole, higher income seniors indicated that they would pay $12 for doughnut 
hole coverage.  These findings help to explain some of the general ambiguity concerning 
the doughnut hole in this study, as it may only be important to certain groups such as high 
income seniors.  Seniors with high incomes also indicated that formulary coverage was 
an important factor to them, and they would be willing to pay generous premiums in 
order to ensure that all of their medications were covered.  Another finding of note is the 
particular affinity that low income seniors have for choosing plans which allow them to 
use their current pharmacy.  This may be due to many reasons, but it is possible that these 
seniors choose a pharmacy which is within close proximity to them so that they may 
access it even without some type of motor transportation.  Alternatively, the pharmacy 
may offer some type of delivery service that the senior citizen may value, but this is an 
area in which more research may prove helpful.   
 
Within the risk factors, the number of chronic conditions and the current use of 
prescription medications were found to affect the choice of plan most.  Specifically, 
seniors taking more than 7 medications had a part worth for premium that was of 
significantly lower magnitude than seniors taking no medications.  These results suggest 
that these seniors may be willing to pay higher premiums for plans which offer more 
generous coverage, a premise that is supported by their significantly higher part worths 
for plans offering full doughnut hole coverage and the greater importance they place on 
formulary coverage.  However, these seniors probably have high medical expenses, so it 
is important to ensure that their costs as relates to medication experience do not become 
overwhelming.   The number of current medications also had a significant effect on the 
amount of doughnut hole coverage seniors are willing to accept. 
 
The senior citizens beliefs of medical care preferences, not their relationship with their 
pharmacist seemed to be significant factors for their selection of a prescription drug plan 
in this study.  This may be due to the fact that the medial care preferences scale is mostly 
concerned with an individual’s perception of their relationship with their physician, and 
their preferences for receiving general health care as opposed to their relationship with 
their pharmacy and pharmacologic therapy.97  This study also did not find that the 
strength of the relationship between patients with their pharmacy or pharmacist had an 
impact on their selection of a prescription drug plan.  This may be due to the fact that 
some seniors choose their pharmacy for reasons other than the pharmacist who works 
there.  Alternatively, it may be the case that in general, the senior population surveyed 
displayed strong preferences for retaining their current pharmacy, so that a significantly 
greater preference than this may be hard to obtain.  Finally, the cost of seniors out of 
pocket cost had a significant impact on how they go about choosing prescription drug 
plans.  Seniors with medication costs of at least $41 monthly had lower premium 
sensitivity when compared to seniors who spent $10 or less per month on their 
medications.  These groups also were relatively less sensitive to increases in the 
deductible amount when compared to seniors who spent $10 or less per month out of 
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pocket on their medicines.  Furthermore, the group which spent at least $80 per month on 
their medications was the only group which exhibited a rational preference order for the 
doughnut hole coverage attribute where the lowest part worth value was when no generic 
medications were covered.  This is fortunate for these senior citizens, as their medication 
costs place them in imminent danger of reaching the doughnut hole, and they are the ones 
who need this coverage the most.12  It is possible however, that seniors may initially have 
low medication related expenses at the time they choose to enroll in a plan and end up 
with some type of condition which subjects them to high medication costs.  Therefore, it 
would be ideal if all seniors demonstrated this rational order in dealing with doughnut 
hole coverage as these part worths are independent of higher premiums.  However, this 
does point to the need for the doughnut hole to be subsidized as promulgated in the 
affordable care act as many seniors do not seem to be able to comprehend the need for 
doughnut hole coverage.12  And once again, the seniors with high medication costs are 
already under increased pressure due to their high medication expenses, so having to 
purchase insurance plans with higher premiums due to doughnut hole coverage only 
exacerbates their situation.    
 
Abaluck and Gruber indicated that seniors over value premiums in relation to other 
determinates of out of pocket costs, and in their statistical models, the coefficient on 
premiums was five times larger than that found on out of pocket costs.53 In this study, the 
importance of the premium was five times larger than the combined importance scores of 
the copayments for generic and brand medications.  They also indicated that seniors 
would have to be paid approximately $80 in order to go to plans with the lowest cost 
sharing in their study (25%) to plans with  the highest cost sharing.53  In this study seniors 
would have to be paid $84 annually to go from a plan with 25% brand cost sharing to the 
attribute level with the highest level of cost sharing.  However, this study shows how 
these figures may be slightly different depending on the group which is being studied.   
For example, for seniors with medications expenses over $80 monthly they would have to 
be paid $108, but seniors with high incomes would have to be paid as little as $36.  
Abaluck and Gruber also indicated that seniors would be willing to pay $50 for generic 
doughnut hole coverage53 while Heiss and colleagues found a value of $33,51 similar to 
the value of $36 found in this study for full doughnut hole coverage.  However, the Heiss 
study alluded to the fact that this amount would be different between seniors with high 
and low costs as this study did.51  In addition, Heiss and associates found that 
beneficiaries would be willing to pay $14 monthly for no deductible plans during 2006-
2007.51  This is smaller than the $18 amount in this study to go from full deductibles to 
no deductibles, yet the deductible amounts were smaller.  In 2006, the deductible was 
$250.62   
 
This study has several limitations.  The internal validity of this sample is limited because 
it is not a random sample, it is possible that there may be unobserved factors which may 
introduce systematic bias.  Furthermore, the respondents are depended upon to provide 
answers to questions about their past or current situation which has the possibility of 
bringing in recall bias.  Also this study is limited in the external validity because the 
results will only be able to be extrapolated to the Shelby County Medicare population as 
this population is distinct in nature from even other areas of Tennessee.  In addition, all of 
114 
 
the information is derived from senior citizens who have attend seniors centers, who may 
have differential preferences in comparison to the senior population at large.  The 
population who attends seniors centers is ambulatory which may make them different 
from other types of senior populations such as those found in a nursing home.   
 
There are several recommendations for research that come as a result of conducting this 
study.  One suggestion is to use the results and part worths in order to determine if they 
are able to assist in developing models which may predict changes in market share as a 
result of changes made to the plan.  Two factors which may be important in choice of 
PDPs which were not studied in this research are the plan’s quality ratings and the 
concept of “brand loyalty”:  that is whether seniors forgo the time and effort needed on an 
annual basis to evaluate their enrollment decision and just decide to remain with their 
current plan without exploring other options.  These were not included due to the 
possibility of presenting the seniors with too much information at one time. This would 
contribute to imperfect market conditions and diminish the efforts of competing plans to 
enhance their products by finding ways to offer lower cost and greater coverage.  In 
addition, although this study explored many secondary characteristics, it did not study 
them all in a simultaneous manner.  It would be prudent to utilize multivariate techniques 
which allow one to study the most important characteristics and evaluate whether their 
effects are independent of others.   
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